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ABSTRACT
Hepatic encephalopathy (HE) contains a spectrum of neuropsychiatric abnormalities 
observed in patients with liver disease. A quick worsening of consciousness and 
increasingly growing cerebral edema, high intracranial pressure, which leads to cerebral 
herniation and death, are characteristics of acute liver failure (ALF). Multiple factors 
are found responsible for the development of HE, whereas, over 100 years, 
hyperammonia is considered the most crucial factor in defining the pathogenesis of HE 
in ALF, which can increase to millimolar concentrations in the brain at the coma 
stages of HE. 
The present thesis comprises 4 articles, which demonstrates new pathogenic 
mechanisms involved in the development of HE and cerebral edema in ALF, and 
elucidates part of the therapeutic mechanism of hypothermia and minocycline in the 
prevention of HE and cerebral edema during ALF. The major findings are listed below: 
(1) Experimental ALF leads to the increase in brain production of proinflammatory 
cytokines (IL-6, IL-1β, TNF-), and provides the first direct evidence that central 
inflammatory mechanisms play a role in the pathogenesis of the encephalopathy and 
brain edema in ALF (chapter 2.1 - article 1; chapter 2.1 - article 2).  
(2) Activation of cerebral microglia, measured by OX-42, OX-6, predicts the presence 
of severe encephalopathy (coma) and brain edema in rats with ischemic ALF, which 

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accompanies the increased production of brain proinflammatory cytokines (chapter 2.1 - 
article 1; chapter 2.2 - article 2).  
(3) Oxidative/nitrosative stress participates in the pathogenesis of brain edema and its 
complications in experimental ALF animals with ischemic liver failure. The increases in 
cerebral NOS isoform expression caused by ALF were sufficient to cause increased NO 
production in the brain (chapter 2.3 - article 3; chapter 2.4 - article 4).  
(4) Anti-inflammatory treatment, such as hypothermia or antibiotics, may be beneficial 
in patients with ALF (chapter 2.1 - article 1; chapter 2.2 - article 2).  
(5) The beneficial effect of both hypothermia and minocycline on the neurological 
complications of experimental ALF is mediated, at least in part, by reduction of brain-
derived oxidative/nitrosative stress (chapter 2.3 - article 3; chapter 2.4 - article 4). 
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RÉSUMÉ
L’encéphalopathie hépatique (EH) se développe chez les patients atteints d’une maladie 
du foie et se caractérise par de nombreuses anomalies neuropsychiatriques. 
L’insuffisance hépatique aiguë (IHA) se caractérise par une perte progressive de l’état 
de conscience, par une augmentation rapide de l’œdème cérébral et une augmentation 
de la pression intracrânienne entraînant une herniation cérébrale et la mort. Plusieurs 
facteurs sont responsables du développement de l’EH mais depuis une centaine 
d’années, l’hyperammonémie qui peut atteindre des concentrations de l’ordre de 
plusieurs millimolaires chez les patients atteints d’IHA aux stades de coma est 
considérée comme un facteur crucial dans la pathogenèse de l’EH.   
La présente thèse comprend 4 articles suggérant l’implication de nouveaux mécanismes 
pathogéniques dans le développement de l’EH et de l’œdème cérébral associés à l’IHA 
et tente d’expliquer l’effet thérapeutique de l’hypothermie et de la minocycline dans la 
prévention de l’EH et de l’œdème cérébral:        
1. L’IHA induite par dévascularisation hépatique chez le rat se caractérise par une 
augmentation de la production de cytokines pro-inflammatoires cérébrales (IL-6, IL-1β, 
TNF-α). Cette observation constitue la première évidence directe que des mécanismes 
neuro-inflammatoires jouent une rôle dans la pathogenèse de l’EH et de l’œdème 
cérébral associés à l’IHA (Chapitre 2.1, articles 1 et 2).  

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2. L’activation de la microglie telle que mesurée par l’expression de marqueurs 
spécifiques (OX42, OX-6) coïncide avec le développement de l’encéphalopathie (stade 
coma) et de l’œdème cérébral et s’accompagne d’une production accrue de cytokines 
pro-inflammatoires cérébrales (Chapitre 2.1, article 1 et 2). 
3. Un stress oxydatif/nitrosatif causé par une augmentation de l’expression de l’oxyde 
nitrique synthétase et une augmentation de la synthèse d’oxyde nitrique cérébral 
participe à la pathogénèse des complications neurologiques de l’IHA (Chapitre 2.3, 
articles 3 et 4).  
4. Des traitements anti-inflammatoires tels que l’hypothermie et la minocycline 
peuvent constituer de nouvelles approches thérapeutiques chez les patients atteints 
d’IHA (Chapitre 2.1, article 1; Chapitre 2.2, article 2). 
5. Les effets bénéfiques de l’hypothermie et de la minocycline sur les complications 
neurologiques de l’IHA expérimentale s’expliquent, en partie, par une diminution du 
stress oxydatif/nitrosatif (Chapitre 2.3, article 3; Chapitre 2.4, article 4).       
Mots Clefs: Insuffisance hépatique aiguë, encéphalopathie hépatique 
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CHAPTER 1 
REVIEW OF THE LITERATURE 
2 
1. Introduction 
HE is defined as: “a spectrum of neuropsychiatric abnormalities seen in patients with 
liver dysfunction after exclusion of other known brain diseases”, a consensus reached in 
1998 [1]. 
1.1 Classification and grading of HE 
1.1.1 Type A, B and C  
Three types of HE should be recognized on principle: 
Type A - encephalopathy associated with ALF 
Type B - encephalopathy associated with portal-systemic bypass and no intrinsic 
hepatocellular disease 
Type C - encephalopathy associated with cirrhosis and portal hypertension 
Type A and type C HE are seen in patients with acute and chronic liver failure, 
respectively. Type C HE is also referred to as portal systemic encephalopathy (PSE). 
Unlike type A and C, type B HE is a very rare disease, resulting from the portal-
systemic bypass rather than a disease primarily involving the liver itself. In more 
complex clinical cases, especially those involving type B and C, HE can be further 
3 
classified into groups of episodic (recurrent), persistent, and minimal based on duration 
and characteristics of the clinical symptoms:   
(1) In episodic (recurrent) HE, neurological symptoms are seen in an episodic and 
recurrent fashion in cirrhotic patients, which could be independent of the presence of 
precipitating factor(s).  
(2) In persistent HE, neurological symptoms persist even after the removal of 
precipitants. It also includes treatment-dependent HE, in which discontinuation 
of the medication leads to persistent neurologic symptoms.  
(3) Minimal encephalopathy, previously named “subclinical encephalopathy” is found 
in approximately 70% of patients suffering from liver disease and characterized by mild 
cognitive impairment [2]. Although minimal encephalopathy can be detected only by 
using specialized neurological tests, this type of HE increases the chances of patients 
getting involved in traffic accidents [3].   
    
Regarding ALF, it is further classified, according to the interval between the onset of 
symptoms (such as jaundice) and the development of encephalopathy [4]. 
4 
  
1 .1 .2  Cl in i ca l  staging  
The West Haven Criteria is the most widely used criteria for grading HE [1, 5]. 
Although originally developed for clinical classification of cirrhotic patients, it can also 
be used to classify ALF patients. In both cirrhotic patients [6] and ALF patients [7], the 
grading of HE could be useful information in predicting the mortality rate and deciding 
the need for liver transplantation.  
Table 2: West Haven Criteria for grading mental state in HE [5] 
============================================================== 
Grade 0 - No psychometric and/or neurophysiological abnormality can be detected.  
Grade 1 - trivial lack of awareness; shortened attention span; euphoria or anxiety; 
irritability; psychomotor slowing, impaired performance of addition and subtraction; 
reversal of sleep rhythm; slight disturbances of mood and personality, untidiness 
Grade 2 - drowsiness, lethargy, apathy; intermittent disorientation, disorientation for 
5 
time or place; major mental disabilities; obvious personality change; inappropriate 
behavior  
  
Grade 3 - somnolence to semi-stupor, but responsive to stimuli; pronounced confusion; 
persistent disorientation, gross disorientation, incoherent speech with perseveration, 
unable to perform mental tasks  
Grade 4 - coma, with (IVa) or without (IVb) response to painful stimuli, unresponsive 
to verbal stimuli, mental state not testable. 
============================================================== 
  
Glasgow coma scale (GCS) was initially designed for neurotrauma patients [8, 9], 
which provides better grading than the West Haven Criteria when HE patients reach 
its grade 3 or 4 [10]. Patients are evaluated for eye, verbal and motor capabilities in 
the GCS. It ranges from 3 (the worst, deep coma) to 15 (the best, awake person) 
points. GCS score of equal or over 13 is considered as minor cerebral injury. GCS 
score of 9 to 12 indicates a moderate cerebral injury. GCS score of equal to or less 
than 8 suggests severe cerebral injury (= coma). 
1.2 Epidemiology and etiology of ALF 
ALF is a rare disease. Only approximately 2000 ALF cases per year are reported in 
the US [11]. The causes of ALF play a significant role in the survival rate and the 
6 
need for liver transplant, in which the survival rate is 25% in idiosyncratic drug 
reaction and 68% in acetaminophen overdose, whereas the percentage of ALF 
patients receiving liver transplantation was 53% in idiosyncratic drug reaction, and 
6% in acetaminophen overdose.  
10% of all liver transplantations in the US are performed to treat ALF, in the Far 
East, approximately 66% of all transplantations are performed to treat ALF and 
acute-on-chronic liver failure. The most common causes of ALF are drug-
intoxications in the western world, however, in the Far East, ALF due to chronic 
HBV is the most common cause, such as in Hong Kong, which accounts for 79% 
of cases, whereas ALF due to hepatitis E and hepatitis B infection accounts for 
38% and 31% respectively in India [12]. Chronic Hepatitis B infection may flare 
up following a super-infection by other viruses, or after cytotoxic or 
immunosuppressant therapy [13]. Although HCV infection is a common (>50%) 
cause of hepatitis virus infection in China [14], it is generally not considered to 
result in ALF alone. In total, only 0.2%-4% of all patients infected with hepatitis 
viruses eventually develope ALF [11, 14].  
  
2. Neuropathology of HE type A 
As early as the 1970s, Ware [15] and Williams [16] reported that brain edema is a 
unique feature of ALF, and recognized that brain herniation is the cause of death in ALF 
patients after studying autopsied brain samples from ALF patients. Later studies revealed 
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that the classic neuropathologic feature of ALF is cytotoxic brain edema, demonstrated 
by the swelling of astrocytes and their processes [17, 18]. Likewise, astrocyte 
swelling has been consistently reported in various animal models of ALF at 
coma stages [18-23]. Astrocyte swelling is more obvious in foot processes than 
in cell bodies [18, 19]. Swollen astrocytes and brain edema are more prominent in 
cortical gray matter than in subcortical white matter [18, 19]. In contrast to the 
change of astrocytes, no neuronal morphologic alteration was found in the brain of ALF 
[20, 21]. 
Astrocyte swelling and cerebral edema could be severe enough to increase intracranial 
pressure (ICP), which leads to brain herniation - the major cause of death in ALF [24, 
25]. The incidence of brain herniation is positively correlated with elevated arterial 
ammonia levels in ALF patients [26]. In recent studies, evidence of cerebral edema 
is provided by diffusion-weighted MRI [27] and CT scanning [28] methods in ALF 
patients with deep encephalopathy.    
3. Pathogenesis of HE type A 
Initial attempts to investigate the pathogenesis of HE with ALF assumed that the 
neurologic impairment was induced by blood-borne toxins, not cleared by the failing 
liver. From the 1960s to the 1980s, theories of synergistic toxins [29] (ammonia, 
mercaptans, phenols, short-chain fatty acids, octanoic acid), GABA alterations and 
energy failure have been proposed and extensively studied. Brain edema was viewed 
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as a distinct feature of ALF from the 1970s [30], which has been since treated as an 
important pathophysiologic end point in experimental studies [31]. Although the major 
causative factors (such as: ammonia) leading to HE have been recognized, their 
precise mechanisms are incomplete or elusive and other new factors are 
continually being discovered.   
3.1 Ammonia: a gut-derived toxin 
3.1.1 The crucial role of ammonia in the pathogenesis of HE  
Ammonia is the most critical factor in the pathogenesis of HE. Ammonia levels increase 
in the cerebrospinal fluid (CSF) and the blood in HE patients [32]. In one study, the 
influx of ammonia into the brain was 45-fold higher in experimental ALF animals than 
those of controls [33]. Further evidence that supports the role of ammonia in the 
development of HE includes: (1) Administration of ammoniagenic substances to 
cirrhotic patients quickly induces HE symptoms [34]. (2) Hyperammonemia induces 
HE-like symptoms in subjects with healthy livers (such as: in urea-cycle defect [35, 
36]). (3) Blood ammonia levels correlate well with the occurrence of cerebral edema, 
increased ICP and cerebral herniation in ALF [26, 37, 38]. (4) Treatments which reduce 
blood ammonia, such as lactulose, antibiotics, L-ornithine-L-aspartate (LOLA), 
hypothermia, improve HE [5, 32, 39, 40].                                                         
3.1.2 Biochemical features of ammonia 
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Ammonia, depending on pH, can be present as an ion (NH4
+)  that cannot pass the 
membranes unless bound to carriers [41, 42], or appears as lipophilic gas (NH3) which 
can freely travel across membranes. Ammonia is involved in many enzymatic reactions, 
but could also be produced as a by-product of other reactions. 
Ammonia (NH3) remains in equilibrium with the ammonium ion (NH4
+
) in aqueous 
solutions  (NH3 + H
+ ↔ NH4
+) [41, 42]. The ratio of NH3 to NH4
+ is influenced by pH 
as described by the Henderson-Hasselbach equation ( ). Thus, 
under normal physiological conditions of pH 7.4, over 98% of ammonia is present as 
NH4
+
, because the pKa of ammonia is 9.15 at 37
o
C [43]. “Ammonia” in this thesis 
refers to total ammonia (NH3 + NH4
+
) levels. 
Although a large amount of ammonia produced after  the digestion of a protein diet 
enters the portal vein, the liver removes most of the gut-derived ammonia and maintains 
arterial ammonia concentration at a low level (~50µM) [44-46]. Liver dysfunction 
results in increased circulating ammonia levels in HE. Inter-organ trafficking of 
ammonia in normal physiological condition versus ALF is shown in Figure 1. 
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Figure 1: Interorgan trafficking of ammonia during normal conditions and ALF. In 
normal conditions, ammonia produced by the gut is removed by the liver as urea or 
glutamine. Urea is excreted into urine. Hence, arterial ammonia concentration is tightly 
controlled. In ALF, liver substantially decreases the capacity to detoxify ammonia. 
The elevated arterial ammonia leads to increased ammonia in muscle and brain, which 
lack a complete urea cycle and rely on glutamine synthesis. Glutamine is thus 
increasingly released from muscle and brain into blood in ALF. Quantitatively, muscle 
becomes the major ammonia detoxifying organ in ALF. Kidney shifts from mainly 
ammonia-releasing into blood (in normal condition) to mostly ammonia excretion into 
urine in ALF, but this way of ammonia excretion by kidney is insufficient to remove 
total blood ammonia. With consistent ammonia production from gut and limited 
capacity for muscle to extract ammonia, blood ammonia levels rise in ALF. 
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3.1.3 Blood ammonia concentrations 
The arterial ammonia level in normal individuals is approximately 50µM [44]. It 
increases to approximately 165µM in ALF patients [26, 44] and rises to 400µM in ALF 
patients in deep coma with uncontrolled high ICP [26, 39]. In ALF animals, blood 
ammonia may increase to 1mM, which is 15-20 times higher than those of controls [47, 
48]. 
As an ammonia detoxification product, blood glutamine can increase from 600µM in 
healthy individuals to 2500µM in ALF patients [44]. In ALF animals, blood glutamine 
levels could increase 5 times as high as those of the control [33]. 
3.1.4 Brain ammonia uptake and concentrations 
Ammonia free base (NH3) moves across cell membranes more easily than NH4
+
. As the 
NH4
+
 to NH3 conversion rate (4.3×10
10
 M
−1
 s
−1
) is so rapid [42], it has been calculated 
that 75% of ammonia enters the brain as NH3 and 25% as NH4
+
. There is a strong 
correlation (r = 0.80) between arterial ammonia concentration and cerebral ammonia 
extraction (arteriovenous difference) in ALF patients [26, 49]. However, it has been 
observed that the rate of ammonia uptake by the brain does not correlate well with 
arterial ammonia concentration over a wide range [50], which indicates the involvement 
of other factors rather than blood ammonia concentrations alone.  
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Based on large clinical and experimental observations, a theory of pH-dependent 
cerebral ammonia uptake has been proposed. According to the Henderson-Hasselbach 
equation, assuming that the pH of blood is 7.4 and cerebral pH is 7.1 [42], the normal 
ratio of brain to blood ammonia is 2, which is consistent with that found in normal 
animals of a ratio 1.5 to 3 (~0.1mM NH3 in the brain). In ischemic ALF, CSF pH 
continually decreases when HE worsens, and can reach to as low as 6.8 as the animal 
enters coma stage. The decrease in CSF pH is considered due to an increase in cerebral 
lactate concentration (see “energy metabolism” section for details). Accordingly, the 
brain to blood ammonia ratio increases in ALF, and could rise to as high as 8 in 
hyperammonemic conditions [51]. In practice, cerebral ammonia levels of 1-5mM have 
been described in various ALF animal models at their comatose stage [31, 52-55]. A 
similar increase of cerebral ammonia concentration has been observed in ALF patients 
[26].   
3.1.5 Brain ammonia metabolism  
Due to the lack of carbamoyl-phosphate synthase I and ornithine transcarbamylase, 
brain cannot remove ammonia with the formation of urea. The predominant way for 
brain ammonia removal in both normal and hyperammonemic conditions is by the 
conversion of ammonia and glutamate into glutamine via glutamine synthetase (GS) 
[56]. Glutamine then can be either stored in the brain or secreted into the blood [42, 57-
59]. In ALF rats, 66% of cerebral extracted ammonia is metabolized, probably into 
glutamine, 33% of this is stored in cerebral ammonia pools [33]. Consequently, cerebral 
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glutamine concentrations are elevated 2 to 5 times in HE animals as well as in HE 
patients [60-66]. Evidence of the exclusive localization of GS in astrocytes [67, 68] 
indicates that astrocytes are important cells responsible for ammonia detoxification. 
On the other hand, several mechanisms have been proposed to explain the incomplete 
cerebral ammonia removal in brain in ALF: (1) Unlike skeletal muscle, GS expression 
in the brain is not significantly altered in hyperammonic conditions [69, 70], (2) 
Cerebral GS activity is fully functioning during normal physiological situations [42], 
and is not significantly increased further in hyperammonia states. 
3.1.6 Ammonia metabolism in muscle during liver failure  
Increased muscle ammonia uptake has been reported in ALF patients [71]. A net 
ammonia consumption by muscle (100 nmo1/100g/min) has been reported in ALF 
patients [44], which correlates with muscle glutamine production. So far, ammonia 
uptake by the muscle has been mostly reported in subjects with decompensated ALF. 
Muscle wasting decreased the rate of ammonia extraction in liver failure patients [71, 
72], which indicates an important role of muscle in ammonia-detoxification. 
Whether muscle glutamine release is stoichiometrically related to muscle ammonia 
uptake is a controversial issue. Using various animals, increased muscle ammonia 
uptake has been observed in ammonia-infused animals [73], concomitant with either 
increased muscle glutamine production [74] or no alteration [75]. In a human study, 
14 
muscle glutamine production was 10 times greater in proportion to the amount of 
muscle ammonia uptake, which indicates a catabolic state in ALF [44].   
In conclusion, muscle plays an important role in ammonia removal in decompensated 
ALF due to the muscle’s large organ mass.  
3.1.7 Hyperammonia-induced brain edema and astrocyte swelling, in type A HE 
Increased arterial ammonia levels in ALF patients are associated with higher 
incidence of brain herniation and increased ICP [26]. The close association 
between high cerebral ammonia (1-5mM) and the development of cerebral edema 
was also observed in ALF animals [31]. Treatment of cerebral cortical slices with 
relevant levels of ammonia seen in comatose animals results in swelling and 
reduction of inulin space [76]. Significant astrocyte swelling was also 
demonstrated in ammonia-administrated primates [77] and ammonia-treated 
cultured astrocytes [78]. 
3.1.8 Glutamine hypothesis in association with hyperammonia-induced cerebral 
edema and HE 
  
It is generally accepted that ammonia is the most important causative factor leading to 
HE [79]. The level of hyperammonia has been found strongly associated with cerebral 
function [66, 80], clinical stages [81]. However, a direct cause-effect relationship 
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between ammonia and HE has been questioned by a few researchers [81-84]. A lack of 
good correlation between cerebral ammonia and HE grade has been described in clinical 
studies [42]. In addition, administration of a GS inhibitor to ALF animals prevents the 
development of cerebral edema and high ICP, but with an unexplained further increase 
in blood and cerebral ammonia [85-87].  Therefore, h yp er ammonia has been viewed as 
necessary and sufficient to induce cerebral  edema in ALF, but the harmful effects 
of hyperammonia were attributed to ammonia’s cerebral metabolites rather than by 
ammonia itself [88]. As an ammonia metabolite, glutamine is proposed as a candidate 
responsible for the development of cerebral edema and HE in ALF.  
The evidence of a harmful role of glutamine in ALF is largely provided by studies using 
the GS inhibitor: methionine sulfoximine (MSO), which decreases cerebral glutamine 
levels [89]. Giving MSO to hyperammonia-exposed animals reduced their death rate 
[89], ameliorates cerebral edema [85, 86], high ICP [85], astrocyte swelling [90-92] and 
high CBF [93], restores cerebral vascular autoregulation [94, 95] and brain glucose 
metabolism [88, 96, 97], attenuates reactive oxygen species (ROS) production [98, 99] 
and high mitochondrial permeability transition (MPT) [100, 101]. In addition, cerebral 
glutamine levels correlate better than ammonia with clinical HE grade and cerebral 
edema in ALF patients [102, 103] and ALF animals [85, 104, 105].   
3.1.8.1 Two glutamine-based hypotheses to explain astrocyte swelling in HE 
3.1.8.1.1 Glutamine-osmolyte-edema hypothesis  
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As the brain lacks a complete urea-cycle, cerebral ammonia detoxification mainly 
depends on glutamine formation [42, 70]. The responsible enzyme GS is exclusively 
localized in astrocytes [67]. Glutamine is an osmolyte [106] and its accumulation in 
astrocytes moves water from the extracellular space into intracellular space [107-109], 
which could lead to astrocyte swelling and cytotoxic brain edema in ALF.   
3.1.8.1.2 Evidence in favour of the ‘‘glutamine-osmolyte-edema hypothesis’’ 
In support of ‘‘glutamine-osmolyte-edema hypothesis’’, a several-fold increase of 
cerebral glutamine has been observed in ALF patients [110, 111]. In animal studies, the 
association between cerebral glutamine accumulation and cerebral edema has been 
demonstrated in hepatectomized ALF animals [112], ischemic ALF animals [31, 47, 60, 
113-115], toxin-induced ALF [105], and hyperammonia-induced HE [57, 58, 85, 116-
118]. Using NMR, a 10 fold increase of 
13
C-labelled glutamine synthesis from glucose 
in the brain, via the anaplerotic pathway, was observed in ischemic ALF animals [114, 
115]. Furthermore, MSO treatment reduced cerebral glutamine and, at the same time, 
attenuated cerebral edema, high ICP and CBF in ALF animals [85, 86, 93, 96, 119, 
120].     
3.1.8.1.3 Evidence against the ‘‘glutamine-osmolyte-edema hypothesis’’  
Evidence weakening the ‘‘glutamine-osmolyte-edema hypothesis’’ has been presented 
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in the literature [25, 114, 115, 121-124]. Using advanced [
1
H-
13
C] NMR in ischemic 
ALF animals, the concentration of cerebral glutamine showed no correlation with brain 
edema [115, 124]. In addition, the improvement of brain edema by hypothermia [114, 
121] and indomethacin [24] was not associated with the prevention of cerebral 
glutamine accumulation.    
3.1.8.1.4 Glutamine-RNOS-edema hypothesis 
An advanced “glutamine-RNOS-edema hypothesis” was developed recently, in order to 
explain the imperfect correlation between glutamine and brain edema in HE, and to 
amend the theory which concerns the role of glutamine in the pathogenesis of HE. In 
this hypothesis, glutamine is considered as an ammonia carrier. Glutamine moves into 
astrocytic mitochondria through a histidine-sensitive glutamine transporter [125], which 
is subsequently hydrolyzed by phosphate-activated glutaminase (PAG) (an inner 
mitochondrial enzyme) [126], and split into glutamate and ammonia [127, 128]. The 
production and accumulation of ammonia in the astrocytic mitochondria lead to 
increased MPT, ROS production, which impairs mitochondrial function, consequently 
resulting in cell swelling. 
3.1.8.1.5 In vitro evidence supporting this “glutamine-RNOS-edema hypothesis” 
3.1.8.1.5.1 Glutamine induce MPT and ROS, which subsequently contribute to 
astrocyte swelling 
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Addition of glutamine to cultured astrocytes induces the opening of MPT [129] and the 
production of free radicals [130], which are not observed in cultured neurons. Increased 
ROS has been shown to lead to cell swelling in cultured astrocytes [131-136] and brain 
slices [131, 137, 138], and to induce MPT opening, which results in further free radicals 
generation [139-141]. In the similar experimental setting, the MPT opening-associated 
astrocyte swelling [100] can be prevented by the treatment with a MPT blocker: 
cyclosporine [142].   
3.1.8.1.5.2 PAG and histidine-sensitive glutamine transporters are required for 
glutamine-induced MPT, ROS and astrocyte swelling  
Administration of 6-diazo-5-oxo-L-norleucine (DON), a PAG inhibitor, to ammonia-
exposed cultured astrocytes significantly attenuate ROS generation, MPT opening [130, 
143] and astrocyte swelling [144]. In addition, treatment with histidine, a blocker of 
glutamine-mitochondria-transporter [125], attenuates ROS production, MPT opening 
and astrocyte swelling in ammonia-exposed cultured astrocytes [145]. 
   
3.1.8.1.5.3 Realization and limitation of in vitro findings 
The presence of PAG has been demonstrated in both cultured astrocytes [146-148] and 
animal cerebral samples using molecular bio-techniques [149-151], which indicates the 
likelihood to transfer in vitro finding to interpret results obtained from animal 
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experiments. However, currently, almost all evidence in support of “glutamine-RNOS-
edema hypothesis” are obtained from in vitro experimental settings [31, 152, 153], 
which rises caution for the over-interpretation of in vitro findings.   
3.2. Brain energy metabolism in ALF  
In general, no evidence of loss of ATP has been demonstrated in clinical ALF. 
However, altered cerebral glucose metabolism has been clearly shown.   
3.2.1 Evidences of changed glucose metabolism in ALF  
Elevated cerebral and CSF lactate has been consistently described in various ALF 
animal models [31, 47, 112, 113, 115, 154-156], and in ALF patients [157-159]. H-/C-
/P-NMR studies confirm the increased de novo synthesis of cerebral lactate from 
glucose in ALF animals [114, 115, 155]. The increased cerebral lactate level is 
positively correlated with the worsening of HE in ALF [47, 154, 156, 160-163]. 
Moreover, increased cerebral alanine has been demonstrated in hyperammonemic 
animals using biochemical methods [31, 47, 61, 164] or NMR [114]. Both of the 
increases in cerebral lactate and alanine indicate impaired cerebral pyruvate oxidation 
in ALF. (In addition, increased alanine could result from ammonia incorporation into 
glutamate by alanine aminotransferase.) As expressed, brain high-energy phosphates 
(phosphocreatine and ATP) were unaltered in ALF animals measured by biochemical 
approach [47, 112] or 
1
H-/
31
P-NMR [47, 112, 154, 155, 165].  
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3.2.2 Hypothesis for altered cerebral glucose metabolism in ALF 
The most popular hypothesis is that hyperammonia inhibits a-ketoglutarate dehy-
drogenase (aKGDH) which impairs the TCA cycle and compromises energy 
metabolism, resulting in increased cerebral lactate accumulation in ALF [166] (Figure 
2). As early as 1961, the accumulation of -ketoglutarate and pyruvate was found in 
ammonia-intoxicated brains [167]. Nearly twenty years later, hyperammonia exposure 
was demonstrated to inhibit KGDH in brain preparations [168, 169]. Years later, with 
advanced techniques (such as NMR), the inhibition of aKGDH by ammonia was 
confirmed to be severe enough to directly cause cerebral lactate accumulation in ALF 
[157], even with adequate oxygen supply. 
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Figure 2. Glucose metabolic pathway. The mitochondria is separated from the outside 
cytosol. Glu, glutamate; Gln, glutamine; -KG, alpha-ketoglutarate; Asp: aspartate. 
3.2.3 Two direct consequences of aKGDH inhibition by ammonia  
As increased cerebral ammonia in ALF [26, 170, 171] inhibits aKGDH [168], two 
important alterations result: 1) stimulates aKG-glutamate-glutamine metabolic pathway, 
2) reduced energy (ATP) production.   
In support of the first change, increased cerebral aKG has been demonstrated in 
ammonia-infused animals [172-174], and in HE patients [175, 176]. In turn, high aKG 
induces glutamate production by glutamate dehydrogenase (GDH) in both astrocytes 
and neurons (the NH-group is derived from amino acids and not from free ammonia in 
this step). Subsequently, glutamate incorporates free ammonia to generate glutamine by 
GS in astrocytes, which is important for ammonia detoxification in the brain [177, 178]. 
Both the inhibition of aKGDH by ammonia and the increased glutamine synthesis by 
ammonia redirects the TCA cycle and stimulates the aKG-glutamate-glutamine 
metabolic pathway. When using NMR, increased PC metabolic flux, in association with 
increased glutamine de novo synthesis, has been demonstrated in the brain of 
hyperammonemic animals [179-181],  ischemic ALF animals [114, 115], and ammonia-
exposed cultured astrocytes [182, 183]. 
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In viewing the second change, as the TCA cycle is responsible for energy (ATP) 
production, inhibited aKGDH results in impaired energy production in association with 
increased PC flux and decreased pyruvate dehydrogenase (PDH) flux, in ALF.  
In normal subjects, astrocytes account for ~5% of glucose-derived ATP production in 
the brain, and neurons account for ~95% of glucose-derived ATP production in the 
brain [184, 185]. Obviously, neurons contribute much more than astrocytes for energy 
production in the brain. Based on this knowledge, decreased PDH flux more closely 
reflects decreased ATP production in neurons or in the whole brain, and increased PC 
flux reflects increased “loss of glucose for ATP production in astrocytes”. PDH flux is 
significantly decreased in the brain of coma stage HE animals [114, 115], which 
indicates an impaired neuronal energy supply at the late/severe condition of HE. 
Ammonia-inhibited aKGDH as well as ammonia-inhibited PDH activity [115] may 
account for reduced PDH flux. On the other hand, the “loss of glucose for ATP 
production in astrocytes” is evident by an increase of astrocytic glucose utilization for 
PC flux from 30% in normal conditions [186] to 80%  in hyperammonia situations [115, 
181, 183, 187]. These findings of alterd PDH and PC flux support the view of a 
potentially impaired energy (ATP) generation in brain in hyperammonemic HE, which 
is more substantial at coma stage HE.   
3.2.4 Increased glucose utilization and lactate accumulation in ALF  
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Increased glucose utilization has been demonstrated in hyperammonic conditions, 
which is believed to be a compensatory response to impending decreased ATP 
production (blocked glucose metabolic flux) due to ammonia-induced aKGDH 
inhibition. In support of this notion, increased cerebral glucose metabolism has been 
described in ammonia-adminstrated animals [188-191], which may attribute to 
increased endothelial/astrocytic glucose transporter GLUT-1 [192, 193], or increased 
cerebral phosphofructokinase activity [194-196] under hyperammonia stimulation. All 
these alterations will at least increase the production of NADH and ATP in cytosol.   
Increased cerebral lactate accumulation in ALF, which reflects a decreased cerebral 
pyruvate oxidation, is believed to be another consequence of ammonia-induced aKGDH 
inhibition. Increased cerebral lactate has been consistently described in various animal 
models of ALF [31, 112, 113, 115, 154-156, 197-200], as well as in ALF patients [157-
159], which correlates well with the worsening of HE and cerebral edema in ALF [114, 
154, 163, 197]. In ALF, the cerebral oxygen supply/delivery only slightly decreased in 
early course, whereas it increased in the late advanced stages of ALF [39, 157, 201], a 
phenomenon that parallels the increase of cerebral blood flow (CBF). On the other 
hand, cerebral oxygen consumption is decreased [39, 157, 201, 202]. When comparing 
results from comatose [39] to early stage [202] ALF patients, cerebral glucose 
consumption increased 3 times, whereas cerebral oxygen consumption decreased 5.2 
times. Therefore, hypoxia could not be used to explain cerebral lactate accumulation in 
ALF, which is more likely due to aKGDH inhibition by hyperammonia.   
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3.3 Astrocyte metabolism and function in ALF 
Astrocytes account for one third of the brain volume, which keeps the homeostasis of 
extracellular environment for normal neuronal function. Evidence of altered astrocytic 
function is substantial in HE. In relating to its ammonia detoxification [67], astrocytic 
neuropathologic changes are the features of ALF [17, 203], with altered astrocytic 
protein function [67, 203-206].  
GFAP is an astrocytic intermediate filament protein [207]. Decreased GFAP expression 
has been demonstrated in the brain of ischemic ALF animals [208] and ammonia-
treated cultured astrocytes [208, 209]. The reduction of GFAP is selective, whereas 
another astrocytic filament protein S-100 is unaltered in these conditions. A decrease 
in GFAP may compromise visco-elastic function and facilitate the astrocyte swelling.  
GS is a cytoplasmic enzyme, largely localized in cerebral astrocytes, which functions to 
detoxify ammonia in the brain. In hyperammoneamic conditions, increased cerebral 
glutamine is observed [63, 65, 210]. However, cerebral GS expression and activity is 
unaltered or decreased [55, 70, 211-213]. 
Decreased glycine transporter (GLYT1) expression (an astrocytic glycine 
transporter) has been observed in the brain of ischemic ALF animals [214] and 
ammonia-stimulated cultured-astrocytes. Accordingly, increased cerebral 
extracellular glycine is demonstrated in ALF animals at coma stage [113]. Glycine 
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could function as a positive allosteric modulator of the NMDA receptor, with 
the potential to lead to increased glutamatergic neurotransmission in HE. 
The “Peripheral-type” benzodiazepine receptor (PTBR) is localized on the outer 
mitochondrial membrane of glia and neurons. PTBR consists of three subunits: 1) 
18 kDa isoquinoline binding protein (IBP), 2) 34 kDa voltage-dependent anion channel 
(VDAC), 3) 30 kDa adenine nucleotide carrier (ANC) [215]. Increased IBP mRNA or 
protein expression have been described in the brain from deceased HE patients [216], 
and ischemic ALF rats [217]. In addition, increased PTBR ligand PK11195 binding has 
been demonstrated in autopsied brain samples from HE patients [218], in the brains of 
animals with thioacetamide (TAA)-induced ALF [219] and ischemic ALF animals [220]. 
The observed increase of PTBR (PK11195) binding correlates with clinical severity of 
HE [66, 218, 221, 222]. Evidence in support of the notion that hyperammonia 
upregulates PTBR was provided by increased IBP expression or PK11195 binding in 
the brain from ALF patients and animals (see above), as well as in the brain of 
ammonia-injected animals [219], in the brains of animals with congenital urea cycle 
deficit [223], and in ammonia-exposed cultured astrocytes [224].   
GLUT-1 is one of the cerebral glucose transporters, expressed in astrocytes and 
endothelial cells, responsible for the uptake of glucose into the brain. Increased cerebral 
GLUT-1 expression has been observed in experimental ALF [192], which correlates the 
increasing cerebral lactate accumulation and cerebral edema [115]. On the other hand, 
the neuronal glucose transporter (GLUT-3) is unaltered in the brain in ALF. Increased 
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GLUT1 expression is considered as a compensatory regulation associated with 
increased glycolysis due to inhibited cerebral TCA by ammonia in ALF. Elevated 
GLUT1 expression may also contribute to increased inward movement of water into the 
glial cerebrovascular endothelial cells in ALF [225].   
Altered cerebral aquaporin IV expression (astrocytic water channel protein) has been 
observed in experimental ALF [226-228]. Aquaporin IV has been shown to facilitate 
cell swelling in in vivo [229] and in vitro [142] experiments. The down-regulation of 
cerebral aquaporin IV in ischemic ALF animals may reflect its compensatory 
adjustment (unpublished data).   
3.4 Synaptic transmission (electrophysiology)  
Suppression of cerebral excitatory synaptic transmissions by ammonia has been 
demonstrated both in in vivo [230, 231] and in vitro [232-235] experimental settings. 
Presynaptically, ammonia may decrease glutamate release from nerve terminals by (1) 
either reducing its synthesis from glutamine [236] or by (2) blocking the transmission of 
the action potential to nerve terminal [231]. Postsynaptically, ammonia may (3) impair 
the interaction between glutamate and glutamate receptors [234]. The suppression of the 
inhibitory postsynaptic potential (IPSP) by ammonia has been evident in in vitro [237, 
238]  and in vivo [239, 240] experiments. Its mechanism involves the inhibition of Cl
-
extrusion from neurons by ammonia [239, 240], which subsequently prohibits the 
opening of Cl
-
 channels by the inhibitory neurotransmitter (for example, GABA).   
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3.5 Changes in cerebral neurotransmission 
Alteration of various neurotransmitter systems have been proposed to induce neurologic 
dysfunction in HE [241], which includes impaired synaptic transmission (discussed 
above), alteration of the glutamate system, serotonin system, and norepinephrine 
system.   
3.5.1 Glutamate system in ALF 
3.5.1.1 Intracellular brain glutamate (whole brain glutamate) 
Decreased cerebral glutamate levels have been demonstrated in ammonia-injected rats 
[105, 242], ischemic ALF animals [31, 52], thioacetamide-injected ALF animals [52, 
156] and hepatectomized animals [243]. Three possible mechanisms are proposed: 1) The 
increased cerebral ammonia, rising from normal 0.05-0.1mM to 1-5mM in ALF [31], 
activates its detoxification reaction to generate glutamine from glutamate, mainly by 
astrocytic GS, which leads to low glutamate and high glutamine in the brain [114, 115, 
187]. 2) Hyperammonia could also reduce glutamate content in cultured neurons [244], 
which may relate to ammonia’s inhibitory effect on PAG [245]. 3) The reduced cerebral 
glutamate partially attributed to reduced de novo synthesis from glucose in neurons [115]. 
As a result, reduced cerebral glutamate results in decreased ammonia removal in 
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astrocytes [211, 246], impaired excitation/inhibition in the nerve terminals [247], and 
altered energy metabolism in multiple cells [248].   
3.5.1.2 Extracellular brain glutamate 
  
The whole brain glutamate concentration (mM) mainly reflects its intracellular levels 
(neuronal intracellular glutamate: ∼10mM; glial intracellular glutamate: ∼50µM). 
Extracellular glutamate are very low (µM) (CSF glutamate: ∼1µM) to give a good signal-
to-noise ratio. An increase of cerebral extracellular glutamate concentrations (∼3µM) has 
been demonstrated in hepatic toxin-induced ALF animals [52, 249, 250], ischemic ALF 
animals [52, 251, 252], ammonia-injected animals [253], and in ALF patients [158]. 
Increased extracellular glutamate in brain parallels the worsening of HE and cerebral edema 
in ALF animals [113, 254] and ALF patients [158].     
A decreased glutamate uptake was proposed as a possible mechanism to explain increased 
cerebral extracellular glutamate accumulation in ALF. Evidence in support of this view is 
provided by brain preparations from thioacetamide-injected animals [255], ammonia-
treated neuronal preparations [256], ammonia-exposed cultured astrocytes [257]. 
Anatomically, astrocytic glutamate transporters EAAT-1 and EAAT-2 are considered 
most responsible for glutamate clearance [258]. Down-regulation of EAAT1 expression 
has been observed in ammonia-exposed cultured astrocytes [259, 260], which 
accompanies decreased L-glutamate [257] or D-aspartate [259, 261] uptake. Decreased 
EAAT2 expression has been described in the brain of ischemic ALF animals [227, 262] 
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and thioacetamide-injected ALF animals [263], which accompanies reduced D-aspartate 
uptake from these animals’ brain preparations [264, 265], and elevated extracellular 
brain glutamate [266]. These findings support the view that ammonia-induced down-
regulation of EAAT1 and EAAT2 are the cause of increased extracellular glutamate in 
brain in ALF. 
In addition, increased glutamate release from cultured astrocytes has been demonstrated in 
ammonia-stimulation [267], hypoosmotic-conditioning [268], or exocytotic activation 
[269, 270], which relates to a pH-mediated, Ca
2+
-dependent mechanism [270, 271]. 
Increased glutamate release gives a second mechanism to explain the increased extracellular 
glutamate level in HE associated with hyperammonia.  
3.5.2 Serotonin system in ALF 
An activation of cerebral serotonin system is evident in ALF. Increased cerebral 5-HT 
or the 5-HT metabolite (5-HIAA) has been described in animals with thioacetamide-
induced ALF and ischemic ALF [272, 273], and in ALF patients [274, 275]. Decreased 
expression of cerebral serotonin transporters was reported in ALF rats [276]. In 
addition, a down-regulation of cerebral serotonin 5-HT2 receptors has been 
demonstrated in thioacetamide-induced ALF [277] and in hyperammonemic animals 
[278], which is considered as a compensatory response. Moreover, administration of a 
nonselective 5-HT antagonist (methysergide) improves locomotive activity in TAA-
induced ALF animals [279].    
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3.5.3 Noradrenaline in ALF 
The neurotransmitter noradrenaline is synthesized from dopamine by dopamine -
hydroxylase. Studies of the noradrenergic systems have been mainly undertaken in 
ALF. (1) Reduced cerebral noradrenaline has been reported in animals with 
hepatectomy [280], ischemic ALF [281], and thioacetamide-induced ALF [272]. (2) An 
increase of cerebral extracellular noradrenaline has been demonstrated in 
hepatectomized animals [282], and in ischemic ALF animals [266], which is considered 
related to the down-regulated cerebral noradrenaline transporter [283]. (3) Decreased 
cerebral noradrenaline α and β receptor binding sites were also described in ALF rats 
[266]. Whether these findings represent a noradrenaline over-stimulation in ALF waits 
further investigation. 
3.6 Osmolytes 
3.6.1 Organic osmolytes in ALF 
Cerebral osmolytes (glutamine, alanine, myo-inositol, taurine) are altered in ALF. The 
consistent findings of several-fold elevated brain glutamine in ALF support the role of 
glutamine in the pathogenesis of astrocyte swelling (which has been described in the 
previous section: glutamine-osmolyte-edema hypothesis). Alanine is another 
recognized organic osmolyte. Increased cerebral alanine has been reported in 
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experimental ALF [31, 115], and the elevation correlates well with the progression 
of HE and brain edema [115]. A special feature of cerebral astrocytes is its capability 
to adapt against cell-swelling by reducing some of the organic osmolytes (myo-inosital 
and taurine) [284, 285]. In the clinical and experimental setting of hyperammonemia, 
increased cerebral glutamine accumulation is often associated with a slight decrease of 
myo-inositol [182, 286]. The reduced myo-inosital is believed to exert a compensatory 
role in the brain of ALF in maintaining an osmotic homeostasis. In addition, a reduction 
of taurine (another astrocytic intracellular osmolyte) was also observed in both in vitro 
[287] and in vivo [124, 288, 289] experimental setting of hyperammonia, which 
indicates a volume regulatory role of taurine.  
  
3.6.2 Inorganic osmolytes in ALF 
Sodium is a very important inorganic osmolyte in the body. The incidence of 
hyponatremia is approximately 25-33% in ALF patients with severe HE [37, 290, 
291]. Clinically, acute hyponatremia can induce brain edema directly [292]. In one 
experimental study, hyponatremia significantly exacerbated ammonia-induced 
cerebral edema in rats [293].   
3.7. The role of inflammation in the pathogenesis of HE and brain edema in ALF 
The role of infection and inflammation in the development of ALF has been recently 
proposed and the mediators of infection and inflammation might have a synergistic 
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effect with ammonia, which will exacerbate and accelerate the pathophysiologic 
change of ALF [294, 295]. In fact, infection and inflammation are common features in 
ALF’s natural history. Infection is documented in at least 80% of ALF patients [296], 
which leads to a rise of proinflammatory cytokines (TNF-, IL-6 and IL-1)  in the 
blood [297-300]. Besides coexisting infection, ALF itself is an inflammatory state, in 
which increased pro-inflammatory cytokine levels are observed [298, 301, 302], most 
obvious in patients with elevated ICP. The production of systematic pro-
inflammatory cytokines might be attributed to stimulation of the immune system by 
infection or mediators released from necrotic liver, or a direct release of cytokines 
from the necrotic liver.    
In two large clinical studies of ALF, retrospective [303] or prospective [304], the 
appearance of SIRS and/or  infection is correlated with the severity of HE, increased 
ICP and higher mortality rate. The results of these two studies support the view that 
inflammation plays a role in the development of brain edema and HE in ALF [305]. In 
another case report of an ALF patient with uncontrolled high ICP, hepatectomy 
decreased ICP and produced hemodynamic stability [306] associated with a 
reduction of circulating TNF-, IL-6 and IL-1β [306], without alteration in arterial 
ammonia levels. This single case provides evidence that necrotic liver-derived 
systematic proinflammatory cytokines might exacerbate brain edema in ALF [306]. 
In the case of acute-on-chronic liver failure, inflammation and infection may be 
important contributing mechanisms [307]. Similarly, the synergistic effect of 
inflammation on ammonia toxicity has been demonstrated in many chronic liver 
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diseases [295, 308, 309]. Intestinal-derived bacteria passing into lymph nodes and 
further into blood provide a possible pathogenic route [310]. Moderate hypothermia 
effectively controls increased ICP in ALF patients [311]. Although multiple beneficial 
effects have been demonstrated by hypothermia treatment, including reduction of 
arterial ammonia, its capability to decrease pro-inflammatory cytokines in blood is 
also a possible mechanism [311].   
In a pig ALF model induced by hepatotoxin-amatoxin, co-treatment with LPS 
worsens and accelerates the progress of brain edema and HE [312]. The findings from 
this study indicate that both necrotic liver and infection could produce pro-
inflammatory cytokines. Levels of inflammation correlated with the pathogenesis of 
HE and brain edema in ALF. Clinical and experimental evidence supports the concept 
that there is a synergistic effect between hyperammonia and inflammation in the 
pathogenesis of HE and brain edema in ALF.   
3.8 CBF in ALF  
3.8.1 Clinical and experimental observations 
In general, increased CBF is observed in ALF patients with high ICP [157, 313-316]. In 
a clinical study, increased CBF has been shown to precede the development of high 
ICP [317]. An impaired CBF autoregulation has also been described in ALF patients, 
as well as abnormal response to hypercapnia [318] and norepinephrine [319, 320] 
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challenges, which represent a state of vasodilatation. Increased CBF and cerebral 
vasodilatation state, observed in ALF, bring out a concept of “luxury cerebral 
perfusion”. In a rat model of portacaval-shunt followed by ammonia infusion [121], a rise 
of CBF has been observed preceding the development of high ICP and brain herniation 
[93]. In this model, increased CBF is positively correlated with brain edema [25, 321].   
3.8.2. Possible mechanisms to induce increased CBF in ALF 
Evidence linking glutamine to high CBF and loss of cerebrovascular autoregulation is 
provided by MSO treatment. Administration of MSO (a GS inhibitor) to 
hyperammonemic animals prevents the accumulation of glutamine, the increase in CBF 
and development of cerebral edema [93], and restores cerebrovascular auto-regulation 
[94, 322, 323].   
Reactive oxygen and nitrogen species have been shown to mediate cerebral vasodilatation 
from different causes [324]. Increased cerebral nitric oxide (NO) (an important 
vasodilator) has been demonstrated in ammonia-infused rats, accompanying an 
increased CBF [93]. MSO prevents both high CBF and cerebral NO production in these 
rats.       
Heme oxygenase catalyzes the degradation of heme to generate carbon monoxide 
(CO), which is involved in vascular muscle relaxation. Hyperammonia-induced 
upregulation of HO-1 mRNA and protein expression has been demonstrated in the brain 
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of ALF animals [325]. Administration of zinc-protoporphyrin II (a non-selective HO-
1,2,3 inhibitor) to ammonia-infused rats, prevented the occurrence of high CBF and 
brain edema [200, 326].   
Increased SIRS grading and circulating cytokines have been shown in association with 
high CBF and brain edema development in ALF [294, 311]. The use of hepatectomy to 
one ALF patient, which decreases circulating pro-inflammatory cytokines, leads to 
significantly reduced CBF and ICP [306]. Moreover, the addition of LPS to ammonia-
infused rats produced more severe levels of high CBF and ICP than either LPS 
administration or ammonia-intoxication alone [327].   
  
Activation of potassium channels in vascular smooth muscle induces vascular smooth 
muscle relaxation. It has been demonstrated that increased extracellular potassium leads 
to potassium channel opening [328], and cerebral vessel relaxation [329]. Increased 
cerebral extracellular potassium has been reported in ALF patients [320, 330] and in 
ammonia-infused rats [331].   
The involvement of the arachidonic acid pathway in regulating CBF has been 
reported previously [332, 333]. Administration of indomethacin (a COX-2 inhibitor) to 
ammonia-infused rats prohibits the rise of high CBF and cerebral edema in these animals 
[24]. This data indicates the possible involvement of prostaglandins in mediating high 
CBF and ICP in ALF.   
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3.8.3 Mechanisms of increased CBF in producing cerebral edema/high ICP in ALF 
Three potential mechanisms have been proposed to explain the influence of high CBF 
on the generation of cerebral edema and high ICP in ALF [334]: (1) high CBF induces 
high hydrostatic pressure on BBB, which facilitates water movement across the BBB 
into the brain; (2) high CBF enhances the cerebral exposure to blood-born toxic factors 
(such as: ammonia, cytokines), which facilitate detrimental effects directly or via their 
uptake by the brain; (3) high CBF increases cerebral blood volume, which increase ICP 
by itself.  
3.9 Alterations in BBB in ALF  
In ALF, BBB is structurally intact [17, 18, 21]. This view is further confirmed by a 
recent MRI study in ALF patients [27]. However, morphologic changes of 
endothelial cells (an increased vacuolization and pinocytosis) have been observed in 
ALF [17, 18, 20, 335]. In both clinical and experimental HE, BBB-related functional 
disturbances have been observed. An increased expression of GLUT1 (the BBB glu-
cose transporter) was observed in rats with ischemic ALF [193], which presumably 
indicates an enhanced water movement into the brain [336]. Altered expression of other 
cerebral endothelial genes, such as eNOS, occludin, VCAM, AQP4 have also been 
reported in experimental ALF [337]. Although the BBB remains impermeable to large 
molecular weight molecules, increased permeability of the BBB to small molecules 
such as inulin [338], sucrose [338], GABA [339, 340], Trypan blue [22, 341] 
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or horseradish peroxidase [19] has been demonstrated in various experimental 
animal models of ALF.   
  
Elevated circulating ammonia has been hypothesized to trigger functional change 
of permeability, despite an anatomically intact BBB [93, 342, 343]. Inflammation is 
another factor which can cause BBB alterations [295, 327, 344-346].   
3.10 Neuroinflammation in ALF: role of microglia 
Microglia comprise nearly 10% of the cerebral cellular population, which function as 
resident mononuclear phagocytes of the brain [347, 348] and give differential response 
to various stimuli [349]. Microglia share lineage-related phenotypes with bone-marrow-
derived monocytes and macrophages [350]. As macrophages, activated microglia could 
eliminate deleterious debris by phagocytosis and support tissue survival by secreting 
neurotrophic factors at cerebral injury sites. Microglia are considered to be major cell 
types in CNS responsible for cytokine production [351-355]. It has been shown that 
activated microglia can generate various cytotoxic substances in in vitro settings, its 
release has been implicated in the development of several 
neuroinflammatory/neurodegenerative diseases, such as Parkinson’s disease, 
Alzheimer’s disease, AIDS dementia, multiple sclerosis, amyotrophic lateral sclerosis, 
traumatic brain injury [356], stroke [357], and Wernicke’s encephalopathy [358].   
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It has been proposed that activated microglia and related inflammatory responses are 
detrimental to the brain. In in vitro settings, microglia have been demonstrated to be 
able to produce several cytotoxic substances, such as ROS [359, 360], NO, proteases, 
arachidonic-acid derivates, glutamate [361], quinolinic acid [361], TNF-a, IL-1b [362-
366]. These factors influence the CNS cellular system in an autocrine and/or a paracrine 
fashion. For instance, it has been suggested that microglia-generated TNF could induce 
RNOS production from astrocytes [367, 368]. Results of the studies described in this 
thesis will provide the first direct evidence for a role of microglial activation in the 
pathogenesis of the encephalopathy and brain edema in ALF. 
4. Clinical Features of ALF 
ALF is defined as the appearance of HE and acute deterioration of liver function in 
patients without any previous history of liver dysfunction. Encephalopathy is seen in 
almost all cases of ALF [11, 291, 369]. Neuro-psychiatric disturbances in ALF develop 
in sequence from insomnia, lack of concentration, to confusion, disorientation, 
coexisting with agitation and manic behaviour, before developing into stupor and coma. 
Neuro-psychiatric deterioration in ALF can proceed into deep coma rapidly in a few 
hours.  
Using continuous EEG monitoring, subclinical seizures occur in 45% of ALF patients 
with severe HE [370]. Two Indian groups reported a 22-25% frequency of seizure in 
ALF patients [37, 290]. The frequency of seizures is positively associated with arterial 
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ammonia levels [37].    
Brain edema is the most serious complication of ALF, seen in 35-50% of ALF patients 
with grade III HE, 50-80% of ALF patients with grade IV HE [371-373]. Cerebral 
edema can lead to increased ICP, which results in brain herniation and death [374-376]. 
In clinical studies, 42% - 75% of deaths in ALF are attributable to increased ICP [377]. 
Multiple factors have been considered to contribute to the development of brain edema 
[204, 378, 379], of which hyperammonia is most important [26]. 
The cranium has a fixed volume with very little room for adaptation. Three 
compartments define its volume: 80-90% of parenchyma, 10% of intravascular blood 
and 3-5% of CSF. In the parenchyma, extracellular fluid accounts for 10-20% of the 
volume, astrocytes account for 30% of total cells [321]. In ALF, astrocyte swelling 
[380], cerebral vasodilation, and increased CBF collectively contribute to the elevation 
of intracranial hypertension. In ALF, brain edema develops rapidly, which leaves little 
time to compensate resulting in increased ICP.       
  
4.1. Prognosis of ALF 
ALF with stage I and II HE is associated with a spontaneous recovery rate of 70%, 
whereas stage III and IV HE is associated with a < 20% spontaneous liver recovery 
[381]. Survival rate without transplantation is highest in acetaminophen related 
cases (68%) and lowest in cases related to idiosyncratic drug reactions (25%) 
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[382]. The overall survival rates have improved from 20-40% in pre-transplant period 
to more than 60% when liver transplantation technique was developed [37, 382]. 
King’s college criteria are considered most accurate and are widely used [383, 
384] in the prediction of the survival and the need for liver transplantation in ALF 
patients (see details in liver transplantation section).   
5. Treatment of HE type A, in ALF patients  
5.1 Initial practical steps to follow, in ALF patients 
Patient’s head should be kept up at a 20 degree angle to encourage venous outflow and 
decrease in ICP [385]. Cerebral perfusion pressure (CPP = mean arterial pressure – 
ICP) must be kept between 50 to 65 mmHg to avoid cerebral hypoperfusion and 
hyperhemia [386, 387]. Vasopressin and its analogues should be used with extreme 
caution, because they may worsen hyperammonemia and increase ICP by elevating 
CBF [316, 388-390]. Spontaneous hypoglycemia must be corrected. Other factors that 
could increase ICP, which must be monitored and corrected, include hyperthermia [372, 
391, 392], hyperglycemia [392], hyponatremia [293, 393], and hypercapnia [394]. The 
acid/base balance should be monitored closely, since hyperlactatemia can worsen 
cerebral hyperemia [115, 158]. Volume extension (with a mix of cystalloids and 
colloids) is needed for most of the patients. Up to 80% of ALF patients complicated 
with high ICP require extracorporeal renal support [395]. The situation of the patient 
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should be discussed with the liver transplantation unit ASAP to determine candidacy 
for liver transplantation.   
5.2 Treatments aimed at reducing ammonia levels 
   
Recent studies have not demonstrated any beneficial effects of lactulose administration 
in ALF patients [396, 397]. In ischemic ALF animals, LOLA prevents the development 
of brain edema [32], by increasing muscle glutamine synthesis [48, 398], which results 
in a reduction of blood ammonia. 
5.3 Treatment aimed at the decrease of cerebral edema and ICP 
Mannitol is a well accepted classic treatment in controlling increased ICP, whose 
mechanisms relate to an increase of osmolality in cerebral capillaries, which results in 
water extraction from the brain, and water excretion by the kidney. Its beneficial effect 
in controlling high ICP has been clearly demonstrated in ALF patients [399].  
Hypertonic saline (30%) is used as a prophylactic measure to prevent brain 
edema in ALF [400].   
5.4 Treatment aimed at reducing CBF 
Mechanical hyperventilation which induces arterial hypocapnia (PaCO2, 3.5-5 kPa) 
could result in a short-term vasoconstriction and a decrease in CBF [401].  Propofol, a 
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short-acting sedative agent, reduces CBF through metabolic suppression, which 
demonstrates beneficial effects in reducing ICP in ALF patients [402, 403]. 
Indomethacin, a cyclo-oxygenase inhibitor [404], induces cerebral vasoconstriction and 
CBF reduction, which decreases ICP in ALF patients [315, 405], and prevents cerebral 
edema in ALF animals [24]. Thiopental Sodium, an ultra-short acting barbiturate, has 
vasoconstructive effects, and should be used only as a last resort in ALF patients [406].   
5.5 Treatment aimed at neurotransmission systems 
Memantine is a NMDA-R inhibitor, which has been shown to improve neurologic 
symptoms and/or prevent brain edema in experimental animals with toxic or ischemic 
liver failure [407]. Administration of phenytoin, a sodium channel blocker, to ALF 
patients did not result in the improvement of subclinical seizures, brain edema or high 
ICP [290, 370]. Benzodiazepine partial inverse agonists (Rol5-4513 or sarmazenil) 
are mild antagonists of GABA-A receptor [408], which has been shown to 
improve HE symptoms in ALF animals [409, 410], probably attributed to its 
interaction with GABA-agonist neurosteroids [411]. 
5.6 Treatment aimed at reducing systemic inflammation 
Treatment with N-acetylcysteine (NAC) in acetaminophen-induced ALF patients 
significantly enhances their survival rate [412-414], by improving glutathione reserves 
and addition of NAC to standard therapy significantly improves ALF patient survival 
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from non-acetaminophen causes [415, 416]. A relatively old study showed that 
dexamethasone did not improve survival in ALF patients [399]. Several studies showed 
that prophylactic antibiotics decreased infection rate (P < 0.05), but did not change 
mortality in ALF patients [417-419]. For practical purposes, empirical wide-
spectrum antibiotics should be administered to ALF patients with progressive HE. 
Hepatectomy, which decreases systemic inflammation, is only recommended in ALF 
patient on the transplant wait list as a last approach, when all other treatments fail [306, 
420, 421]. 
5.7 Mild Hypothermia: a treatment involving multiple mechanisms 
The beneficial effects of mild hypothermia (32-35°C) in the control of high ICP in 
ALF patients have been demonstrated in clinical studies [39, 311, 314, 377, 422, 423]. 
Mild hypothermia effects multiple mechanisms in ALF, which include: (1) decreased  
cerebral and arterial ammonia levels [39, 311, 424-427], (2) prevent cerebral osmolyte 
accumulation  [114, 124], (3) prevent extracellular glutamate and lactate accumulation 
in the brain [197, 254, 428], (4) restore cerebro-vascular autoregulation and decrease 
CBF [121, 314], (5) improve cerebral glucose metabolism [39, 114, 311], (6) attenuate 
systemic and cerebral inflammation [311, 314], and (7) improve cardiovascular 
dysfunction [311]. 
  
5.8 Liver transplantation 
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Liver transplantation is currently the only radical solution for ALF. Survival 
after OLT (orthotopic liver transplantation) is similar in the Far East and the West 
(60-80%), which is much higher than those who do not receive a graft (15-20%) 
[429, 430]. In both acetaminophen-induced ALF [431-433] and non-
acetaminophen-related ALF [432, 434, 435], King’s College criteria give more 
predictive values and accuracy than Clichy criteria.   
  
5.9 Artifical and bio-artifical liver support systems 
“High-volume plasmapheresis” has been used in successful reduction of ammonia, 
and improvement in mental state, hemodynamics, and cerebral perfusion [45, 436]. 
Molecular Adsorbent Recirculating System (MARS) [437] has been shown to be 
effective in the improvement of HE symptoms, reduction of ammonia, bilirubin, 
creatinine, and aromatic amino acids in ALF patients [438], and attenuates cerebral 
edema and high ICP in ALF animals and patients [439, 440]. 
Regarding bioartificial liver support systems, about 1010 hepatocytes are needed to 
represent 10-30% of the liver mass in fulfilling its synthetic, detoxifying, and excretory 
functions [441]. The ELAD system is beneficial in attenuating HE symptoms, ICP, and 
haemodynamic abnormalities, but has no effect on survival in ALF patients [442]. The 
bioartificial liver device (BAL) system reduces ICP and improves blood parameters 
(such as glucose, ammonia, and bilirubin) [443], and significantly increased survival in 
a subgroup of patients with ALF [444]. 
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6. Summary  
HE comprises a spectrum of neuropsychiatric abnormalities observed in ALF patients. 
A quick worsening of consciousness and increasing progress of cerebral edema, which 
leads to high ICP, cerebral herniation and death, are characteristics of ALF. Multiple 
factors are found responsible for the development of HE in ALF, whereas 
hyperammonemia (which can rise to millimolar concentrations at coma stages) is 
considered the most crucial factor in defining the pathogenesis of HE in ALF. 
Body ammonia is mainly produced from (1) intestines, through the breakdown of amino 
acids and urea, and (2) kidneys, via the degradation of glutamine. The rate of ammonia 
generation by intestines is not altered in ALF, whereas kidney shifts into ammonia 
excretory status during hyperammonemia. In ALF, decreased periportal urea synthesis 
and reduced perivenous glutamine synthesis lead to impaired ammonia detoxification 
and hyperammonemic state. Muscle and brain glutamine synthesis are both important 
extra-hepatic pathway for ammonia removal in ALF. In the brain, the astrocyte is the 
main cellular type for ammonia removal, by the conversion of glutamate into glutamine. 
In ALF, increased cerebral ammonia leads to glutamine accumulation in astrocytes, 
which is responsible for the development of cerebral edema in ALF. The underlying 
mechanisms have been explained by two mutual completing hypotheses: “glutamine-
osmolyte-edema hypothesis” and “glutamine-RNOS-edema hypthesis”.   
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Ammonia at millimolar concentration induces multiple system dysfunctions, 
including a direct inhibitory effect on both CNS synaptic excitation and inhibition, 
and an increase of cerebral tryptophan uptake by glutamine-tryptophan 
exchange, which results in increased synthesis of serotonin and metabolites in 
the brain. In addition, altered cerebral glucose metabolism in ALF has been attributed 
to hyperammonemia, with altered TCA cycle flux and cerebral lactate accumulation. 
Furthermore, altered astrocytic protein expression (including GFAP, the 
glutamate transporter, the glycine transporters, and PTBR) have been demonstrated 
in ALF. These changes are associated with astrocytic morphologic and functional 
changes. Other toxic substances may act synergistically with ammonia in ALF. 
Alterations of neurotransmitter systems have been demonstrated in ALF, which 
include increased extracellular glutamate, elevated NMDA receptor activation, and 
altered serotonin and noradrenaline systems. Recently, systemic inflammatory 
response has been demonstrated contributing significantly to the development of HE in 
ALF. Additional factors, such as increased CBF and altered BBB function, should also 
be taken into account for the pathogenesis of HE in ALF. 
During the therapeutic management of HE in ALF, the treatment of precipitating 
factors, HE itself, the failing liver, and multi-organ systems are needed. Reducing 
ammonia production and increasing ammonia removal are traditional strategies in the 
treatment of HE. In ALF, therapeutic interventions in an attempt to prevent and treat 
impending cerebral edema and high ICP have been developed, which include mannitol, 
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hypertonic saline, prophylactic antibiotics, NAC, hemofiltration, hyperventilation, etc. 
In addition, therapeutic approaches aimed at modulating neurotransmitter 
systems have been designed and showed beneficial effects in ALF, which 
includes: NMDA receptor antagonist (memantine), and benzodiazepine receptor 
inverse agonists. Mild/moderate hypothermia is a promising new approach in 
the improvement of HE and cerebral edema in ALF, and involves multiple 
mechanisms, including reducing blood and brain ammonia, enhancing cerebral 
glucose oxidation, ameliorating systematic inflammation, etc. Liver transplantation is 
an efficent and radical approach in prolonging the survival of ALF patients, which 
provides up to 90% survival rate in post-transplantation populations. With the 
increasing understanding of the pathophysiology of HE in ALF and the advance in new 
technologies, more effective new therapeutic interventions will be created.  
48 
7. Objectives of the proposed studies 
The objectives of the studies now proposed are, using a well-validated animal 
model of ALF characterized by liver devascularization, hyperammonemia and 
brain edema, the following: 
1. To demonstrate that neuroinflammation characterized by microglial 
activation and increased proinflammatory cytokines occurs in ALF 
2. To demonstrate that mild hypothermia attenuates neuroinflammation and 
brain edema in ALF 
3. To investigate the effect of minocycline, an antibiotic shown in previous 
unrelated studies to reduce microglial activation, attenuates brain 
proinflammatory cytokines and brain edema 
4. To evaluate the benefit of mild hypothermia and minocycline on 
oxidative/nitrosative stress taken in relation to the attenuation of brain 
edema 
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CHAPTER 2 
STUDIES ON THE PATHOGENESIS AND NEW THERAPEUTIC 
INTERVENTION OF HE. 
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Article 1: 
Direct  evidence for central  proinflammatory mechanisms in rats 
with experimental acute l iver failure:  protective effect of  
hypothermia 
J Cereb Blood Flow Metab. 2009 May;29(5):944-52. Epub 2009 Mar 4 
Wenlei Jiang, Paul Desjardins and Roger F Butterworth  
Neuroscience Research Unit, Hopital Saint-Luc (C.H.U.M.), University of Montreal, 
Montreal, Quebec, Canada 
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Abstract 
It has been proposed that proinflammatory mechanisms are involved in the pathogenesis 
of brain edema in acute liver failure (ALF). The aim of this study was to assess the 
contribution of cerebral inflammation to the neurologic complications of ALF and to 
assess the antiinflammatory effect of mild hypothermia. Upregulation of CD11b/c 
immunoreactivity, consistent with microglial activation, was observed in the brains of 
ALF rats at coma stages of encephalopathy. Interleukin-1 (IL-1), tumor necrosis 
factor- (TNF-), and interleukin-6 (IL-6) mRNAs were increased two to threefold in the 
brains of ALF rats compared with that in sham-operated controls. The magnitude of 
increased expression of proinflammatory cytokines in the brain was correlated with the 
progression of encephalopathy and the onset of brain edema. Significant increases in IL-
1, IL-6, and TNF- levels were also found in the sera and cerebrospinal fluid (CSF) of 
these animals. Mild hypothermia delayed the onset of encephalopathy, prevented brain 
edema, and concomitantly attenuated plasma, brain, and CSF proinflammatory 
cytokines. These results show that experimental ALF leads to increases in brain 
production of proinflammatory cytokines, and afford the first direct evidence that central 
inflammatory mechanisms play a role in the pathogenesis of the cerebral complications 
of ALF. Antiinflammatory agents could be beneficial in the management of these 
complications. 
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Introduct ion  
ALF that results from viral infection or toxic liver injury is a life-threatening 
condition. HE and brain edema are serious neurologic complications of ALF, and 
their appearance heralds the need for emergency liver transplantation [380]. Several 
theories have been proposed to explain the pathogenesis of HE and brain edema, 
among which ammonia toxicity has received the most attention [204, 378]. 
However, ammonia is not the only pathophysiologic entity with the potential to 
adversely affect cerebral function in ALF. In particular, there is evidence that 
inflammation may also play a significant role. For example, large clinical studies 
have convincingly shown a higher prevalence of the ‘‘systemic inflammatory 
response syndrome’’ in ALF patients [303]. Systemic inflammatory response 
syndrome is a response to the presence of proinflammatory cytokines, such as the 
interleukins, IL-1 and IL-6, as well as to tumor necrosis factor- (TNF-), and 
increased circulating levels of cytokines have been reported consistently in ALF 
patients [298, 299, 314, 445]. Cytokines may also be formed and released by the 
necrotic liver. Studies on arteriovenous difference by Jalan et al (2003) suggest a net 
production of proinflammatory cytokines in the brains of patients with ALF [314].                       
. 
However, direct evidence for a role of increased brain cytokines in the pathogenesis 
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of the cerebral complications of ALF is still lacking. Therefore, the aim of this study 
was to measure TNF-, IL-1, and IL-6 mRNA, and protein expression as a 
function of neurologic status in the brains of rats with ALF because of hepatic 
devascularization. These cytokines were chosen in view of earlier reports of their 
selective increase in both experimental and human ALF (above). In addition, given 
the recent upsurge of interest in hypothermia in the management of patients with 
ALF [39, 314, 446, 447] and the earlier report that hypothermia led to a delay in 
the onset of coma and brain edema in hepatic devascularized rats [254], the effect 
of hypothermia on cytokine expression in the serum and brains of these animals 
was also examined. 
Materials  and methods 
Surgical Procedures 
Adult male Sprague-Dawley rats (200 to 250 g) purchased from Charles River (Saint-
Constant, Quebec, Canada) were tested routinely for common pathogens and were 
free from infection at the time of surgery. Rats were anesthetized using isoflurane, 
and an end-to-side portacaval anastomosis was performed according to the 
guidelines of Lee and Fisher (1961)[448]. Briefly, rats underwent a laparotomy, the 
inferior vena cava and portal vein were isolated and clamped using an anastomosis 
clamp (Roboz Instruments Inc, Washington DC, USA), and an elliptical portion 1.5 
times the diameter of the portal vein was removed. The portal vein was ligated and 
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cut, and an end-to-side anastomosis was performed under a dissecting microscope. 
Total surgery time was < 30mins. Sham-operated control rats, matched for weight, 
were anesthetized similarly and the inferior vena cava was clamped for 20 mins. 
After surgery, all animals were individually housed with free access to food and 
water under constant conditions of temperature, humidity, and light cycles. Twenty-
four hours after portacaval anastomosis, rats were reanesthetized and subjected to 
hepatic artery ligation (HAL). After HAL, arterial blood glucose levels were 
monitored and glucose was administered subcutaneously as needed to maintain 
normoglycemia. Body temperature was monitored every 15 min and maintained at 
37°C ± 0.5°C using heating pads. Hypothermia occurred spontaneously in the 
absence of external heating, and body temperature in the hypothermic ALF animals 
was again maintained at 33°C±0.5°C using heating pads when necessary. A group of 
animals was killed at precoma (before the appearance of encephalopathy and brain 
edema) 6 h after HAL (ALF-6 h). A second group (ALF-coma) was killed at the 
coma stage of encephalopathy (defined as the loss of righting and corneal reflexes), at 
which time the animals had significant brain edema. Hypothermic animals (ALF-33) 
were killed in parallel with time-matched comatose normothermic ALF animals and 
sham-operated controls. Their brains were rapidly removed, dissected on ice, and 
were immediately frozen in isopentane. All tissues were stored at -70°C until use. All 
the above surgical methods were performed in accordance with the Guidelines of 
Canadian Council of Animal care and were approved by the Animal Research 
Committee at Saint-Luc Hospital (C.H.U.M.). 
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Brain Water Measurement 
Brain water was quantitated using the wet-weight/dryweight method. Half of the 
brain sample was weighed before and after 48 h of incubation in a 120°C oven. Water 
content of the brain samples are expressed as percentage of water content according 
to the following equation: %water = (wet weight–dry weight)/wet weight × 100. 
Ammonia Concentration 
Plasma and CSF ammonia concentrations were determined using a commercial 
ammonia test kit (Sigma Aldrich, St-Louis, MO, USA) on the basis of the enzymatic 
method using the glutamate dehydrogenase reaction [449]. 
Immunohistochemistry 
Animals were deeply anesthetized using pentobarbital (60 mg/kg). After being 
transcardially perfused with 240-mL ice-cold saline followed by 240mL of neutral-
buffered formalin (containing 4% formaldehyde, 0.5% sodium phosphate buffer, 
1.5% methanol, pH 7.0), their brains were removed, postfixed in 10% formalin at 4°C 
for 12 h, and transferred into an ice-cold phosphate-buffered saline (PBS) solution 
for storage. Coronal sections that were 50-µm thick were obtained using a vibratome 
from -4.0 to -5.5 mm relative to the bregma according to the rat brain atlas of Paxinos 
and Watson (1986) [450]. Sections were incubated with 0.3% hydrogen peroxide in 
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PBS for 10min to block the endogenous peroxidase activity. After washing with PBS, 
the sections were blocked with 2% horse serum and 0.5% Triton X-100 in PBS, 
washed, and incubated at 4°C overnight with mouse anti-CD11b/c (OX-42) (1/1000) 
(Cedarlane Laboratories, Burlington, NC, USA). After washing with PBS, the 
sections were incubated for 1 h with horse antimouse biotinylated secondary 
antibody (1:100) (Vector Laboratories, Burlingame, CA, USA). Furthermore, after 
washing with PBS, the sections were incubated with the Vectastain ABC reagent 
(Vector Laboratories) and immunoreactivity was detected by incubation with 3-3’-
diaminobenzidine containing urea–hydrogen peroxide (Sigma Aldrich). The sections 
were mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, CA, USA), 
dehydrated stepwise in ethanol and xylene, and coverslipped with Permount (Fisher 
Scientific). Sections without primary antibodies were used as negative controls and 
showed no immunoreactivity. Quantitative analysis was performed by counting the 
immunopositive cells in 10 selected representative areas of 0.5 mm2. Cell counts 
were performed by an investigator who was unaware of the animal treatment group. 
Measurement of Cytokine Gene Expression by Quantitative Real-Time Reverse-
Transcription Polymerase Chain Reaction (qRT-PCR) 
In view of the established diurnal variations of IL-1 and TNF- mRNAs, all 
experiments were performed at the same time of day (pm). Animals were 
transcardially perfused with 240mL ice-cold saline to remove the residual blood from 
the brain. Total RNA was isolated from rat brain cortex using the Trizol reagent 
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(Invitrogen Ltd, Carlsbad, CA, USA), according to the manufacturer’s instructions. 
cDNA was synthesized using thermoscript RT-PCR system (Invitrogen). Expression 
levels were assessed using real-time PCR in a RotorGene 3000TM Real time DNA 
detection system (Corbett Life Science, Sydney, Australia) with the Quantitect 
SYBRGreen I PCR kit (Qiagen, Valencia, CA, USA). Oligonucleotide primers were 
designed using the Primer 3 software [451] on the basis of the following GeneBank 
accession numbers: V01217 (-actin), M98820 (IL-1), M26744 (IL-6), and X66539 
(TNF-), and included at least one intron. The specificity of the oligonucleotide 
primers was verified using the program BLASTN from the National Center for 
Biotechnology Information (NCBI, Bethesda, MD, USA). For each primer pair, the 
amplified cDNA fragments were verified by agarose gel to confirm the absence of the 
intron and of any nonspecific products. The forward and reverse primers used were 5
’
-
CCACAGCTGA GAGGGAAATC-3
’
 and 5
’
-TCTCCAGGGAGGAAGAGGAT-3
’
 for -
actin; 5
’
-TCTTCTCATTCCTGCTCGTG-3
’
 and 5
’
-GATG AGAGGGAGCCCATTT-3
’
for TNF-; 5
’
-CTCAACTGTGAAATAGCAGCTTTC-3
’
 and 5
’
-
GGACAGCCCAAGTCAAGG-3
’
 for IL-1; and 5
’
-
CTTCACAAGTCGGAGGCTTAAT-3’ and 5’-ACAGTGCATCATCGCTGTTC-3’ for 
IL-6. A relative quantification was performed by comparing the threshold cycle values 
of samples with serially diluted standards. Expression levels were normalized to the 
housekeeping gene, -actin. 
Plasma, CSF Collection, and ELISA (Enzyme-Linked Immunosorbent Assay) 
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Plasma and CSF samples were collected 6 h after HAL (precoma) and at the coma 
stage of encephalopathy. Cisterna magna catheters were installed in groups of animals 
to collect CSF as described earlier [52]. In brief, the animal’s head was mounted with 
the skull in a horizontal position on a stereotaxic apparatus. A 3-cm incision was 
made on the skin from the back of its head, and the overlying connective tissue was 
removed to expose the skull. A small hole was drilled in the skull using a dental burr 
(009) on the midline immediately rostral to the interparietal–occipital bone suture. 
The hole was drilled in such a way that the occipital bone could be used as a guideline 
while inserting the cannula (PE-10 tubing, Clay Adams, Parsipanny, NJ, USA). The 
catheter was inserted into the cisterna magna. Correctness of placement was 
accompanied by a spontaneous flow of clear CSF. Protein levels of IL-1, IL-6, IL-
10, and TNF- were measured in plasma and in CSF samples using commercial 
ELISA kits (R&D Systems, Minneapolis, MN, USA; Biosource, Camarillo, CA, 
USA) according to the manufacturer’s instructions. The plates were read at 450 nm 
and the absorbances were converted to pg/mL using standard curves prepared with 
recombinant cytokines. 
Statistical Analysis 
All data are expressed as the mean ± s.e.m., and statistical analysis was performed 
using ANOVA (one-way analysis of variance) followed by Tukey’s post hoc analysis. 
A probability of P<0.05 was chosen to establish significance between the groups. Data 
were analyzed using the Prism 4.0 software (Prism 4.0, San Diego, CA, USA). 
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Results  
Neurologic Status and Brain Edema 
After hepatic devascularization, normothermic ALF rats (maintained at 37°C) 
developed progressive encephalopathy, which progressed to loss of corneal reflex 
(coma). At 6 h after surgery (ALF-6 h), ALF rats showed no overt neurologic 
symptoms. Hypothermia (ALF rats maintained at 33°C) significantly delayed the 
onset of encephalopathy. Sham-operated controls and ALF-6 h rats showed normal 
behavior and unchanged reflexes throughout the entire period of the experiments. 
Brain water content was not significantly different between sham-operated control 
rats and normothermic rats 6 h after HAL (79.4 ± 0.07% versus 79.5 ± 0.14%), but 
was elevated significantly in normothermic rats that were at the coma stage of 
encephalopathy (80.8 ± 0.06%, P< 0.001). Hypothermia (ALF-33) significantly 
attenuated brain water content (ALF-33 versus ALF-coma: 79.5 ± 0.15% versus 80.8 
± 0.06%, P< 0.001) in ALF rats compared with normothermic rats killed at 
equivalent time points (Figure 1). 
Plasma and CSF Ammonia 
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Serum ammonia levels were elevated in normothermic ALF rats starting 6 h after 
HAL (ALF-6 h versus sham-operated controls: 729 ± 32 versus 62 ± 9 mmol/L, 
P<0.001) with further increases at the coma stage of encephalopathy (1566 ± 72 
mmol/L, P< 0.001). CSF ammonia levels were also increased 6 h after HAL (ALF-6 h 
versus sham-operated controls: 1049 ± 78 versus 109 ± 7 mmol/L, P< 0.001) with 
further increases again apparent at the coma stage of encephalopathy (2067 ± 176 
mmol/L, P<0.001). Hypothermia significantly attenuated the rise of both serum 
(ALF-33 versus ALF-coma: 637 ± 57 versus 1566 ± 72 mmol/L, P< 0.001) and CSF 
ammonia concentrations (ALF-33 versus ALF-coma: 682 ± 62 versus 2067 ± 176 
mmol/L, P< 0.001) (Figure 1). 
Figure 1: CSF and plasma ammonia and brain water content in ALF rats maintained 
normothermic (ALF-6 h, ALF-coma) or hypothermic (ALF-33) compared with sham-
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operated controls (sham). Data represent mean±s.e.m. of 10 animals in each group. *P < 
0.001 versus sham; †P < 0.001 versus ALF-coma. 
Effects of ALF on Microglial Activation 
Formaldehyde-fixed floating cerebral cortical sections from ALF rats stained with 
CD11b/c (OX-42), the major histocompatibility complex class II antigen marker, 
reveal microglial activation, which was correlated with the onset of brain edema and 
coma stage of encephalopathy (Figure 2). Comparable increases in OX-42-positive 
cells were also observed in the thalamus and hippocampus (Table 1). 
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Figure 2: Microglial activation in the brains of rats with ALF at the coma stage of 
encephalopathy. Representative micrographs showing the effect of ALF on OX-42 staining 
in cerebral cortex from sham-operated controls (sham) and comatose ALF rats (ALF-coma) 
(original magnification 200 ×). 
Effects of ALF and Hypothermia on Circulating IL-1, IL-6, and TNF-
In normothermic ALF rats, serum IL-1 protein levels were increased 3.8-fold at 6 h 
after HAL (sham-operated controls versus ALF-6 h: 36.7 ± 10.6 versus 140.2 ± 10.4 
pg/mL, P< 0.05) and IL-6 levels were increased 40-fold (sham-operated controls 
versus ALF-6 h: 72.5 ± 1.8 versus 2933 ± 196 pg/mL, P< 0.001), whereas TNF-
concentrations remained at the level of sham-operated controls (sham versus ALF-6 
h: 3.7 ± 0.3 versus 3.4 ± 0.3 pg/mL) (Figure 3). At coma stage, IL-1 concentrations 
were increased 6.5-fold (239.3 ± 49.3 pg/mL, P<0.001), IL-6 levels were increased 
47-fold (3419 ± 218.3 pg/mL, P<0.001), and TNF- concentrations were increased 
2.8-fold (4.2 ± 0.7 pg/mL) (P < 0.001). In hypothermic ALF rats, increases in serum 
levels of IL-1, IL-6, and TNF- were attenuated by 55% (P<0.01), 81% (P<0.001), 
and 60% (P<0.001), respectively, compared with normothermic ALF rats (Figure 3). 

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Concentrations of the antiinflammatory cytokine IL-10 were increased 16-fold 
(P<0.001) in the plasma of normothermic ALF animals, but this increase was only 
marginally influenced by hypothermia (data not shown). 
Figure 3: Plasma IL-1, IL-6, and TNF- levels in ALF rats maintained normothermic 
(ALF-6 h, ALF-coma) or hypothermic (ALF-33) compared with sham-operated controls 
(sham). Data represent mean ±s.e.m. of 10 animals in each group. *P < 0.05 versus sham; 
**P < 0.001 versus sham; 
†
P < 0.01 versus ALF-coma; 
††
P < 0.001 versus ALF-coma. 
Effects of ALF and Hypothermia on Cerebral (CSF) IL-1, IL-6, and TNF-
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The IL-1 protein levels in CSF were increased 2.3-fold in normothermic ALF rats 
at the coma stage of encephalopathy (ALF-coma versus shamoperated controls: 5.4 
± 0.6 versus 2.4 ± 0.3 pg/mL, P<0.001), but were not changed significantly in the 6 
h(precoma) after-HAL group of animals (Figure 4). IL-6 protein concentrations were 
increased in normothermic ALF rats 6 h after HAL (shamoperated controls versus 
ALF-6 h: 35.8 ± 4.0 versus 60.7 ± 4.8 pg/mL, P<0.05) with further increases at the 
coma stage of encephalopathy (108.2 ± 9.5 pg/mL, P<0.001). The TNF- levels in 
CSF were not changed significantly in the ALF-6 h group, but were increased 
significantly at the coma stage of encephalopathy (sham-operated controls versus 
ALF-coma: 1.1 ± 0.2 versus 2.3 ± 0.2 pg/mL, P<0.001). In hypothermic ALF rats, 
increases in CSF levels of IL-1, IL-6, and TNF- were attenuated by 65% 
(P<0.001), 67% (P<0.001), and 34% (P<0.05), respectively, compared with 
normothermic ALF rats (Figure 4). The antiinflammatory cytokine, IL-10, was 
increased fivefold (P<0.001) in the CSF of normothermic ALF animals, but again this 
increase was marginally influenced (P>0.05) by hypothermia (data not shown). 
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Figure 4: CSF IL-1 IL-6, and TNF- levels in ALF rats maintained normothermic (ALF-
6 h, ALF-coma) or hypothermic (ALF-33) compared with sham-operated controls (sham). 
Data represent mean ±s.e.m. of 10 animals in each group. *P < 0.05 versus sham; **P < 
0.001 versus sham; 
†
P < 0.01 versus ALF-coma; 
††
P < 0.001 versus ALF-coma. 
Effects of Hypothermia on IL-1, IL-6, and TNF- Gene Expression in ALF 
Rats 
Brain samples from ALF rats were thoroughly perfused transcardially with saline to 
prevent the influence of circulating cytokines on measurements of brain cytokines. 
Using quantitative real-time PCR, cytokine mRNA levels were normalized to -actin 
mRNA levels. The IL-1 gene expression in the brain was elevated 3.2-fold in 
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normothermic comatose ALF rats (ALF-coma versus sham-operated controls: 324.5 ± 
41.3 versus 100 ± 10.2, P<0.001), but was not changed significantly 6 h after HAL 
(Figure 5). Brain IL-6 mRNA levels were increased 2.1-fold in normothermic ALF 
rats 6 h after HAL (sham-operated controls versus ALF-6 h: 100 ± 13.6 versus 208.6 
± 14.0, P<0.05) with further increases at the coma stage of encephalopathy (388.0 ± 
42.0, P<0.001). TNF- gene expression in the brain was increased 2.8-fold in 
normothermic ALF rats at the coma stage (sham-operated controls versus ALF-
coma: 100.1 ± 8.8 versus 282.1 ± 26.5, P<0.001) but was not changed significantly 6 
h after HAL. In hypothermic ALF rats, increases in brain IL-1, IL-6, and TNF-
mRNA levels were attenuated by 89%, 47%, and 37%, respectively (P<0.001), 
compared with that in normothermic ALF rats (Figure 5). 
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Figure 5: Brain IL-1 IL-6, and TNF- mRNA levels in ALF rats maintained 
normothermic (ALF-6 h, ALF-coma) or hypothermic (ALF-33) compared with sham-
operated controls (sham). Data represent mean±s.e.m.of 10 animals in each group. 
*P<0.05 versus sham; **P<0.001 versus sham; 
†
P<0.05 versus ALF-coma; 
††
P<0.001 
versus ALF-coma; NS: not significantly different from sham. 
Discuss ion 
Results of this study provide direct evidence for brain-derived proinflammatory 
mechanisms in the pathogenesis of the neurologic complications of ALF. This 
evidence includes activation of microglia, as shown by increased immunoreactivity 
of the major histocompatibility complex marker, OX-42, together with the increased 
production of brain proinflammatory cytokines. Increased cytokine transcripts in the 
hepatic devascularized rat model of ALF were found to be selective in terms of their 
identity, the magnitude of the increase in their expression, and the timing of the 
increased expression in relation to the progression of ALF. Early increases in IL-6 
mRNA levels were followed by more substantial increases in the expression of IL-1
and TNF- and occurrence of severe encephalopathy and brain edema was associated 
with a generalized increase in the expression of all three cytokines. Although 
astrocytes when activated, are theoretically an alternative source of cytokines, there 
is no evidence for reactive astrocytosis in this model of ALF [208]. The finding of 
increased brain proinflammatory cytokines in association with encephalopathy in 
ALF adds to a growing body of evidence implicating these cytokines in 
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neuropsychiatric disorders. Earlier studies show that expression of TNF- in the 
brain results in poor performance in cognitive tasks [452], and that altered 
expression of TNF- and IL-1 in the brain leads to impaired sleep quality [453]; in 
this regard, it is interesting to note that HE is characterized in its early stages by 
sleep disorders and cognitive deficits. 
It may be tempting to speculate that the increased brain cytokines in this study 
originated from infection. Alternatively, apparent increases in brain cytokines could 
have originated from blood contamination of the brain tissue. However, neither 
possibility is likely, because the presence of infection was precluded by rigorous 
screening for bacteria and other pathogens in all animals before entry into the study. 
Blood contamination of the brain tissue was prevented by transcardial perfusion of 
all animals to remove residual blood from the brain before cytokine assays. Serum 
concentrations of TNF-, IL-1 and IL-6 were increased significantly in hepatic 
devascularized rats (this study), and this cytokine profile resembles that reported 
earlier in rodent models of ALF resulting from acetaminophen [454] or 
azoxymethane [455] hepatotoxicity, as well as in sera from patients with ALF 
because of acetaminophen toxicity or viral hepatitis [299]. In this study, increases in 
IL-1 IL-6, and TNF- levels were measured as a function of severity of liver 
failure and were sensitive to mild hypothermia. Given the similar identity of the 
increased serum and brain cytokines in this study, it may be tempting to conclude 
that increased brain cytokines originated from failing liver. There are known routes 
whereby peripheral cytokines can directly cross the blood–brain barrier [456]. 
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However, a uniquely peripheral source of cytokines is unlikely, given the present 
findings of increased expression of genes coding for TNF-, IL-1 and IL-6 together 
with the increased expression of their respective proteins in the brain. 
  
The precise mechanism(s) that are responsible for microglial activation in ALF are 
unknown. However, one potential mechanism involves ammonia toxicity. ALF results 
in sustained hyperammonemia, and brain ammonia concentrations in the 1 to 5 
mmol/L range have been reported [31]. Ammonia inhibits a-ketoglutarate 
dehydrogenase in rat brain mitochondria [97], resulting in decreased glucose 
oxidation and in lactate accumulation. Increased brain lactate production has been 
shown unequivocally in experimental ALF [115], and CSF lactate levels are 
positively correlated with the severity of HE in both experimental [161] and human 
[162] ALF. Results of this study show that increases in TNF-, IL-6, and IL-1
levels in the brain follow a time course that is comparable with that of brain ammonia 
[31], and CSF [197] and brain [115] lactate suggestive of a pathophysiologic link. 
Moreover, cultured astroglia exposed to lactate in concentrations equivalent to those 
reported in brain in experimental ALF cause increased production and release of 
these cytokines [457]. Conversely, there is evidence to suggest that TNF- IL-6, and 
IL-1 have the capacity to increase permeability of cerebrovascular endothelial cells 
to ammonia [458, 459], suggesting that their presence could increase the blood–brain 
barrier permeability to ammonia providing an explanation for the disproportionately 
increased brain ammonia reported in experimental ALF [31]. 
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Mild hypothermia is increasingly being considered as a useful tool to prevent and 
treat intracranial hypertension in ALF [311, 445, 447]. Several mechanisms by 
which hypothermia exerts its beneficial effects have been proposed. Such 
mechanisms include improvement in hepatic function [446], improvement of brain 
energy metabolism [114, 124, 197], and effects on the expression of genes coding for 
oxidative stress proteins [460]. Results of this study suggest an additional 
mechanism, namely reduction of brain proinflammatory cytokines. Further studies 
are needed to determine whether mild hypothermia is beneficial when instigated 
after the onset of ALF. Approaches aimed at the reduction of brain levels of 
proinflammatory cytokines have the potential to limit the cerebral consequences of 
ALF. 
Disclosure 
The authors state no conflict of interest. 
72 
Article 2: 
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Abstract 
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). 
The precise pathophysiologic mechanisms responsible have not been fully elucidated but it 
has been recently proposed that microglia-derived proinflammatory cytokines are involved. 
In the present study we evaluated the role of microglial activation and the protective effect 
of the anti-inflammatory drug minocycline in the pathogenesis of HE and brain edema in 
rats with ALF resulting from hepatic devascularisation. ALF rats were killed 6 h after 
hepatic artery ligation before the onset of neurological symptoms and at coma stages of 
encephalopathy along with their appropriate sham-operated controls and in parallel with 
minocycline-treated ALF rats. Increased OX-42 and OX-6 immunoreactivities confirming 
microglial activation were accompanied by increased expression of interleukins (IL-1, IL-
6) and tumor necrosis factor-alpha (TNF-) in the frontal cortex at coma stage of 
encephalopathy in ALF rats compared with sham-operated controls. Minocycline treatment 
prevented both microglial activation as well as the up-regulation of IL-1, IL-6 and TNF-
mRNA and protein expression with a concomitant attenuation of the progression of 
encephalopathy and brain edema. These results offer the first direct evidence for central 
proinflammatory mechanisms in the pathogenesis of brain edema and its complications in 
ALF and suggest that anti-inflammatory agents may be beneficial in these patients. 
Keywords: acute liver failure, hepatic encephalopathy, microglia, minocycline, 
proinflammatory cytokines.  
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Introduction 
ALF resulting from viral infection or toxic liver injury is a life-threatening 
condition. Mortality rates are extremely high with death resulting predominantly 
from brain herniation due to intracranial hypertension caused by brain edema. There 
is increasing evidence to suggest that inflammation plays a significant role in the 
pathogenesis of brain edema in ALF. For example, the presence of systemic 
inflammation is associated with a more rapid progression of encephalopathy and 
brain edema in ALF patients [303]. Systemic inflammation in ALF results in 
increased circulating levels of proinflammatory cytokines including tumor necrosis 
factor alpha (TNF-), and the interleukins (IL-1, IL-6) [294, 445]. Moreover, 
arterio-venous difference studies in ALF patients with uncontrolled intracranial 
hypertension suggest net brain efflux of TNF-, IL-1 and IL-6 consistent with 
increased brain production of these cytokines [314, 461]. However, conclusive 
evidence for increased brain cytokine production in ALF is lacking. 
The objective of the present study was to assess brain inflammatory mechanisms in 
ALF. In particular, microglial activation and expression of proinflammatory 
cytokines weremeasured as a function of encephalopathy and brain edema severity 
using a well-characterized animal model of ALF, the hepatic devascularized rat 
[462]. In a second series of studies, the beneficial effects of minocycline, a 
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semisynthetic tetracycline shown to limit microglial activation in a wide range of 
neurodegenerative conditions [463], was investigated. Effects of minocycline on 
progression of encephalopathy and brain edema in hepatic devascularized rats was 
studied as a function of microglial activation and expression of proinflammatory 
cytokines. Microglial activation was measured by western blotting (OX-6) and 
CD11b/c (OX-42) immunohistochemistry. 
Materials and methods 
Hepatic devascularization and treatments 
Adult male Sprague-Dawley rats (200–250 g) purchased from Charles River (Saint-
Constant, Quebec, Canada) were routinely tested for common pathogens and were 
free of infection at the onset of surgery. Animals were anesthetized with isoflurane, 
and an endto-side portacaval anastomosis was performed according to the guidelines 
of Lee and Fisher (1961)[448]. Briefly, rats underwent a laparotomy, the inferior 
vena cava and portal vein were isolated and clamped using an anastomosis clamp 
(Roboz Instruments Inc, Washington, DC, USA) and an elliptical portion 1.5 times 
the diameter of the portal vein was removed. The portal vein was ligated and cut, and 
an end-to-side anastomosis was performed under a dissecting microscope. Total 
surgery time was < 30 min. Sham-operated control rats (n = 10), matched for 
weight, were similarly anesthetized and the inferior vena cava was clamped for 20 
min. Following surgery, all animals were individually housed with free access to 
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food and water under constant conditions of temperature, humidity, and light cycles. 
Twenty four hours after portacaval anastomosis, rats were reanesthetized and 
subjected to hepatic artery ligation (HAL). Following HAL, arterial blood glucose 
levels were monitored and glucose was administered subcutaneously as needed to 
maintain normoglycemia. Body temperature was monitored every 15 min and 
maintained at 37
o
C ± 0.5
o
C by means of heating pads. A group of animals (n = 10) 
was killed 6 h following HAL (ALF-6 h) before the appearance of encephalopathy 
and the onset of brain edema and a second group (n = 10) was killed at coma stage 
of encephalopathy (ALF-coma) (defined as the loss of corneal reflexes). In a second 
series of experiments, group (n = 10) of ALF animals (ALF-mino) or sham-operated 
controls were administered minocycline (22.5 mg/kg twice daily; i.p.) on days -2, -1 
and day 0 of HAL operation. Control rats (n = 10) were given equivalent volumes of 
saline. Minocycline-treated animals were killed in parallel with comatose saline-
treated ALF controls. Brains were rapidly removed, dissected on ice and were 
immediately frozen in isopentane. All tissues were stored at –70
o
C until use. In a 
third series of experiments (Table 1), a group (n = 10) of ALF animals was 
administered saline or minocycline and progression of encephalopathy was 
monitored until the appearance of precoma (loss of righting reflexes) or coma (loss of 
corneal reflexes) stages of encephalopathy. All the above procedures were conducted 
in accordance with the Guidelines of Canadian Council of Animal care and were 
approved by Animal Research Committee at Saint-Luc Hospital (C.H.U.M.). 
Brain water measurement 
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Brain water was quantitated by the wet-weight/dry-weight method. Half of the brain 
was weighed before and after 48 h incubation in a 120oC oven. Water content of the 
brain samples is expressed as percentage of water content according to the following 
equation: %Water = (Wet Weight - Dry Weight)/Wet Weight × 100. 
Real-time reverse-transcription polymerase chain reaction (QRT-PCR) 
Animals were transcardially perfused with 240 mL ice-cold saline to remove residual 
blood in the brain. Total RNA was isolated from rat brain cortex using the Trizol 
reagent (Invitrogen Ltd, Carlsbad, CA, USA), according to the manufacturer’s 
instructions. The cDNA was synthesized using thermoscript RT-PCR system 
(Invitrogen). Expression levels were assessed by real-time PCR in a RotorGene 
3000
TM
 Real-time DNA detection system (Corbett Life Science, Sydney, Australia) 
with the Quantitect SYBRGreen I PCR kit (Quiagen, Valencia, CA, USA). 
Oligonucleotide primers (Invitrogen) were designed using the PRIMER3 program 
[451] at http://primer3.sourceforge.net/ and selected to include at least one intron. 
The specificity of the oligonucleotide primers was verified using the program 
BLASTN from the National Center for Biotechnology Information (NCBI, 
Bethesda, MD, USA). For each primer pair, the amplified cDNA fragments were 
analyzed by agarose gel to confirm the absence of the intron and of any nonspecific 
PCR products. The forward and reverse oligonucleotide primer sequences were 5
’
-
CCACAGCTGAGAGGGAAATC-3
’
 and 5
’
-TCTCCAGGGAGGAAGAGGAT-3
’
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for -actin (GeneBank accession #V01217); 5
’
-
CTCAACTGTGAAATAGCAGCTTTC-3’ and 5’-GGACAGCCCAAGTCAAGG-3’
for IL-1 (GenBank accession #M98820); 5’-CTTCACAAGTCGGAGGCTTAAT-3’
and 5
’
-ACAGTGCATCATCGCTGTTC-3
’
 for IL-6 (GenBank accession #M26744); 
5
’
-TCTTCTCATTCCTGCTCGTG-3
’
 and 5
’
-GATGAGAGGGAGCCCATTT-3
’
 for 
TNF- (GenBank accession #X66539). A relative quantification was performed by 
comparing the threshold cycle values of samples with serially diluted standards. 
Expression levels were normalized to the housekeeping gene -actin. 
CSF removal and enzyme-linked immunosorbent assay 
CSF samples were collected 6 h post-HAL and at the coma stage of encephalopathy. 
Cisterna magna catheters were installed in groups of animals just before the 
collection of CSF as previously described [52]. In brief, the animal’s head was 
mounted with the skull in a horizontal position in a stereotaxic apparatus. A 3-cm 
incision was made in the skin from the back of the head and the overlying 
connective tissue was removed to expose the skull. A small hole was drilled in the 
skull using a dental burr (009) on the midline immediately rostral to the 
interparietal–occipital bone suture. The hole was drilled in such a way that the 
occipital bone could be used as guideline while inserting the cannula (PE-10 tubing, 
Clay Adams, Parsipanny, NJ, USA). The catheter was inserted into the cisterna 
magna. Correctness of placement was accompanied by a spontaneous flow of clear 
CSF. IL-1, IL-6 and TNF- protein levels were measured in CSF samples using a 
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quantitative sandwich enzyme immunoassay technique with monoclonal antibodies 
specific for rat IL-1, IL-6 and TNF- (R&D Systems, Minneapolis, MN, USA; 
Biosource, Camarillo, CA, USA). Detection limits were IL-6 (14 pg/mL), IL-1 (1 
pg/mL), TNF- (0.5 pg/mL). The plates were read at 450 nm and the absorbances 
were converted to pg/ml using standard curves prepared with recombinant cytokines. 
Western blot analysis 
Brain samples from frontal cortex were homogenized in ice-cold RIPA buffer [50 
mM Tris–HCl pH 7.6, 150 mM NaCl, 1% Tergitol (Sigma-Aldrich, St-Louis, MO, 
USA), 1% sodium deoxycholate, 0.1% SDS] containing a protease inhibitor cocktail 
(Sigma-Aldrich) and centrifuged at 12 000 g for 45 min. Protein concentrations were 
measured using a DC Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, 
CA, USA). Proteins (100 µg) were solubilized in Laemmli buffer (50 mM Tris–HCl, 
pH6.8, 10% glycerol; 2% SDS, 10% dithiothreitol, 0.1% bromophenol blue) and 
boiled for 10 min. Proteins were resolved by 8% denaturing SDS-polyacrylamide 
gels and transferred overnight to polyvinylidene difluoride membranes (Bio-Rad 
Laboratories). The filters were blocked for 1 h in Tris-buffered saline containing 5% 
dry milk and 0.1% Tween 20, then incubated for 1 h with mouse anti-OX-6 (1/250) 
(AbD Serotec, Raleigh, NC, USA) or with mouse anti-beta-actin (1/50 000) (Sigma-
Aldrich). The blots were subsequently probed with the goat anti-mouse horseradish 
peroxidase-conjugated antiserum (Perkin-Elmer, Waltham, MA, USA) diluted 1/10 
000 in the same buffer. After extensive washing with Tris-buffered saline, the 
80 
peroxidase activity was detected by chemiluminescence using the ECL detection 
system (Amersham, Arlington Heights, IL, USA). Expression levels were quantitated 
using an MCID-M1 imaging system (Imaging Research, ON, Canada). Results are 
expressed as percentage of the housekeeping protein -actin to normalize for loading 
variation. 
Immunohistochemistry 
Animals were deeply anesthetized with pentobarbital (60 mg/kg; i.p.). After being 
transcardially perfused with 240 mL ice-cold saline followed by 240 mL neutral-
buffered formalin (containing 4% formaldehyde, 0.5% sodium phosphate buffer, pH 
7.0), brains were removed, post-fixed in 10% formalin at 4
o
C for 12 h and 
transferred into ice-cold phosphate-buffered saline (PBS) solution for storage. 50 
µm thick coronal sections were obtained using a vibratome from -4.0 mm to -5.5 
mm relative to the bregma according to the rat brain atlas of Paxinos and Watson 
(1986) [450]. Sections were incubated with 0.3% hydrogen peroxide in PBS for 10 
min to block endogenous peroxidase activity. Sections were blocked with 2% horse 
serum and 0.5% Triton X-100 and incubated at 4oC overnight with mouse anti-
CD11b/c (OX-42) (1/1000) (Cedarlane Laboratories, Burlington, NC, USA). After 
washing with PBS, sections were incubated for 1 h with horse anti-mouse 
biotinylated secondary antibody (1/100) (Vector Laboratories, Burlingame, CA, 
USA) and thereafter with Vectasain ABC reagent (Vector Laboratories). OX-42 
immunoreactivity was detected by incubation with 3-3
’
-diaminobenzidine containing 
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urea-hydrogen peroxide (Sigma-Aldrich). The sections were mounted on Superfrost 
Plus slides (Fisher Scientific, Pittsburgh, CA, USA), dehydrated stepwise in ethanol 
and xylene and coverslip with Permount (Fisher Scientific). Sections without 
primary antibodies were used as negative controls and showed no immunoreactivity. 
Quantitative analysis was performed by counting cell numbers positively stained in 
10 selected representative areas of 0.5 mm
2
. Cell counts were made by an 
investigator who was unaware of the animal treatment group. 
Statistical analysis 
All data are expressed as the mean ± SEM and statistical analysis was performed 
using unpaired student t-test (two group comparisons) or one-way analysis of 
variance (ANOVA) followed by Tukey’s post hoc analysis (multiple comparisons). 
A probability of p < 0.05 was chosen to establish significance between the groups. 
Data were analyzed by using Prism 4.0 software (Prism 4.0, San Diego, CA, USA). 
Results 
Hepatic devascularization induces encephalopathy and brain edema 
Following HAL, rats developed a progressive encephalopathy, starting with lethargy 
(evident 6 h after HAL) progressing to loss of righting and corneal reflexes and coma 
(Table 1). Sham-operated rats exhibited normal behavior and neurological reflexes 
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throughout the period of the experiments. Brain water content was not significantly 
different between sham-operated rats and ALF rats 6 h after HAL (ALF-6 h vs. sham: 78.23 
± 0.14% vs. 78.09 ± 0.07%), but was significantly elevated in ALF rats at coma stage 
(ALF-coma vs. sham: 80.78 ± 0.10% vs. 78.09 ± 0.07%, p < 0.001) (Fig. 1a). 
Time to loss of righting reflexes and loss of corneal reflexes in ALF rats treated with 
minocycline (ALF-mino) compared with saline-treated ALF controls (ALF-saline) expressed 
in hours (h). Data represent mean ± SEM of n= 10 animals per treatment group; significant 
changes compared with ALF saline group indicated by *p < 0.001 (Student’s t-test). 
Microglial activation occurs at coma stage of encephalopathy and correlates with 
the onset of brain edema 
Formaldehyde-fixed floating cerebral cortical sections of ALF rats stained with CD11b/c 
(OX-42) (Fig.2a) show activation of microglia at the coma stage of encephalopathy (ALF-
COMA) compared with sham-operated controls (SHAM). Comparable increases in 
numbers of OX-42-positive cells was also observed in the thalamus and hippocampus (Fig. 
2b and Table 2). Western blot analysis of the major histocompatibility complex class II 
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antigen OX-6 at various time points during the progression of ALF reveals that microglial 
activation is correlated with the onset of brain edema and severe (coma stage) 
encephalopathy (ALF-coma) (Fig. 1b and c). 
Fig. 1 Western blot analysis of OX-6 expression in ALF rats reveals that inhibition of 
microglial activation by minocycline treatment is correlated with attenuation of brain 
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edema. (a) Percentage of brain water content of cerebral cortex from sham-operated controls 
(sham), ALF rats 6h post-HAL (ALF-6 h), ALF rats at coma stage of encephalopathy (ALF-
coma) and in ALF rats treated with minocycline (ALF-mino); (b) OX-6 protein expression 
in cerebral cortex from sham-operated controls (lanes 1–3), ALF rats 6 h post-HAL (lanes 
4–6), ALF rats at coma stage of encephalopathy (lanes 7–9) and in ALF rats treated with 
minocycline (lanes 10–12); (c) Histogram representation of OX-6 expression in the various 
treatment groups. Data represent mean ± SEM of n= 10 animals per treatment group. 
Significant differences indicated by *p < 0.001 versus sham-operated controls and ALF-6 
h; †p < 0.001 versus ALF-coma (ANOVA with post hoc Tukey’s test). 
Fig. 2 Microglial activation in the brains of rats with ALF resulting from hepatic 
devascularization. Representative micrographs showing the effect of ALF on (a) CD11b/c 
(OX-42) immunoreactivity in cerebral cortex of sham-operated controls (SHAM) and ALF 
rats at coma stage of encephlopathy (ALF-COMA) (magnification: 200×) and (b) OX-42 
staining in cerebral cortex, hippocampus and thalamus from ALF rats at coma stage of 
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encephalopathy (magnification: 50×). Note the generalized regional distribution of OX-42 
immunostaining. 
OX-42-positive cells (per × 200 optical fields) in brain regions of sham-operated controls, 
ALF-rats 6 h post-HAL (ALF-6 h), ALF rats at coma stage of encephalopathy (ALF-coma) 
and in ALF rats treated with minocycline (ALF-mino). Data represent mean ± SEM of 10 
measurements per animal (n = 6); significant differences indicated by *p < 0.001 versus 
sham-operated controls and **p < 0.001 versus ALF-coma (ANOVA with post-hoc 
Tukey’s test). 
Minocycline treatment ameliorates the neurological status of ALF rats, prevents 
brain edema and attenuates microglial activation 
In the saline-treated ALF group, rats progressively lost righting reflexes (precoma stage) 9.7 
± 0.2 h after HAL and lost corneal reflexes (coma stage) 13.0 ± 0.4 h after HAL. In 
comparison, minocycline-treatment significantly (p < 0.001) delayed the onset of 
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both precoma (loss of righting reflexes) and coma (loss of corneal reflexes) stages of 
encephalopathy to 13.1 ± 0.5 h and 15.8 ± 0.4 h after HAL, respectively (Table 1). 
Administration of similar doses of minocycline to sham-operated animal did not 
induce any neurological symptoms. As expected, minocycline was found to prevent 
microglial activation as shown by decreased OX-42 staining (Table 2) and OX-6 
immunoreactivities (Fig. 1b and c). Analysis of brain water content in minocycline-
treated ALF rats also revealed a significant attenuation of brain edema (p < 0.001) 
(Fig. 1a). 
Minocycline treatment attenuates up-regulation of IL-1, IL-6 and TNF-
expression in ALF rat brain 
IL-1, IL-6 and TNF- protein levels in CSF were elevated 2.3-fold, 3.0-fold and 
2.1-fold, respectively (p < 0.001) in comatose ALF rats (ALF-coma) compared with 
sham-operated control (sham) but were not significantly changed 6 h post-HAL 
(ALF-6 h) (Fig. 3). IL-1, IL-6 and TNF- gene expression in brain were elevated 
3.2-fold, 3.9-fold and 2.8-fold, respectively (p < 0.001) in comatose ALF rats (ALF-
coma) compared with sham-operated control (sham) but were not significantly 
changed 6 h post-HAL (ALF-6h) (Fig.4). Minocycline treatment prevented 
induction of IL-1, IL-6 and TNF- mRNAs and protein (p < 0.001) (Figs 3 and 4). 
Minocycline treatment of sham-operated control animals had no significant effect on 
neurological status, brain water content or CSF cytokine levels (Fig S1). 
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Discussion 
Results of the present study provide the first direct evidence for a role of cerebral 
inflammation in the pathogenesis of the encephalopathy and brain edema in ALF. 
Increased expression of the microglial marker proteins OX-6 and OX-42 in brain 
preparations indicative of microglial activation were found to predict the presence of 
severe encephalopathy (coma) and brain edema in rats with ALF due to hepatic 
devascularization. These findings add to a growing body of evidence that excessive 
microglial activation is a key feature of a wide range of neurological disorders that 
include neurodegenerative diseases as well as traumatic brain injury [356], stroke 
[357], and Wernicke’s encephalopathy [358]. In some of these disorders, microglial 
activation occurs prior to the appearance of neuronal cell death. However, microglial 
activation may occur following treatment with subacute doses of lipopolysaccharide 
with no evidence of neuronal cell death [464]. Results of the present study represent 
a further such example; neuronal cell death is not a feature of ALF [465]. Microglial 
activation was accompanied by significant increases in expression of the 
proinflammatory cytokines IL-1, IL-6 and TNF- in brains of ALF rats at coma 
(edema) stages of encephalopathy. These findings constitute direct evidence for 
increased brain cytokines in experimental ALF and extend previous findings in ALF 
patients of arterio-venous differences for these cytokines [314, 461] consistent with 
their production in brain. 
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Fig. 3 Minocycline attenuates brain IL-1, IL-6 and TNF- expression in ALF rats. IL-1, 
IL-6 and TNF- protein levels were determined in the CSF of sham-operated controls 
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(sham), ALF rats 6 h post-HAL (ALF-6h), at coma stage of encephalopathy (ALF-coma) 
and ALF rats treated with minocycline (ALF-mino). Data represent mean ± SEM of n= 10 
animals in each group. Significant differences indicated by *p < 0.001 versus sham-
operated controls and ALF-6 h; †p < 0.001 versus ALF-coma (ANOVA with post hoc 
Tukey’s test). 
Hepatic encephalopathy in ALF is characterized by both cognitive and sleep 
disturbances, both of which could potentially result from increased brain cytokines. 
For example, over-expression of TNF- and IL-1 in brain result in poor 
performance in cognitive tasks [452] and sleep dysregulation [466]. More 
importantly in the context of ALF, previous studies show that brain edema is 
significantly correlated with the presence of proinflammatory cytokines such as 
TNF- and IL-1 [467, 468] and transient brain edema results from intracerebral 
administration of IL-1 to normal rats [469]. 
As expected from its anti-inflammatory properties [470-472], results of the present 
study demonstrate that treatment with minocycline reduces microglial activation and 
leads to significant decreases in expression of IL-1, IL-6 and TNF- in the brains 
of ALF rats. Moreover, these effects of minocycline were accompanied by 
significant decreases in brain water content, strengthening the notion that microglial 
activation and brain accumulation of inflammatory cytokines are implicated in the 
pathogenesis of brain edema in ALF. These findings are in line with previous reports 
that minocycline treatment is effective in limiting brain edema that accompanies 
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intracerebral hemorrhages [473]. Moreover, brain edema resulting from 
experimental hypoxia/ischemia is significantly reduced in IL-1 receptor-deficient 
animals [474]. However, results of the present study reveal that an almost complete 
normalization of IL-1 mRNA and protein following minocycline treatment led to 
significant but incomplete inhibition of brain edema in ALF animals suggesting that 
other cytokines or other pathophysiologic mechanisms could also be implicated. 
Brain edema in ALF is cytotoxic in nature resulting almost exclusively from swelling 
of astrocytes [17, 206]. Moreover, experimental ALF results in significant 
alterations in expression of genes coding for key astrocytic proteins with the ability 
to modulate astrocyte volume including a loss of glial fibrillary acidic protein [208], 
the glutamate transporter EAAT-2 [262], the glucose transporter GLUT-1 [193], 
aquaporin IV [475] and the mitochondrial peripheral-type benzodiazepine receptor 
[217]. Although such protein modifications had previously been attributed to the 
toxic actions of ammonia in ALF, there is evidence to suggest that proinflammatory 
cytokines could also be implicated. For example, intracerebral administration of IL-
1 leads to up-regulation of peripheral-type benzodiazepine receptor sites [476] 
while exposure of cultured astrocytes to IL-1 and TNF- up-regulate aquaporin IV 
[477] and down-regulate glial fibrillary acidic protein [478] respectively. Moreover, 
high affinity transport of glutamate into cultured astrocytes is significantly impaired 
by exposure to IL-1 consistent with down-regulation of glutamate transporters 
[258, 479]. Whether or not treatment with minocycline would be beneficial in 
preventing these changes in protein expression in ALF awaits further studies. 
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Fig.4 Minocycline attenuates brain IL-1, IL-6 and TNF- gene expression in ALF rats. 
Cytokine mRNAs were determined in cerebral cortex of sham-operated controls (sham), 
ALF rat 6 h post-HAL (ALF-6h), at coma stage of encephalopathy (ALF-coma) and ALF 
rats treated with minocycline (ALF-mino). Data represent mean ± SEM of n= 10 animals in 
each group. Significant differences indicated by *p < 0.001 versus sham-operated controls 
and ALF-6 h; †p < 0.001 versus ALF-coma (ANOVA with post hoc Tukey’s test). 
Findings of increased brain cytokines is generally considered to reflect increases in 
their local synthesis by microglia or cerebrovascular endothelial cells. However, 
some cytokines may be transported through circumventricular organs that lack a 
blood–brain barrier [480]. Furthermore, vagal or sympathetic afferent cytokine 
signaling has also been proposed although the importance of this latter route has 
been questioned [456]. Circulating levels of TNF- and IL-1 are significantly 
increased in ALF [306] and, although neuropathologic investigations reveal no 
significant alterations of the blood–brain barrier in ALF [17], entry of cytokines via 
circumventricular organs remains a possibility. Alternative (or additional) 
mechanisms could involve brain accumulation of ammonia and lactate in ALF. 
Brain concentration of ammonia [31] and lactate are correlated with severity of 
encephalopathy [115, 161] and EEG changes [481] in experimental ALF and 
pathophysiologically-relevant concentrations of ammonia [482] and lactate [457] 
have been shown to cause release of TNF- and IL-1 from cultured microglial 
cells. 
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The findings of microglial activation and increased brain proinflammatory cytokines 
may have important implications for current and future therapies in ALF. Albumin 
dialysis improves neurological status in ALF patients and removes circulating 
cytokines [483] and mild hypothermia shown to reduce ICP in ALF patients [39] 
was recently shown to lower brain concentrations of TNF- and IL-1 in 
experimental ALF [484]. Minocycline has been shown to be effective in the 
treatment of multiple sclerosis in clinical trials [485]. However, long-term use of 
minocycline may result in liver damage [486], a property that could limit its use in 
ALF. Experimental therapeutic studies with other anti-inflammatory agents with the 
capacity to limit microglial activation and brain production of proinflammatory 
cytokines in ALF are warranted. 
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A B S T R A C T  
Encephalopathy and brain edema are serious complications of acute liver failure 
(ALF). The precise pathophysiologic mechanisms responsible have not been fully 
elucidated but it has been suggested that oxidative/nitrosative stress is involved. In 
the present study we evaluated the role of oxidative/ nitrosative stress in the 
pathogenesis of HE and brain edema in rats with ALF resulting from hepatic 
devascularization. We also studied the effect of hypothermia, a treatment 
previously shown to delay the progression of encephalopathy and the onset of 
brain edema, on ALF-induced oxidative stress. ALF rats were sacrificed at precoma 
and coma stages of encephalopathy along with their appropriate sham-operated 
controls. Hypothermic ALF rats were sacrificed in parallel with normothermic 
comatose ALF rats. Nitric oxide production in plasma and brain was assessed 
indirectly by measuring the level of its stable end products, nitrite/nitrate (NOx), 
using the Griess reagent. Expression of nitric oxide synthase (NOS) isoforms and 
heme oxygenase-1 (HO-1) were measured using real-time quantitative PCR, 
Western blot analysis and immunohistochemistry. Increased nitrite/nitrate levels 
were observed in the plasma and frontal cortex in ALF rats at coma stage of 
encephalopathy compared to sham-operated controls. Increased expression of HO-1 
protein and mRNA was observed in the frontal cortex of ALF rats at both precoma 
and coma stages of encephalopathy. Significant increases in expression of 
endothelial and inducible NOS mRNA isoforms also occurred at precoma and coma 
stages of encephalopathy. Expression of the neuronal nitric oxide synthase isoform 
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(nNOS) was not altered by ALF. Hypothermia normalized nitrite/nitrate levels in 
brain and significantly attenuated HO-1, eNOS and iNOS expression. These results 
suggest that, oxidative/nitrosative stress participates in the pathogenesis of brain 
edema and its complications in ALF and that the beneficial effect of hypothermia 
depends in part on its ability to inhibit oxidative/nitrosative stress-related 
mechanisms. 
Keywords: Hepatic encephalopathy, Acute liver failure, Nitric oxide synthase, 
Oxidative/nitrosative stress, Brain edema, Hypothermia 
1. Introduction 
ALF resulting from viral infection or toxic liver injury is a life-threatening 
condition. Mortality rates are extremely high with death resulting predominantly 
from brain herniation due to intracranial hypertension caused by cytotoxic brain 
edema. Hyperammonemia is a critical factor in the pathogenesis of cerebral edema 
and herniation development following ALF [79]. While the precise mechanism 
responsible for ammonia’s toxic effects on CNS function are unclear, there is 
increasing evidence to suggest that oxidative/ nitrosative stress plays a significant 
role. ROS are produced in rat brain following acute ammonia intoxication [487] as 
well as in cultured astrocytes exposed to pathophysiologic concentrations of 
ammonia [99]. Acute ammonia intoxication also leads to glutathione depletion, 
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lipid peroxidation and decreased activity of antioxidant enzymes such as 
superoxide dismutase, catalase and glutathione peroxidase [488].
The objective of the present study was to assess oxidative stress in relation to 
encephalopathy and brain edema in ALF. Nitrite/nitrate levels as well as 
expression of heme oxygenase-1 (HO-1) and the NOS isoforms were measured as 
a function of encephalopathy and brain edema severity using a wellcharacterized 
animal model of ALF, the hepatic devascularized rat [462]. In a second series of 
studies, the beneficial effects of mild hypothermia previously shown to delay the 
progression of encephalopathy and the onset of brain edema in experimental ALF 
[254] as well as in ALF patients [489] was evaluated in relation to ALF-mediated 
oxidative stress markers and progression of neurological symptoms. 
2. Materials and methods 
2.1. Hepatic devascularization and treatments 
Adult male Sprague-Dawley rats (200–250g) purchased from Charles River (Saint-
Constant, Quebec, Canada) were routinely tested for common pathogens and were 
free of infection at the onset of surgery. Animals were anesthetized with 
isoflurane, and an end-to-side portacaval anastomosis was performed according to 
the guidelines of Lee and Fisher (1961)[448]. Briefly, rats underwent a laparotomy, 
the inferior vena cava and portal vein were isolated and clamped using an 
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anastomosis clamp (Roboz Instruments Inc., Washington DC) and an elliptical 
portion 1.5 times the diameter of the portal vein was removed. The portal vein was 
ligated and cut, and an end-to-side anastomosis was performed under a dissecting 
microscope. Total surgery time was <30 min. Sham-operated control rats (n = 10), 
matched for weight, were similarly anesthetized and the inferior vena cava was 
clamped for 20 min. Following surgery, all animals were individually housed with 
free access to food and water under constant conditions of temperature, humidity, 
and light cycles. Twenty-four hours after portacaval anastomosis, rats were 
reanesthetized and subjected to hepatic artery ligation (HAL). Following HAL, 
arterial blood glucose levels were monitored and glucose was administered 
subcutaneously as needed to maintain normoglycemia. Body temperature was 
monitored every 15 min and maintained at 37 ± 0.5 °C by means of heating pads. 
Hypothermia occurred spontaneously in the absence of external heating and body 
temperature was maintained at 33 ± 0.5 °C using heating pads when necessary. A 
group of animals (n = 10) was sacrificed 6 h following HAL (ALF-6h) and a second 
group (n =10) was sacrificed at coma stage of encephalopathy (ALF-coma) (defined 
as the loss of corneal reflexes occurring 14–18 h post-HAL). Hypothermic animals 
(ALF-33) were sacrificed in parallel with time-matched comatose normothermic 
ALF animals and sham-operated controls. Brains were rapidly removed, dissected 
on ice and were immediately frozen in isopentane. All tissues were stored at -70 
°C until use. All the above surgical methods were conducted in accordance with 
the Guidelines of Canadian Council of Animal care and were approved by Animal 
Research Committee at Saint-Luc Hospital (C.H.U.M.). 
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2.2. Brain water measurement 
Brain water was quantitated by the wet-weight/dry-weight method. Half of the 
brain was weighed before and after 48 h incubation in a 120 °C oven. Water content 
of the brain samples is expressed as percentage of water content according to the 
following equation: % water = (wet weight - dry weight)/wet weight × 100. 
2.3. Ammonia measurements 
Immediately after decapitation, the head was flash frozen in isopentane cooled to 
liquid nitrogen temperature and the brain was subsequently chiselled out with 
special care to keep it frozen at all times. Brains were stored at -70 °C until analysis 
at which time frozen brains were weighed and powdered over liquid nitrogen. 
Frozen powder was extracted by homogenization in ice-cold 1 M perchloric acid 
and centrifuged at 16,000 × g for 15 min at 4°C. 50 µL of supernatant were added to 
a suspension of Dowex 50WX8-200 ion exchange resin (Sigma–Aldrich, St.-Louis, 
MO) and allowed to react for 5 min with constant shaking. After extensive washing, 
the colorimetric reaction was initiated by the addition of phenol and hypochlorite in 
the presence of nitroferricyanide. Absorbance was measured using a spectro-
photometer at a wavelength of 630 nm. Plasma ammonia concentrations were 
determined using a commercial ammonia test kit (Sigma–Aldrich) based on the 
enzymatic method using the glutamate dehydrogenase reaction. 
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2.4. Nitrite/nitrate levels (NOx) 
Nitrite concentrations in brain and plasma were determined using Griess reagent 
[490]. Brain tissue were homogenized in water and diluted to 5 µg/µl. Brain and 
plasma samples (100 µl) were diluted 2-fold in water and deproteinized by adding 
10 µl of 30% ZnSO4. After centrifugation (10,000 × g, 5 min), the supernatant was 
incubated with cadmium for 24 h to reduce nitrate to nitrite. Samples (100 µl) or 
serial dilution of NaNO2 standard (linear range 0–100 µM) were applied to a 
microtiter plate well. Total nitrite in each sample was then determined by adding 50 
µl Griess reagent 1 (1% sulfanilamide in 1 N HCl), followed by Griess reagent 2 
(0.1% N-(1-napthyl)-ethylenediamine). The mixture was incubated for 10 min in 
the dark. Optical density was measured at 540 nm spectrophotometrically. 
Nitrate/nitrite levels were expressed as micromoles per gram tissue protein or 
micromoles per liter. 
2.5. Western blot analysis 
Brain samples from frontal cortex were homogenized in ice-cold RIPA buffer (50 
mM Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% 
SDS) containing a protease inhibitor cocktail (Sigma–Aldrich) and centrifuged at 
12,000 × g for 45 min. Protein concentrations were measured using a DC Bio-Rad 
protein assay kit (Bio-Rad Laboratories, Hercules, CA). Proteins (100 µg) were 
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solubilized in Laemmli buffer (50 mM Tris–HCl, pH 6.8, 10% glycerol; 2% SDS, 
10% dithiothreitol, 0.1% bromophenol blue) and boiled for 10 min. Proteins were 
resolved by 10% denaturing SDS-polyacrylamide gels and transferred overnight to 
PVDF membranes (Bio-Rad Laboratories). The filters were blocked for 1 h in Tris-
buffered saline (TBS) containing 5% dry milk and 0.1% Tween 20, then incubated 
for 1 h with rabbit anti-HO-1 (1/700) (Assay Design, Ann Arbor, MI). The blots 
were subsequently probed with the goat anti-rabbit horseradish peroxidase-
conjugated antiserum (PerkinElmer, Waltham, MA) diluted 1/10,000 in the same 
buffer. After extensive washing with TBS, the peroxidase activity was detected by 
chemiluminescence using the ECL detection system (Amersham, Arlington Heights, 
IL). Equal loading of proteins was confirmed by Ponceau S staining. Expression 
levels were quantitated using an MCID-M1 imaging system (Imaging Research, ON, 
Canada). 
2.6. Real-time reverse-transcription polymerase chain reaction (qRT-PCR) 
Animals were transcardially perfused with 240 ml ice-cold saline to remove 
residual blood in the brain. Total RNA was isolated from rat brain cortex using the 
Trizol reagent (Invitrogen Ltd., Carlsbad, CA), according to the manufacturer
’
s 
instructions. The cDNA was synthesized using thermoscript RT-PCR system 
(Invitrogen). Expression levels were assessed by real-time PCR in a RotorGene 
3000
TM
 Real time DNA detection system (Corbett Life Science, Sydney, Australia) 
with the Quantitect SYBRGreen I PCR kit (Quiagen, Valencia, CA). Oligonucleotide 
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primers (Invitrogen) were designed using the PRIMER3 program [451] at 
http://primer3.sourceforge.net/ and selected to include at least one intron. The 
specificity of the oligonucleotide primers was verified using the program BLASTN 
from the National Center for Biotechnology Information (NCBI, Bethesda, MD). 
For each primer pair, the amplified cDNA fragments were analyzed by agarose gel 
to confirm the absence of the intron and of any nonspecific PCR products. The 
forward and reverse oligonucleotide primer sequences were 5’-
CCACAGCTGAGAGGGAAATC-3’ and 5’-TCTCCAGGGAGGAAGAGGAT-3’ for -
actin (GeneBank accession # V01217); 5’-TCAACAGTGGGAGCAAAGC-3’ and 5’-
CTTTGT- GCGATTTGCCATC-3’ for nNOS (GenBank accession # X59949); 5’-
GATCCAGTGGGGGAAACTG-3’ and 5’-GCCTCGGTTTGTTGCATACT-3’ for 
eNOS (GenBank accession # AB176831); 5’-CCAAGGTGACCTGAAAGAGG-3’ and 
5’-TTGATGCTTGTGACTCTTAGGG-3’ for iNOS (GenBank accession # U26686); 
5’- GAGCCAGCCTGAACTAGCC-3’ and 5’-GATGTGCACCTCCTTGGTG-3’ for 
HO-1 (GenBank accession # J02722). A relative quantification was performed by 
comparing the threshold cycle values of samples with serially diluted standards. 
Expression levels were normalized to the housekeeping gene -actin. 
2.7. Statistical analysis 
All data are expressed as the mean ± S.E.M. and statistical analysis was performed 
using unpaired Student
’
s t-test (two-group comparisons) or one-way analysis of 
variance (ANOVA) followed by Tukey
’
s post hoc analysis (multiple comparisons). A 
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probability of p<0.05 was chosen to establish significance between the groups. Data 
were analyzed by using Prism 4.0 software (Prism 4.0, San Diego, CA). 
3. Results 
3.1. Mild hypothermia improves neurological status and prevents brain edema in 
hepatic devascularized ALF rats 
Following HAL, rats developed a progressive encephalopathy, starting with lethargy 
(evident 6 h after HAL) progressing to loss of righting and corneal reflexes and coma. 
Sham-operated control rats exhibited normal behavior and neurological reflexes 
throughout the period of the experiments. Brain water content was not significantly 
different between sham-operated rats and ALF rats 6 h after HAL (ALF-6 h) but was 
significantly elevated in ALF rats at coma stages (sham vs. ALF-coma: 78.04 ± 0.19% 
vs. 80.83 ± 0.05%, p< 0.001) (Table 1). Mild hypothermia significantly (p < 0.001) 
delayed progression of encephalopathy i.e. time to precoma (loss of righting reflexes) 
and time to coma (loss of corneal reflexes) (Table 2). Brain water content was also 
significantly reduced (78.31 ± 0.09%, p< 0.001) in hypothermic ALF rats (ALF-33) 
(Table 1). 
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Percentage of water content of cerebral cortex, plasma and brain ammonia and 
nitrite/nitrate levels in sham-operated controls (sham), ALF rats 6 h post-HAL 
(ALF-6 h), at coma stage of encephalopathy (ALF-coma) and in hypothermic ALF 
rats (ALF-33). Data represent mean ± S.E.M. of n=10 animals per treatment group. 
*p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma; ††p < 0.01 vs. ALF-coma. 
3.2. Effect of mild hypothermia on nitrite/nitrate and ammonia levels in plasma 
and brain of ALF rats 
Plasma ammonia levels were increased 11.8-fold (p < 0.001) 6 h after HAL (ALF-6 
h) and 25.4-fold (p < 0.001) in comatose ALF rats (ALF-coma) (Table 1). Brain 
ammonia levels were increased 9.6-fold (p < 0.001) 6 h after HAL and 18.9-fold (p < 
0.001) at coma stages of encephalopathy (Table 1). Mild hypothermia reduced 
plasma ammonia levels by 59.3% (p < 0.001) and brain ammonia levels by 67.0% (p 
< 0.001). Nitrite/nitrate levels in plasma were elevated 1.5-fold 6 h after HAL and 
remained at the same levels in comatose ALF rats (p < 0.001). Nitrite/nitrate levels in 
plasma were significantly reduced by 27.6% (p < 0.001) due to mild hypothermia 
(Table 1). Nitrite/nitrate levels in brain were elevated 1.5-fold in comatose ALF rats 
but were unchanged 6 h after HAL. Mild hypothermia reduced brain nitrite/nitrate 
levels by 30.7% (p < 0.01) (Table 1). Plasma ammonia levels in rats maintained at 
either 37°C or 33°C were not significantly altered when measured at coma stage of 
encephalopathy. 
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Time to precoma (loss of righting reflexes) and coma (loss of corneal reflexes) stages 
of encephalopathy in normothermic and hypothermic ALF rats. Data represent 
mean ± S.E.M. of n = 10 animals per treatment group. *p < 0.001. 
3.3. Mild hypothermia inhibits upregulation of HO-1, iNOS and eNOS 
expression in ALF rat brain 
HO-1 mRNA level in brain was elevated 1.3-fold (p < 0.01) 6 h post-HAL and 1.7-
fold (p < 0.001) in comatose ALF rats compared to sham-operated controls (Fig. 1). 
HO-1 protein expression was increased 1.2-fold (p < 0.05) 6 h post-HAL and 1.6-fold 
(p < 0.001) at coma stage of encephalopathy compared to sham-operated controls 
(Fig. 2). Mild hypothermia reduced HO-1 mRNA expression by 23.9% (p < 0.001) 
and HO-1 protein expression by 22.3% (p < 0.001). nNOS mRNA expression in 
brain was not statistically different between ALF rats and sham-operated controls 
(data not shown). However, iNOS and eNOS mRNA levels were elevated 5.0-fold 
and 1.8-fold, respectively, 6 h post-HAL (p < 0.001) and were further increased 9.0-
fold and 2.7-fold (p < 0.001) in comatose ALF rats (Figs. 3 and 4). Mild hypothermia 
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decreased iNOS mRNA levels by 69.9% (p < 0.001) and eNOS mRNA expression by 
24.8% (p < 0.01). 
Fig. 1. Upregulation of brain HO-1 mRNA expression is attenuated by mild 
hypothermia in the cerebral cortex of ALF rats. Expression of HO-1 mRNA in the 
cerebral cortex of sham-operated controls (sham), ALF rats 6 h post-HAL (ALF-6h), 
ALF rats at coma stage of encephalopathy (ALF-coma) and hypothermic ALF rats 
(ALF-33). Data represent mean ± S.E.M. of n=10 animals per experimental group. 
*
p < 0.01 vs. sham; 
**
p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma. 
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Fig. 2. Upregulation of brain HO-1 protein expression is attenuated by mild 
hypothermia in the cerebral cortex of ALF rats. Expression of HO-1 protein in the 
cerebral cortex of sham-operated controls (sham) (lanes 1–3), ALF rats 6 h post-HAL 
(ALF-6 h) (lanes 4–6), ALF rats at coma stage of encephalopathy (ALF-coma) (lanes 
7–9) and hypothermic ALF rats (ALF-33) (lanes 10–12). Data represent mean ± 
S.E.M. of n=10 animals per experimental group. 
*
p < 0.05 vs. sham; 
**
p < 0.001 vs. 
sham; †p < 0.001 vs. ALF-coma. 
4. Discussion 
Results of the present study demonstrate that ALF resulting from hepatic 
devascularization leads to selective increases in expression of the gene coding for 
inducible and endothelial isoforms of NOS as well as for heme oxygenase-1 (HO-1) 
in brain. The magnitude of induction, in all cases, was a function of the duration of 
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liver ischemia, the presence of severe encephalopathy (coma), cerebral edema and of 
blood and brain ammonia concentrations. Increased iNOS and eNOS isoform gene 
expression was accompanied by significant increases in brain concentrations of 
nitrite/nitrate (NOx) confirming that the increases in NOS isoform expression 
caused by ALF were sufficient to cause increased NO production. Further studies 
are required in order to ascertain the precise cellular localization of the iNOS 
increases. Previous studies in a hepatotoxin model of ALF had provided evidence 
for oxidative stress in brain. Such evidence consisted of increased lipid peroxidation 
[491] and decreases in the GSH/GSSG ratio [492, 493] in the brains of these 
animals. However, a third study using a partial hepatectomy model of ALF failed to 
observe any significant changes in ascorbate status in this model [494], a finding 
that could be attributed to the relative early stage of ALF used in this study. 
Fig. 3. Upregulation of brain iNOS mRNA expression is attenuated by mild 
hypothermia in the cerebral cortex of ALF rats. Expression of iNOS mRNA in the 
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cerebral cortex of sham-operated controls (sham), ALF rats 6 h post-HAL (ALF-6h), 
ALF rats at coma stage of encephalopathy (ALF-coma) and hypothermic ALF rats 
(ALF-33). Data represent mean ± S.E.M. of n=10 animals per experimental group. 
*
p < 0.001 vs. sham; 
**
p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma. 
Fig. 4. Upregulation of brain eNOS mRNA expression is attenuated by mild 
hypothermia in the cerebral cortex of ALF rats. Expression of eNOS mRNA in the 
cerebral cortex of sham-operated controls (sham), ALF rats 6 h post-HAL (ALF-6h), 
ALF rats at coma stage of encephalopathy (ALF-coma) and hypothermic ALF rats 
(ALF-33). Data represent mean ± S.E.M. of n=10 animals per experimental group. 
*
p < 0.001 vs. sham; 
**
p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma. 
The precise cause of oxidative/nitrosative stress in brain of ALF in unclear. 
However, there is a great deal of indirect evidence to suggest that ammonia plays a 
role. Mice with hyperammonemia resulting from dietary loading display evidence 
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of lipid peroxidation in brain [495] and exposure of cultured astrocytes to 
concentrations of ammonia equivalent to those encountered in brain in ALF results 
in the generation of ROS [99] accompanied by decreased levels of GSH. Lipid 
peroxidation and increased production of nitric oxide have been reported in the brains 
of animals with portacaval shunts administered ammonia sufficient to produce 
brain edema [93]. The notion of a link between increased brain ammonia and 
nitrosative stress in ALF is strengthened by the finding of the present study of a 
correlation between brain ammonia increases and increased expression of NOS 
isoforms and HO-1 as a function of the presence of encephalopathy and brain 
edema in hepatic devascularized rats. In vitro studies suggest that ammonia-induced 
oxidative/nitrosative stress leads to cell swelling and involves alterations of the 
MPT complex and/or impaired cellular energy metabolism [496]. Whether or not 
similar mechanisms occur in ALF awaits further studies. Evidence against a unique 
role of ammonia generated oxidative/nitrosative in the pathogenesis of HE are the 
rather poor correlations observed in the present study between brain concentrations 
of ammonia and nitrite/nitrate levels as well as those between brain nitrite/nitrate 
levels and severity of encephalopathy clearly indicating that additional 
mechanisms could also be implicated. 
Potential consequences of oxidative/nitrosative stress in ALF involve 
modifications of key brain proteins. For example, portacaval anastomosis results in 
nitration of glutamine synthase [497], an astrocytic enzyme uniquely responsible 
for removal of ammonia in the brain and
13
C NMR studies revealed decreased 
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capacity for brain glutamine synthesis in hepatic devascularized rats [115]. A 
second target protein is the astrocytic glutamate transporter EAAT-2 (formerly 
GLT-1) which is known to be inactivated by oxidative stress [258]; GLT-1 
expression is significantly reduced in the brains of hepatic devascularized rats [262]
and in rats with toxic liver injury [263]. Ammonia results in inactivation of the 
tricarboxylic cycle enzyme alphaketoglutarate dehydrogenase [168], an effect 
which has been attributed to the generation of ROS [498]. 
Further evidence that oxidative/nitrosative stress is implicated in the pathogenesis of 
brain edema and encephalopathy in ALF is provided by the findings of the present 
study where mild hypothermia (33°C) sufficient to delay encephalopathy and 
prevent brain edema significantly attenuates the increases in expression of HO-1 
and NOS isoforms with consequent reduction of brain levels of nitrites/nitrates. 
Mild hypothermia also resulted in a significant attenuation of the increased brain 
concentrations of ammonia that are characteristic of ALF. Such action could result 
from decreased blood–brain barrier ammonia transfer, improvement in hepatic 
function or modulation of CBF [314, 446]. Decreased expression of oxidative 
stress markers could result, at least in part, from the lowering of brain ammonia 
concentrations. Mild hypothermia is currently in use in the management of ALF 
where beneficial effects on both hepatic and brain function have been described 
[39, 314, 446, 447]. Findings of the present study suggest that one of the beneficial 
effects of mild hypothermia in relation to the cerebral consequences of ALF relates 
to its potential to reduce oxidative/nitrosative stress-related mechanisms. 
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Abstract 
In the present study, the effects of minocycline on progression of encephalopathy and 
brain edema in rats with acute liver failure (ALF) resulting from hepatic 
devascularization were studied in relation to the antioxidant action of the drug. ALF rats 
were sacrificed at precoma and coma stages of encephalopathy along with their 
appropriate sham-operated controls. Minocycline-treated ALF rats were sacrificed in 
parallel with comatose vehicle-treated ALF controls. Microglial activation was assessed 
using CD11b/c (OX-42) immunohistochemistry. Nitrite/nitrate levels in plasma and 
brain were measured using the Griess reaction. Expression of nitric oxide synthase 
(NOS) isoforms and heme oxygenase-1 (HO-1) were measured using real-time 
quantitative PCR and Western blot analysis. Increased nitrite/nitrate levels were 
observed in the plasma of ALF rats at coma stage of encephalopathy compared to sham-
operated controls. Increased expression of HO-1 mRNA and protein was observed in 
the frontal cortex of ALF rats at both precoma and coma stages of encephalopathy. 
Significant increases in expression of endothelial (eNOS) and inducible (iNOS) 
isoforms of NOS mRNA and protein occurred only at coma stages of encephalopathy 
accompanied by increased brain nitrite/nitrate concentrations. As expected, minocycline 
attenuated microglial activation as confirmed by decreased OX-42 immunoreactivity, 
normalized nitrite/nitrate levels in brain and significantly attenuated HO-1, eNOS and 
iNOS expression. These results indicate that the beneficial effect of minocycline on the 
neurological complications of ALF is mediated, at least in part, by reduction of 
oxidative/nitrosative stress. 
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1. Introduction 
Hepatic encephalopathy (HE) and brain edema leading to intracranial hypertension are 
serious neurological complications of ALF. Hyperammonemia is a critical factor in the 
pathogenesis of the central nervous system complications of ALF [79] and cerebral 
herniation in ALF patients has been shown to correlate with arterial ammonia 
concentrations [26]. However, it appears that other factors may also contribute to the 
cerebral complications of ALF. In particular, microglial activation and brain 
inflammation are correlated with the progression of encephalopathy and the onset of 
brain edema in rats with ALF resulting from hepatic devascularization [499]. Moreover, 
increased expression of the endothelial and inducible isoforms of nitric oxide synthase 
as well as heme oxygenase-1 have been reported in this model [500] suggesting that 
oxidative/nitrosative stress also plays a significant role in the pathogenesis of the 
cerebral complications of ALF. 
Minocycline, a semisynthetic tetracycline with potent antimicrobial properties is known 
to limit microglial activation in a wide range of neurodegenerative conditions [463] and 
a previous study showed that it also delays progression of encephalopathy and the onset 
of brain edema in ALF rats [501]. It has been proposed that minocycline has antioxidant 
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properties [502]. Consequently, the objective of the present study was to assess the 
protective action of minocycline on oxidative/nitrosative stress in the brains of rats with 
ALF. Nitrite/nitrate levels as well as expression of heme oxygenase-1 (HO-1) and nitric 
oxide synthase (NOS) isoforms were measured in brain as a function of encephalopathy 
and brain edema severity using a well-characterized animal model of ALF, the hepatic 
devascularized rat [462]. 
2. Materials and methods 
2.1. Hepatic devascularization and treatments 
Adult male Sprague–Dawley rats (200–250 g) purchased from Charles River (Saint-
Constant, Quebec, Canada) were routinely tested for common pathogens and were free 
of infection at the onset of surgery. Animals were anesthetized with isoflurane, and an 
end-to-side portacaval anastomosis was performed according to the guidelines of Lee 
and Fisher (1961)[448]. Briefly, rats underwent a laparotomy, the inferior vena cava 
and portal vein were isolated and clamped using an anastomosis clamp (Roboz 
Instruments Inc., Washington DC) and an elliptical portion 1.5 times the diameter of the 
portal vein was removed. The portal vein was ligated and cut, and an end-to-side 
anastomosis was performed under a dissecting microscope. Total surgery time was 
<30 min. Sham-operated control rats (n = 10), matched for weight, were similarly 
anesthetized and the inferior vena cava was clamped for 20 min. Following surgery, all 
animals were individually housed with free access to food and water under constant 
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conditions of temperature, humidity, and light cycles. Twenty-four hours after 
portacaval anastomosis, rats were reanesthetized and subjected to hepatic artery ligation 
(HAL). Following HAL, arterial blood glucose levels were monitored and glucose was 
administered subcutaneously as needed to maintain normoglycemia. Body temperature 
was monitored every 15 min and maintained at 37 ± 0.5 °C by means of heating pads. A 
group of animals (n = 10) was sacrificed 6 h following HAL (ALF-6 h) and a second 
group (n = 10) was sacrificed at coma stage of encephalopathy (ALF-coma) (defined as 
the loss of corneal reflexes). In a second set of experiments, a group (n = 10) of ALF 
animals (ALF-mino) were administered minocycline (22.5 mg/kg twice daily; i.p.) on 
days −2, −1 and day 0 of HAL operation. Control ALF rats (n = 10) were given 
equivalent volumes of saline. Minocycline-treated animals were sacrificed in parallel 
with comatose saline-treated ALF controls. Brains were rapidly removed, dissected on 
ice and were immediately frozen in isopentane. All tissues were stored at −70 °C until 
use. All the above surgical methods were conducted in accordance with the Guidelines 
of Canadian Council of Animal care and were approved by Animal Research 
Committee at Saint-Luc Hospital (C.H.U.M.). 
2.2. Brain water measurement 
Brain water was quantitated by the wet weight/dry weight method. Half of the brain was 
weighed before and after 48 h incubation in a 120 °C oven. Water content of the brain 
samples are expressed as percentage of water content according to the following 
equation: %water = (wet weight − dry weight)/wet weight × 100. 
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2.3. Ammonia measurements 
Plasma and brain ammonia concentrations were determined using a commercial 
ammonia test kit (Sigma–Aldrich, St. Louis, MO) based on the enzymatic method using 
the glutamate dehydrogenase reaction. 
2.4. Nitrite/nitrate levels 
Nitrite/nitrate levels in brain and plasma were determined using Griess reagent [490]. 
Brain tissue were homogenized in water and diluted to 5 g/l. Brain and plasma 
samples (100 l) were diluted 2-fold in water, deproteinized by adding 10 l of 30% 
ZnSO4 and centrifuged at 10,000 × g for min. To reduce nitrate to nitrite, the 
supernatant was incubated for 24 h at room temperature with 0.5 g of cadmium that 
were washed sequentially in 0.1 M hydrochloric acid and 0.1 M ammonium hydroxide 
before use. Samples (100 l) or serial dilution of NaNO2 standard (linear range 0–
100 M) were applied to a microtiter plate well. Total nitrite in each sample was then 
determined by adding 50 l Griess reagent 1 (1% sulfanilamide in 1N HCl), followed 
by Griess reagent 2 (0.1% N-(1-napthyl)-ethylenediamine). The mixture was incubated 
for 10 min in the dark. Optical density was measured spectrophotometrically at 540 nm. 
Nitrate/nitrite levels were expressed as micromoles per gram tissue protein or 
micromoles per liter. 
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2.5. Immunohistochemistry 
Animals were deeply anesthetized with pentobarbital (60 mg/kg; i.p.). After being 
transcardially perfused with 240 ml ice-cold saline followed by 240 ml neutral-buffered 
formalin (containing 4% formaldehyde, 0.5% sodium phosphate buffer, pH 7.0), brains 
were removed, post-fixed in 10% formalin at 4 °C for 12 h and transferred into ice-cold 
phosphate-buffered saline (PBS) solution for storage. 50 m thick coronal sections were 
obtained using a vibratome from −4.0 to −5.5 mm relative to the bregma according to 
the rat brain atlas of [450]. Sections were incubated with 0.3% hydrogen peroxide in 
PBS for 10 min to block endogenous peroxidase activity. Sections were blocked with 
2% horse serum and 0.5% Triton X100 and incubated at 4 °C overnight with mouse 
anti-CD11b/c (OX-42) (1/1000) (Cedarlane Laboratories, Burlington, NC). After 
washing with PBS, sections were incubated for 1 h with horse anti-mouse biotinylated 
secondary antibody (1/100) (Vector Laboratories, Burlingame, CA) and thereafter with 
Vectasain ABC reagent (Vector Laboratories). OX-42 immunoreactivity was detected 
by incubation with 3-3’-diaminobenzidine containing urea-hydrogen peroxide (Sigma–
Aldrich). The sections were mounted on Superfrost Plus slides (Fisher Scientific, 
Pittsburgh, CA), dehydrated stepwise in ethanol and xylene and coverslip with 
Permount (Fisher Scientific). Sections without primary antibodies were used as negative 
controls and showed no immunoreactivity. 
2.6. Western blot analysis 
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Brain samples from frontal cortex were homogenized in ice-cold RIPA buffer (50 mM 
Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
containing a protease inhibitor cocktail (Sigma–Aldrich) and centrifuged at 12,000 × g
for 45 min. Protein concentrations were measured using a DC Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Hercules, CA). Proteins (100 g) were solubilized in Laemmli 
buffer (50 mM Tris–HCl, pH 6.8, 10% glycerol; 2% SDS, 10% dithiothreitol, 0.1% 
bromophenol blue) and boiled for 10 min. Proteins were resolved by 7–10% denaturing 
SDS-polyacrylamide gels and transferred overnight to PVDF membranes (Bio-Rad 
Laboratories) The filters were blocked for 1 h in Tris-buffered saline (TBS) containing 
5% dry milk and 0.1% Tween 20, then incubated for 1 h with rabbit anti-HO-1 (1/700, 
Assay Design, Ann Arbor, MI), rabbit anti-iNOS (1/250, Santa Cruz Biotechnology, 
Santa Cruz, CA), rabbit anti-eNOS (1/250, BD Biosciences, Franklin Lakes, NJ), or 
mouse anti-beta-actin (1/10000, Sigma–Aldrich). The blots were subsequently probed 
with goat anti-rabbit or anti-mouse horseradish peroxidase-conjugated antiserum 
(PerkinElmer, Waltham, MA) diluted 1/10,000 in the same buffer. After extensive 
washing with TBS, the peroxidase activity was detected by chemiluminescence using 
the ECL detection system (Amersham, Arlington Heights, IL). Intensity of the bands 
was measured by densitometry using quantified using Quantity-One software (Bio-Rad 
Laboratories). Results are expressed as percentage of the housekeeping protein beta-
actin to normalize for loading variation. 
2.7. Real-time reverse-transcription polymerase chain reaction (qRT-PCR) 
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Animals were transcardially perfused with 240 ml ice-cold saline to remove residual 
blood in the brain. Total RNA was isolated from rat brain cortex using the Trizol 
reagent (Invitrogen Ltd., Carlsbad, CA), according to the manufacturer's instructions. 
The cDNA was synthesized using thermoscript RT-PCR system (Invitrogen). 
Expression levels were assessed by real-time PCR in a RotorGene 3000™ Real time 
DNA detection system (Corbett Life Science, Sydney, Australia) with the Quantitect 
SYBRGreen I PCR kit (Quiagen, Valencia, CA). Oligonucleotide primers (Invitrogen) 
were designed using the primer3 program [451] at http://www.primer3.sourceforge.net/
and selected to include at least one intron. The specificity of the oligonucleotide primers 
was verified using the program BLASTN from the National Center for Biotechnology 
Information (NCBI, Bethesda, MD). For each primer pair, the amplified cDNA 
fragments were analyzed by agarose gel to confirm the absence of the intron and of any 
nonspecific PCR products. The forward and reverse oligonucleotide primer sequences 
were 5’-CCACAGCTGAGAGGGAAATC-3’ and 5’-
TCTCCAGGGAGGAAGAGGAT-3’ for -actin (GeneBank accession # V01217); 5’-
TCAACAGTGGGAGCAAAGC-3’ and 5’-CTTTGTGCGATTTGCCATC-3’ for 
nNOS (GenBank accession # U67309); 5’-GATCCAGTGGGGGAAACT G-3’ and 5’-
GCCTCGGTTTGTTGCATACT-3’ for eNOS (GenBank accession # AB176831) 5’-
CCAAGGTGACCTGAAAGAGG-3’ and 5’-TTGATGCTTGTGACTCTTAGGG-3’ 
for iNOS (GenBank accession # U26686); 5’-GAGCCAGCCTGAACTAGCC-3’ and 
5’-GATGTGCACCTCCTTGGTG-3’ for HO-1 (GenBank accession # J02722). A 
relative quantification was performed by comparing the threshold cycle values of 
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samples with serially diluted standards. Expression levels were normalized to the 
housekeeping gene -actin. 
2.8. Statistical analysis 
All data are expressed as the mean ± SEM and statistical analysis was performed using 
one-way analysis of variance (ANOVA) followed by Tukey's post hoc analysis. A 
probability of p < 0.05 was chosen to establish significance between the groups. Data 
were analyzed by using Prism 4.0 software (Prism 4.0, San Diego, CA). 
3. Results 
3.1. Minocycline attenuates microglial activation and delays the progression of 
neurological complications in ALF rats 
Following HAL, rats developed a progressive encephalopathy, characterized by 
lethargy (evident 6 h after HAL) progressing to loss of righting and corneal reflexes and 
coma. Sham-operated rats exhibited normal behavior and neurological reflexes 
throughout the period of the experiments. Brain water content was not significantly 
different between sham-operated rats and ALF rats 6 h after HAL (ALF-6 h) but was 
significantly elevated in ALF rats at coma stage (sham vs. ALF-coma: 78.09 ± 0.07% 
vs. 80.78 ± 0.1%, p < 0.001) (Table 1). Brain edema in ALF rats is correlated with 
microglial activation as shown by increased OX-42 immunostaining in frontal cortex 
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and other brain regions [499]. Minocycline attenuated microglial activation as shown by 
decreased OX-42 immunoreactivity (60.1%, p < 0.001) in the frontal cortex of ALF rats 
(Fig. 1) and concomitantly delayed progression of encephalopathy with longer times to 
precoma (loss of righting reflexes) (saline vs. minocycline: 9.1 ± 0.3 h vs. 13.1 ± 0.5 h, 
p < 0.001) and coma (loss of corneal reflexes) (saline vs. minocycline: 13.1 ± 0.4 h vs. 
15.8 ± 0.4 h, p < 0.001). As previously reported, brain water content was also 
significantly (p < 0.001) reduced in minocycline-treated (79.38 ± 0.15%) ALF rats 
(Table 1) [501]. 
Table 1. Effect of minocycline on brain edema, ammonia and nitrite/nitrate levels in 
plasma and brain. 
Water content of cerebral cortex, plasma and brain ammonia and nitrite/nitrate levels in 
sham-operated controls (sham), ALF rats 6 h post-HAL (ALF-6 h), at coma stage of 
encephalopathy (ALF-coma) and in minocycline-treated ALF rats (ALF-mino). Data 
represent mean ± SEM of n = 10 animals per treatment group. * p < 0.001 vs. sham; 
†
p < 0.001 vs. ALF-coma. 
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Fig. 1. Attenuation of microglial activation by minocycline in the brains of ALF rats 
Representative micrographs showing the effect of ALF on CD11b/c (OX-42) 
immunoreactivity in cerebral cortex of (A) sham-operated controls; (B) ALF rats 6 h 
post-HAL; (C) ALF rats at coma stage of encephlopathy; and (D) minocycline-treated 
ALF rats (magnification: 200×).  
3.2. Effect of minocycline on nitrite/nitrate and ammonia levels in plasma and 
brain of ALF rats
Plasma ammonia levels were increased 11.8-fold (p < 0.001) 6 h after HAL and 25.4-
fold (p < 0.001) in comatose ALF rats (ALF-37) (Table 1). Brain ammonia levels were 
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increased 9.6-fold (p < 0.001) 6 h after HAL and 18.9-fold (p < 0.001) in comatose ALF 
rats. Minocycline reduced plasma and brain ammonia levels by 54.0% (p < 0.001) and 
41.0% (p < 0.001), respectively (Table 1). Nitrite/nitrate levels in plasma were elevated 
1.5-fold 6 h after HAL and remained at the same levels in comatose ALF rats 
(p < 0.001) (Table 1). Nitrite/nitrate levels in brain were elevated 1.5-fold in comatose 
ALF rats but were not increased 6 h after HAL. Nitrite/nitrate levels in plasma were not 
changed by minocycline but were significantly reduced in brain at coma stages of 
encephalopathy (44.3%, p < 0.001) (Table 1). 
3.3. Minocycline attenuates upregulation of HO-1, iNOS and eNOS expression in 
ALF rat brain 
HO-1 mRNA levels in brain was elevated 1.3-fold (p < 0.01) 6 h post-HAL with further 
increases (1.7-fold, p < 0.001) in comatose ALF rats compared to sham-operated 
controls (Fig. 2a). Minocycline significantly reduced HO-1 mRNA expression by 
32.7% (p < 0.001). HO-1 protein levels was increased 1.2-fold (p < 0.01) 6 h post-HAL 
and 1.6-fold (p < 0.001) at coma stages of encephalopathy (Fig. 2b). Minocycline 
significantly reduced HO-1 protein expression by 13.4% (p < 0.01). 
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Fig. 2. Upregulation of brain HO-1 expression is attenuated by minocycline in the 
cerebral cortex of ALF rats. (A-) Expression of HO-1 mRNA and (B-) HO-1 protein in 
the cerebral cortex of sham-operated controls (SHAM) (lanes 1–3), ALF rats 6 h post-
HAL (ALF-6 h) (lanes 4–6), ALF rats at coma stage of encephalopathy (ALF-coma) 
(lanes 7–9) and minocycline-treated ALF rats (ALF-mino) (lanes 10–12). Data 
represent mean ± SEM of n = 10 animals per experimental group. *p < 0.01 vs. sham; 
**p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma; ††p < 0.01 vs. ALF-coma. 
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nNOS mRNA expression in brain was not statistically different between ALF rats and 
sham-operated controls (Fig. 3a). However, iNOS and eNOS mRNA levels were 
elevated 5.0-fold and 1.8-fold, respectively, 6 h post-HAL (p < 0.001) and were further 
increased 8.0-fold and 2.7-fold (p < 0.001) in comatose ALF rats (Fig. 3b and c). 
Minocycline significantly attenuated the iNOS and eNOS mRNA increases by 40.0% 
(p < 0.01) and 37.9% (p < 0.001), respectively. iNOS and eNOS protein levels were 
unchanged 6 h-post HAL but were significantly increased 1.7-fold (p < 0.001) and 1.4-
fold (p < 0.05), respectively at coma stages of encephalopathy (Fig. 4 and Fig. 5). 
Minocycline significantly attenuated iNOS and eNOS protein expression by 41.5% 
(p < 0.001) and 42.5% (p
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Fig. 3. Effect of minocycline on NOS isoform gene expression in the cerebral cortex of 
ALF rats. Expression of neuronal NOS (nNOS) (A-), inducible NOS (iNOS) (B-) and 
endothelial NOS (eNOS) (C-) mRNAs in the cerebral cortex of sham-operated controls 
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(SHAM), ALF rats 6 h post-HAL (ALF-6 h), ALF rats at coma stage of encephalopathy 
(ALF-coma) and minocycline-treated ALF rats (ALF-mino). Data represent 
mean ± SEM of n = 10 animals per experimental group. *p < 0.001 vs. sham; 
**p < 0.001 vs. sham; †p < 0.01 vs. ALF-coma; ††p < 0.001 vs. ALF-coma. 
Fig. 4. Effect of minocycline on inducible NOS (iNOS) protein expression in the 
cerebral cortex of ALF rats. Expression of iNOS protein in the cerebral cortex of sham-
operated controls (SHAM) (lanes 1–3), ALF rats 6 h post-HAL (ALF-6 h) (lanes 4–6), 
ALF rats at coma stage of encephalopathy (ALF-coma) (lanes 7–9) and minocycline-
treated ALF rats (ALF-mino) (lanes 10–12). Data represent mean ± SEM of n = 10 
animals per experimental group. *p < 0.001 vs. sham; †p < 0.001 vs. ALF-coma. 
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Fig. 5. Effect of minocycline on endothelial NOS (eNOS) protein expression in the 
cerebral cortex of ALF rats. Expression of eNOS protein in the cerebral cortex of sham-
operated controls (SHAM) (lanes 1–3), ALF rats 6 h post-HAL (ALF-6 h) (lanes 4–6), 
ALF rats at coma stage of encephalopathy (ALF-coma) (lanes 7–9) and minocycline-
treated ALF rats (ALF-mino) (lanes 10–12). Data represent mean ± SEM of n = 10 
animals per experimental group. *p < 0.05 vs. sham; †p < 0.05 vs. ALF-coma. 
4. Discussion 
Results of the present study reveal that ALF resulting from ischemic liver failure leads 
to increased expression of the inducible and endothelial isoforms of NOS in brain. The 
magnitude of increase of NOS isoform expression was a function of the duration of 
liver ischemia and the presence of severe encephalopathy (coma) and cerebral edema. 
Furthermore, increased expression of iNOS and eNOS isoforms was accompanied by 
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increased brain concentrations of nitrites/nitrates confirming that the increases in NOS 
isoform expression caused by ALF were sufficient to lead to increased NO production. 
Previous studies in a model of ALF resulting from toxic liver injury also showed 
evidence of oxidative/nitrosative stress in brain [491] and [492]. 
The precise cause of oxidative/nitrosative stress in brain in ALF has not been 
definitively established. However, there is indirect evidence to suggest that ammonia 
plays a role. Hyperammonemic mice manifest evidence of lipid peroxidation in brain 
[495] and exposure of cultured astrocytes to low millimolar concentrations of ammonia 
(equivalent to those encountered in brain in ALF) results in the production of ROS [99]. 
ROS are produced in rat brain following acute ammonia intoxication [487] leading to 
glutathione depletion, lipid peroxidation and decreased activity of antioxidant enzymes 
such as superoxide dismutase, catalase and glutathione peroxidase [503]. Moreover, 
lipid peroxidation and increased NO synthesis have been reported in the brains of 
animals with portacaval shunts administered ammonia sufficient to produce brain 
edema [93]. This notion of a pathophysiologic link between brain ammonia and 
nitrosative stress in ALF is strengthened by the findings of the present study of a 
correlation between brain ammonia increases, increased expression of NOS isoforms 
and nitrite/nitrate concentrations as a function of the presence of encephalopathy and 
brain edema. 
Attenuation of increased circulating levels of ammonia in ALF by minocycline 
treatment could be the consequence, at least in part, of effects of the drug on gut 
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ammonia production. Further studies are warranted in order to address this possibility. 
Evidence that oxidative/nitrosative stress is implicated in the pathogenesis of brain 
edema and encephalopathy in ALF is provided by the findings of the present study 
where administration of minocycline led to a delay in onset of coma, prevented brain 
edema and also led to significant attenuation of the increases in expression of markers 
of oxidative/nitrosative stress (HO-1 and NOS isoforms) with consequent reduction of 
brain levels of nitrites/nitrates. On the other hand, the beneficial effect of minocycline 
on brain, but not circulating, nitrates/nitrites levels is consistent with the central anti-
inflammatory properties of the drug. A previous study showed that minocycline had 
neuroprotective properties in mixed cultures of neural cells exposed to oxidative stress 
with a potency similar to that of vitamin E [502] and it was suggested that minocycline's 
antioxidant properties could be attributed to the presence of a substituted phenol ring in 
its chemical structure again, similar to that of vitamin E. It is conceivable that the 
beneficial effect of minocycline on oxidative/nitrosative stress also relates to its 
property to inhibit microglial activation. Under certain defined conditions such as 
exposure to excitotoxic agents, microglia may be activated and release NO [471]. These 
findings suggest that the beneficial effects of minocycline in relation to the cerebral 
consequences of ALF relates, at least in part, to its potential to reduce 
oxidative/nitrosative stress. 
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CHAPTER 3 
GENERAL DISCUSSION 
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1. Neuroinflammation plays a key role in the pathogenesis of HE and brain edema 
in ALF 
1.1 Clinic and experimental evidence of inflammation in the pathogenesis HE and 
brain edema in ALF 
Infection and inflammation are common features in ALF’s natural history. Infection is 
documented in at least 80% of ALF patients [296], which leads to a rise of 
proinflammatory cytokines (TNF-, IL-6 and IL-1)  in blood [297-300]. Besides 
coexisting infection, ALF itself is an inflammatory state, in which increased pro-
inflammatory cytokines levels are observed [298, 301, 302], most obvious in patients 
with elevated ICP. The production of systemic pro-inflammatory cytokines might be 
attributed to the stimulation of the immune system by infection or mediators 
released from necrotic liver, or a direct release of cytokines from the necrotic liver.    
In two large clinical studies of ALF, retrospective [303] or prospective [304], the 
presence of SIRS and/or  infection was correlated with the severity of HE, increased ICP 
and high mortality rate. The results of these two studies support the view that 
inflammation plays a role in the development of brain edema and HE in ALF [305]. 
In a case report of an ALF patient with uncontrolled high ICP, hepatectomy caused a 
decrease of ICP and produced hemodynamic stability [306], associated with a 
reduction of circulating TNF-, IL-6 and IL-1β [306], but without alteration of 
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arterial ammonia levels. This case provides evidence that necrotic liver-derived 
systemic proinflammatory cytokines exacerbate brain edema in ALF [306]. In a pig 
ALF model induced by hepatotoxin-amatoxin, co-treatment with LPS worsens and 
accelerates the progress of brain edema and HE [312].  
In acute-on-chronic liver failure, inflammation and infection are important 
contributing mechanisms [307]. Similarly, the synergistic effect of inflammation on 
ammonia toxicity has been demonstrated in many chronic liver diseases [295, 308, 
309]. Intestinal bacteria passing into lymph nodes and into blood might be possible 
pathogenic routes [310].   
This increase in clinical and experimental evidence supports the concept that there is a 
synergistic effect between hyperammonia and inflammation in the pathogenesis of HE 
and brain edema in ALF.   
1.2 Effects of systemic and central-derived cytokines on the development of HE 
and brain edema in ALF  
In the multi-factorial hypothesis of the development of HE and brain edema in ALF, the 
central role of ammonia has not been questioned, based on extensive amounts of 
experimental and clinical evidence [504, 505]. The question is how the inflammation 
generates a synergistic harmful effect with ammonia during the pathogenesis of ALF. 
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Pro-inflammatory cytokines are large molecules, whose translocation from the 
circulation into the brain is constrained by the BBB. Because the BBB is generally 
regarded as intact in ALF patients, systemic cytokines are traditionally considered to 
be unable to affect the CNS directly. Emerging new experimental evidence suggests 
that systemic-derived and central-derived cytokines could affect brain via different 
pathways. Systemic inflammation might be able to send signals to the brain through a 
vagus nerve-dependent mechanism [506]. The activation of nucleus tractus solitarius 
from vagus nerve has been demonstrated in LPS peripherally injected animals [507]. 
Vagotomy inhibits cerebral IL-1b mRNA expression, induced by peripheral IL-1b 
stimulation [508]. The rapid signalling from the vagus nerve to the brain may explain 
the “sickness behaviour” during inflammation in ALF [509]. Systemic cytokines could 
also send signals to brain through stimulation of BBB endothelial cells that express 
IL-1 and TNF receptors [510-512]. Through cytokine-binding and activation, 
endothelial cells produce secondary messengers and result in the intra-cerebral 
synthesis of NO and prostanoids [456, 511, 513, 514]. Perivascular microglia might be 
activated during systemic-derived cytokine stimulation [515]. This pathway could 
contribute to the observed changes of CBF and astrocytes in ALF (Figure 3).  
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Figure 3: Potential mechanisms that link the peripheral and central inflammation to 
the development of cerebral edema and HE in ALF. The synergistic effect between 
inflammation and ammonia via BBB and CBF is noteworthy. 
Systemic cytokines may also enter the CNS directly, through places devoid of a BBB, 
such as the circum-ventricular organs (the orgnum vasculosum of the lamina terminalis 
and area postrema) [456]. After crossing the blood vessel, cytokines diffuse into 
cerebral parenchyma, and stimulate astrocytes and microglia, to produce toxic 
mediators and exert their detrimental effects [516]. Systemic cytokines TNF-α, IL-1β, 
and IL-6 may also be able to cross the BBB via a saturable carrier-mediated transport 
mechanism [517-520].  
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A central mechanism of de novo cytokine synthesis has been proposed in human and 
experimental ALF. Increased cerebral efflux of IL-1, TNF and IL-6 was 
demonstrated in ALF patients with uncontrolled ICP [306, 521, 522], whereas such 
cytokines efflux can be reduced by hypothermia treatment to control high ICP [39, 
311]. Results in the present thesis demonstrate unequivocally the direct evidence for 
brain-derived proinflammatory mechanisms in the pathogenesis of the neurologic 
complications of ALF. This evidence includes activation of microglia, as shown by 
increased immunoreactivity of the major histocompatibility complex marker, OX-
42, together with the increased production of brain proinflammatory cytokines. 
Increased cytokine transcripts in the hepatic devascularized rat model of ALF were 
found to be selective in terms of their identity, the magnitude of the increase in their 
expression, and the timing of the increased expression in relation to the progression 
of ALF. Early increases in IL-6 mRNA levels were followed by more substantial 
increases in the expression of IL-1 and TNF- and occurrence of severe 
encephalopathy and brain edema was associated with a generalized increase in the 
expression of all three cytokines [523].   
This increased cerebral cytokine expression may be implicated in the altered gene 
expression found in HE. Altered expression of cerebral GFAP [208], the glutamate 
transporter EAAT-2 [262], the glucose transporter GLUT-1 [193], aquaporin IV 
[475] and the mitochondrial peripheral-type benzodiazepine receptor [217] have 
been demonstrated in experimental ALF animals, and found to be associated with 
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the development of brain edema. Although such protein modifications had 
previously been attributed to the toxic effects of ammonia in ALF, there is evidence 
to suggest that pro-inflammatory cytokines could also be implicated. Consistent with 
this notion, intracerebral administration of IL-1 leads to up-regulation of 
peripheral-type benzodiazepine receptor sites [476] while exposure of cultured 
astrocytes to IL-1 and TNF- up-regulate aquaporin IV [477] and down-regulate 
GFAP [478] respectively. Moreover, high affinity transport of glutamate into cultured 
astrocytes is significantly impaired by exposure to IL-1 consistent with down-
regulation of glutamate transporters [258, 479].   
Systemic inflammation has detrimental effects on BBB permeability, other than BBB 
signal transduction. It has been suggested that circulating cytokines could alter BBB 
permeability in humans, probably by stimulating the vascular endothelium [344]. 
Systematic inflammation worsens clinical symptoms of HE in cirrhotic patients fed an 
ammoniagenic diet, which suggests an increased BBB permeability to blood-born 
toxins by inflammation [295]. Increased BBB permeability has also been demonstrated 
in endotoxin-induced inflammation in experimental ALF [345], and in naïve rats co-
administration with LPS and ammonia, which results in increased CBF and ICP [327]. 
Furthermore, more obvious astrocyte swelling, along with anatomically intact BBB, 
has been demonstrated in LPS treated hyperammonemic rats, which indicates 
functional change of BBB, probably increasing BBB permeability to circulating 
toxins (ammonia) by systemic inflammation [346]. In addition, in vitro experiments 
have demonstrated various mechanisms on how different cytokines affect BBB. IL-1β
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[459] and TNFα [459, 524, 525] have been shown to impair BBB integrity and function 
in endothelial cells. TNF-α and IL-6 increase ammonia diffusion across endothelial cells 
[458]. Furthermore, TNF-α and IFN-γ could compromise tight-junction integrity 
[526]. Incubation with TNF- leads to astrocyte swelling in culture [527]. However, 
caution should be taken when translating in vitro results into in vivo interpretation. 
Systemic inflammation might also induce elevated CBF in ALF. It has been 
recognized that increased CBF plays a role in the pathogenesis of brain edema and 
higher ICP in ALF patients [313, 528] (details in CBF section). Increased SIRS and 
pro-inflammatory cytokines have been shown to be associated with elevated CBF in 
ALF patients with higher ICP [294]. Hepatectomy, which decreases circulating pro-
inflammatory cytokines, without change in blood ammonia, leads to a subsequent 
reduction in both CBF and ICP [306]. In a recent animal experiment, the synergistic 
effect of inflammation with hyperammonemia in producing increased CBF and 
ICP has been demonstrated in rats [327]. Inflammation significantly increases CBF 
and ICP, with an unaltered blood ammonia level [327], which suggests that 
observed brain edema and higher ICP is at least partially due to high CBF-induced 
increased ammonia extraction by the brain [529].  
The various mechanisms mentioned above afford possible explanations for the 
concept of synergistic effects between inflammation and ammonia on the 
pathogenesis of brain edema and HE in ALF. However, the precise molecular and 
pathophysiologic mechanisms await further investigation. In view of the frequency of 
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infection and inflammation in ALF observed in the clinical setting, anti-inflammatory 
treatments affecting the different stages (up-stream and down-stream) in the rise of 
cytokines may offer new therapeutic approaches. 
  
2. The role of RNOS in the pathogenesis of HE and brain edema in ALF 
2.1 Evidence of oxidative/nitrosative stress in the pathogenesis of HE and brain 
edema 
Alzheimer type II astrocytosis [530] is a typical pathology found in postmortem HE 
brain. The observation of increased lipofuscin pigment accumulation in these Alzheimer 
type II astrocytes indicates an enhanced oxidative stress which leads to raised lipid 
peroxidation [531, 532]. Although not many investigations on oxidative stress have 
been performed in human subjects with HE, animal experiments and cell culture 
systems have provided much evidence suggesting the involvement of RNOS (reactive 
oxygen and nitrogen species) in the pathogenesis of HE [98, 533].  
Increased brain production of nitric oxide has been observed in different animal 
models, including ammonia-injected naïve rats [534], portacaval-shunted rats given 
ammonia infusions [93], rats with ischemic liver failure (Jiang et al, in press), as well as 
sepsis [535]. Increased brain generation of superoxide radical has also been 
demonstrated in ammonia-intoxicated animals [488, 503, 536, 537]. Hypothermia 
reduces free radical production [538], which may account for some of its beneficial 
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effects in HE. In addition, increased cerebral HO-1 expression has been found in 
hyperammoneamia animals, which indicates oxidative stress in the brain of these 
animals [325, 539, 540]. 
Nitric oxide and superoxide react to form a more toxic product peroxynitrite, which 
may modify proteins to generate a stable product - nitrotyrosine. Consistent with 
this notion, increased protein tyrosine nitration is observed in ammonia-administrated 
animals [378, 497]. Likewise, increased cerebral oxidative stress and protein tyrosine 
nitration are demonstrated in experimental animals administrated diazepam and 
endotoxin - two HE precipitation factors [541-544]. Using immunohistochemistry, the 
enhanced nitrotyrosine was found to occur with GS and GFAP (two astrocytic 
proteins), in brain samples from ammonia-, diazepam-, or endotoxin-administrated 
animals, indicating that protein tyrosine nitration is mainly in astrocytes [326, 378, 497, 
543, 544].  
Astrocyte swelling is a well known feature of HE. The role of RNOS in mediating the 
development of astrocyte swelling is supported by many experiments. Astrocyte 
swelling, with a reduction of myo-inositol, taurine and hypotaurine, has been observed 
in hydrogen peroxide-treated astrocyte cultures [545]. Astrocyte swelling could also 
be induced by ammonia treatment, with involvement of RNOS generation [99, 546], as 
well as by glutamate stimulation, in association with the production of RNOS [547, 
548]. Furthermore, two groups of agents, GS inhibitors and NMDA receptor blockers, 
which prevent ammonia-induced protein tyrosine nitration, inhibit the clinical signs of 
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HE in ammonia-toxicated experimental animals [51, 90, 407, 488, 549-552]. Together, 
this evidence supports the hypothesis that RNOS and nitrotyrosine are involved in the 
development of HE and brain edema in ALF.     
2.2 Mechanisms of increased RNOS production in HE 
Several possible mechanisms have been proposed to explain the elevation of 
oxidative/nitrosative stress in HE: (1) increase of NOS1, NOS2 and NOS3 expression, 
(2) activation of NMDA receptors, (3) mitochondrial dysfunction, (4) decreased 
activities of antioxidant enzymes, and (5) astrocyte swelling. These mechanisms are not 
mutually exclusive. They likely represent either successive steps leading to RNOS 
generation or parallel pathways inducing RNOS production.   
2.2.1 Increase of NOS1, NOS2 and NOS3 expression 
Increased cerebral NOS1/nNOS (nitric oxide synthase) activity has been found in 
portacaval shunted rats [553]. And, increased cerebral NOS1/nNOS mRNA and 
protein expressions were also found in acute hyperammonemia animals [554], as 
well as portacaval-shunted rats with chronic hyperammonemia [555].  In 
investigating the role of ammonia as a causative factor, ammonia-treatment induces 
increased L-arginine uptake. L-arginine is the obligate precursor for NOS1/nNOS, in 
nerve terminal (synaptosomal) preparations [556] and in primary astrocyte cultures 
[557]. This ammonia-stimulated increase of L-arginine uptake occurs with 
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increased nNOS activities, in both in vitro and in vivo settings [553, 555]. In 
addition, the selective NOS1/nNOS inhibitor - nitroarginine - prevents several 
acute hyperammonemia-induced toxic effects in experimental animals [554]. 
However, nitroarginine and 1-2-trifluoromethylphenyl imidazole (TRIM), 
NOS1/nNOS inhibitors, did not prevent brain edema in portacaval shunted rats 
following ammonia administration [25], which indicates that either nNOS is not the 
only source of RNOS production in HE (which is evident by recent finding on iNOS 
and eNOS expression in ALF animals), or RNOS is not the major factor in HE 
pathogenesis.   
Results of the present thesis demonstrate that ALF resulting from hepatic 
devascularization leads to selective increases in expression of the gene coding for 
inducible and endothelial isoforms of NOS (iNOS/NOS2 and eNOS/NOS3) in 
brain. The magnitude of induction, in all cases, was a function of the duration of 
liver ischemia, the presence of severe encephalopathy (coma), cerebral edema and of 
blood and brain ammonia concentrations. Increased iNOS and eNOS isoform gene 
expression was accompanied by significant increases in brain concentrations of 
nitrite/nitrate (NOx) confirming that the increases in NOS isoform expression 
caused by ALF were sufficient to cause increased NO production [337, 553]. In 
addition, increased iNOS protein expression, along with high nitrite production, has also 
been demonstrated in ammonia-intoxicated rats, as well as ammonia-treated astrocyte 
culutres [497]. In addition, increased nitrite release and iNOS protein expression was 
observed in LPS or cytokine treated astrocyte cultures [558]. Elevated cerebral eNOS 
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protein was also demonstrated in portacaval-shunted rats given ammonia treatment 
[559].   
   
2.2.2 Activation of NMDA receptors 
  
Consistent with an earlier report that hyperammonia-induced free-radical production 
may be mediated by NMDA-receptor activation [560], ammonia-intoxicated animals 
produce increased cerebral superoxide, NO and nitrotyrosine, in an NMDA receptor-
dependent manner [378, 561]. Administration of NMDA receptor inhibitors, which 
block ammonia-induced astrocyte-swelling, reduce cerebral NO production and 
nitrotyrosine in ammonia-intoxicated animals [93, 407, 551, 561].  
Evidence provided from in vitro experiments shows that NMDA activation leads to in-
creased intracellular calcium concentration; and this increased intracellular calcium 
induces mitochondrial RNOS production, and iNOS expression and NO generation 
(through calcium-IkB pathway) [497, 551]. Similarly, NMDA receptor activation and 
increased intracellular calcium concentrations are also necessary steps in inducing 
increased astroglial nitrotyrosine by diazepam and TNF-α stimulation [543, 544]. 
However,  further experiments are needed to prove the existence of this molecular 
pathway in vivo [562]. 
2.2.3 Mitochondrial dysfunction 
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Ammonia-induced mitochondrial malfunction [166] could be a source of increased ROS 
production [563]. Increased superoxide radical production from cerebral mitochondria 
has been demonstrated in acute ammonia-toxication [488, 503]. Increased RNOS 
production by ammonia could relate to the ammonia metabolite - glutamine, since GS 
inhibitors prevent ammonia-induced RNOS production, increased nitrotyrosine, and 
astrocyte-swelling in cultured astrocytes [78, 99, 497]. Increased free radical generation 
was observed in cultured-astrocytes treated with glutamine [130, 564]. And, ammonia 
released from glutamine hydrolysis was suspected, since PAG inhibition prevents free 
radical production [127, 128]. Astrocytic glutamine is mainly metabolized by 
mitochondrial PAG (in vitro setting), and glutamine hydrolysis leads to high 
mitochondrial ammonia, which impairs mitochondrial activity and increases ROS 
production. In addition, PTBR ligands induce free radical production in cultured 
astrocytes [565]; and since PTBR is located on mitochondrial membranes, and 
increased cerebral expression of PTBR is observed in ALF [566], this finding 
indicates that PTBR may play a role in RNOS production. Following further 
investigation, increased opening of the MPT pore, in the inner mitochondrial membrane, 
has been demonstrated in cultured astrocytes following exposure to ammonia [100], 
glutamine [129], PTBR ligands [567], or RNOS [568, 569]. Opening of the MPT pore 
causes mitochondrial dysfunction and increases ROS production.  
    
2.2.4 Decreased activities of antioxidant enzymes 
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The antioxidant enzyme system (a defence line against RNOS) is compromised during 
HE. Reduced activities of cerebral superoxide dismutase, catalase and glutathione 
peroxidase were observed in rats following acute ammonia intoxication [503]. And, 
decreased antioxidant enzyme activities has also been demonstrated in sepsis [570], 
which has detrimental effects on astrocyte function [558]. Moreover, antioxidant 
administration has beneficial effects on hyperammonemic animals with HE [571].  
2.2.5 Astrocyte swelling 
Astrocyte swelling may itself induce RNOS production. Using hypo-osmotic-treated 
astrocyte cultures as a model, astrocyte swelling leads to increased RNOS production 
and high nitrotyrosine [572], which could be prevented by co-treatment with the 
NMDA receptor antagonist: MK-801 and EGTA [572]. Furthermore, increased 
intracellular calcium, induced by hypoosmotic situations, was inhibited by MK-801 
[572], and increased nitrotyrosine, after hypoosmotic induction, was prevented by pre-
treating astrocytes with MK-801, EGTA, a calmodulin antagonist W13, non-specific 
NOS inhibitors, SOD plus catalase, and uric acid [572]. These findings indicate that 
astrocyte swelling activates the NMDA receptor, increases intracellular calcium, 
enhances RNOS production, and subsequently increases nitrotyrosine levels [572].  
Mechanisms involved in the NMDA receptor stimulation by swelling astrocyte are not 
clear. One possibility is astrocytic depolarization after hypoosmolarity [573], which 
leads to the deletion of the Mg
2+
 blockade on NMDA receptors [574]. Another 
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possibility is glutamate release from the swollen astrocyte, which could stimulate 
NMDA-R. RNOS production after astrocyte swelling could also result from increased 
release of ascorbate [575] and glutathione [576]. 
Moreover, as mentioned in the previous paragraph, increased RNOS levels could 
induce astrocyte swelling, and since swollen astrocytes could also enhance RNOS 
generation, then a vicious cycle could be established, with the potential to accelerate 
the progression of astrocyte swelling. 
2.3 Astrocyte is the main cellular source of RNOS in brain in HE 
The astrocyte has been considered as the main cellular source of cerebral RNOS 
production in HE. In one study, MSO, a GS inhibitor, prevented increased RNOS and 
nitrotyrosine formation in ammonia-treated cultured astrocytes [99, 497]. MSO also 
decreased cerebral production of NO and nitrotyrosine in ammonia-administrated 
animals [93, 561]. Because GS is an astrocyte specific protein, MSO experiments 
indicate that the astrocyte is closely involved in RNOS production. In cultured 
astrocytes, increased RNOS and nitrotyrosine formation has been observed following 
exposure to ammonia, PTBR ligands, and TNF- [99, 497, 543, 544, 565]. In 
addition, ammonia exposure leads to increased argininosuccinate synthetase and lyase 
expression [577] and high arginine uptake [557] in cultured astrocytes, but not in 
neurons [577]. Ammonia and glutamine treatments lead to increased ROS and MPT 
production in astrocytes, but not neurons [100, 143]. Moreover, non-selective NOS 
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inhibition ameliorates hyperammonia-treated animals, but not by neuron-specific 
nNOS inhibition [25, 528, 536, 554].  These findings strongly support a key role for 
the astrocyte but do not exclude the role of microglia for RNOS production in HE. 
2.4 RNOS in HE: possible mechanisms 
How the generated RNOS and subsequent nitrotyrosine formation is involved in the 
pathogenesis of HE is not clear.  Several molecular and pathophysiologic mechanisms 
have been proposed. Oxidation and nitrotyrosine formation could modify multiple 
proteins and affect their functions. In line with this view, nitrotyrosine residues have 
been found on PTBR, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), GS, 
MAP-kinase and Erk-1 in ammonia-exposed astrocyte culture [497]. Increased PTBR 
oxidation leads to increased binding affinity of PTBR for its ligand PK11195 and 
increased inward transport of cholesterol into mitochondrial [578], which is involved 
in the alterations of cerebral neurosteroids synthesis, GABA receptor inhibition, and 
astrocytic energy metabolism [579, 580] (see more in PTBR section). Increased 
GAPDH oxidation could lead to its inactivation and proteasomal degradation [581] 
and impair energy metabolism in HE [582]. 
GS tyrosine nitration in ammonia-treated astrocytes is associated with its inactivation 
[497]. Similarly, tyrosine nitration of hepatic GS from LPS-treated rats and of sheep 
GS after peroxynitrite-treatment is associated with enzyme inhibition [544, 583, 584]. 
In contrast, giving the NMDA receptor antagonist (MK-801) [585] or the NOS 
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inhibitor (nitroarginine) [554] increases cerebral GS activity. And, preventing GS 
tyrosine nitration by epicatechin [586], partly restores GS activity [583]. These results 
support the view that GS activity is inhibited by tyrosine nitration. In liver failure, 
whether the modification of GS by tyrosine nitration occurs in only neurons, or in only 
astrocytes, or in both cell types, is waiting to be elucidated. But, reduced cerebral GS 
activity and decreased de novo cerebral glutamine synthesis capacity have been a consistent 
observation in liver failure [55, 587, 588]. Reduced GS enzyme activity decreases the 
capacity for ammonia removal in the brain.   
Several studies suggest that RNOS could induce astrocyte swelling by influencing MPT 
function. Cyclosporin-A treatment prevents ammonia-induced astrocyte swelling, 
through the involvement of MPT pore [101, 129, 144]. In a recent experiment, PTBR 
was found to be involved in ammonia-induced RNOS production, unlock of MPT 
pore in cultured astrocytes, and subsequent astrocyte swelling [589]. 
Protein tyrosine nitration is observed in BBB-forming cerebral perivascular astrocytes 
in several animal models of HE [378, 497, 543, 544]. Several studies have shown that 
protein tyrosine nitration by peroxynitrite impairs BBB integrity [563]. In an 
experimental allergic encephalomyelitis (EAE) animal model, the increased BBB per-
meability was partially prevented by uric acid, a peroxynitrite scavenger [590-592]. 
The possible mechanism of increased BBB permeability by elevated nitrotyrosine 
modification may be attributed to functional alterations of substrate transport into 
astrocytes in HE. 
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The increased nNOS/iNOS/eNOS expression and increased NO generation may cause 
cerebral vasodilation and induce high CBF, a well-known phenomenon observed in 
ALF patients (see more in CBF section).   
  
Some studies show that astrocytes are less sensitive than neurons to RNOS [593, 594]. 
Astrocyte-generated RNOS may impair nearby neurons in the brain. In one study, co-
cultured peroxynitrite-treated astrocytes with embryonic motor neurons led to 
apoptosis of these neurons [593]. In another study, adding NO-producing astrocytes to 
cultured neurons makes these neurons vulnerable to glutamate treatment, and results 
in permanent damage to the respiratory chain and ATP reduction [595]. It is possible 
that astrocyte-produced RNOS may alter and impair neuronal function in HE.   
The precise molecular pathways that link RNOS to HE remain to be elucidated. The 
synergistic action of ammonia, glutamate, benzodiazepines, hyponatremia and 
inflammatory cytokines in inducing RNOS formation from different mechanisms is 
worth noting. However, we need to keep the possibility open that protein tyrosine 
nitration might only be a marker of RNOS, and that other pathophysiologically more 
relevant mechanisms, induced by high RNOS production, may exist. Further studies 
are necessary to be carried out, in order to accurately assess the role of RNOS in the 
development of HE. 
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3. The involvement of microglia in the pathogenesis of HE and brain edema in 
ALF 
3.1 General background of microglia 
Microglia comprise nearly 10% of the cerebral cellular population, which function as 
resident mononuclear phagocytes of the brain [347, 348] and give differential response 
to various stimuli [349]. Microglia share lineage-related phenotypes with bone-marrow-
derived monocytes and macrophages [350]. As macrophages, activated microglia could 
eliminate deleterious debris by phagocytosis and support tissue survival by secreting 
neurotrophic factors at cerebral injury sites. Microglia are considered to be major cell 
types in CNS responsible for cytokine production [351-355]. It has been shown that 
activated microglia can generate various cytotoxic substances in in vitro settings, its 
release has been implicated in the development of several 
neuroinflammatory/neurodegenerative diseases, such as Parkinson’s disease, 
Alzheimer’s disease, AIDS dementia, multiple sclerosis, amyotrophic lateral sclerosis, 
traumatic brain injury [356], stroke [357], and Wernicke’s encephalopathy [358].   
3.2 Mechanisms of detrimental effects of microglia activation in ALF 
It has been proposed that activated microglia and related inflammatory responses are 
detrimental to the brain. In in vitro settings, microglia have been demonstrated to be 
able to produce several cytotoxic substances, such as ROS [359, 360], NO, proteases, 
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arachidonic-acid derivates, glutamate [361], quinolinic acid [361], TNF-a, IL-1b [362-
366]. These factors influence the CNS cellular system in an autocrine and/or a paracrine 
fashion. For instance, it has been suggested that microglia-generated TNF could induce 
RNOS production from astrocytes [367, 368].    
Results of the studies described in this thesis provide the first direct evidence for a 
role of microglial activation in the pathogenesis of the encephalopathy and brain 
edema in ALF. Cerebral microglial activation, found in ALF animals, could well 
explain the increased expression of the proinflammatory cytokines (IL-1, IL-6 and 
TNF-) and elevated nitrite/nitrate levels in brains of these animals at coma (edema) 
stages of encephalopathy, which is consistent with previous reports of increased 
cerebral cytokine efflux (by measuring arterio-venous differences) in ALF patients 
[314, 461].  
Healthy neurons express several molecules that actively down-regulate microglia and 
macrophage activation states [596-598]. The precise mechanisms responsible for 
microglial activation in ALF are unknown. However, one potential mechanism 
involves ammonia toxicity. ALF results in sustained hyperammonemia, and brain 
ammonia concentrations in the 1 to 5 mmol/L range have been reported [31]. 
Ammonia inhibits α-ketoglutarate dehydrogenase in rat brain mitochondria [97], 
resulting in decreased glucose oxidation and in lactate accumulation. Increased brain 
lactate production has been shown unequivocally in experimental ALF [115], and 
CSF lactate levels are positively correlated with the severity of HE in both 
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experimental [161] and human [162] ALF. It has been shown that exposure of 
cultured microglia to lactate in concentrations equivalent to those reported in brain 
in experimental ALF leads to increased production and release of TNF-, IL-6, IL-
[457]. From our study, increased expression of the microglial marker proteins OX-6 
and OX-42 (which indicates microglial activation) was found in the brains of 
ischemic ALF animals which correlates well with the worsening of HE and cerebral 
edema in these animals. Moreover, increased cerebral expression of TNF-, IL-6, 
and IL-1 parallels the increase of cerebral lactate [115, 197] in ischemic ALF 
animals. These findings support the view that cerebral lactate accumulation activates 
microglia and induces subsequent cytokine generation in ALF.  
In addition, activated microglia expresses various chemokines and cadhesion molecules, 
such as CCL2/monocyte chemotactic protein-1 (MCP-1), CCL3/Macrophage 
inflammatory protein-1(MIP-1), CX3CL1/ fractalkine, CXCL10/ IP-10 and IL-
8/CXCL8 [599-602] which not only move resident microglia to the sites of 
inflammation, but also recruit blood-borne leukocytes into the neuro-inflammation sites 
[603-607]. In this way, activated microglia could amplify cerebral inflammatory 
response according to the needs against various pathogens. The significance of these 
peripheral-derived immune cells in the development of cerebral inflammatory response 
in ALF awaits further investigation.  
  
As expected from its anti-inflammatory properties [470-472], results of the present 
study demonstrate that treatment with minocycline reduces microglial activation and 
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leads to significant decreases in expression of IL-1, IL-6 and TNF- in the brains 
of ALF rats. Moreover, these effects of minocycline were accompanied by 
significant decreases in brain water content, strengthening the notion that microglial 
activation and brain accumulation of inflammatory cytokines are implicated in the 
pathogenesis of brain edema in ALF. These findings are in line with previous reports 
that minocycline treatment is effective in limiting brain edema that accompanies 
intracerebral hemorrhages [473]. Moreover, brain edema resulting from 
experimental hypoxia/ischemia is significantly reduced in IL-1 receptor-deficient 
animals [474]. However, results of the present study reveal that an almost complete 
normalization of IL-1 mRNA and protein following minocycline treatment led to 
significant but incomplete inhibition of brain edema in ALF animals suggesting that 
other cytokines or other pathophysiologic mechanisms could also be implicated. 
Future studies, using genomic and proteomic profiling [608, 609] to follow the course 
of microglia change over time [610-613], will help to elucidate the role of microglia in 
the pathogenesis of HE and cerebral edema in ALF. 
4. Mechanisms of beneficial effect of mild hypothermia in the treatment of ALF 
  
4.1 Protective effects of mild hypothermia in experimental ALF 
The beneficial effects of mild hypothermia in treating ALF have been demonstrated in 
various animal models, such as ischemic liver failure, hepatectomy and portacaval-
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shunted rat given an ammonia salt. Mild hypothermia delivers reliable therapeutic effects 
slowing the development of HE, brain edema and high ICP, in these ALF models [121, 
197] . 
4.2 Mechanisms explaining the beneficial effect of mild hypothermia in ALF 
In ALF, HE, brain edema and high ICP result from multiple pathophysiologic 
alterations, such as altered brain osmolarity, cerebrovascular hemodynamics, cerebral 
energy metabolism, and neuro-inflammation [204, 378]. The capacity of mild 
hypothermia to influence various mechanisms during ALF may explain its beneficial 
effects.  
4.2.1 Cerebral and arterial ammonia levels 
Increased cerebral and arterial ammonia is a consistent finding in ALF, with increased 
brain-to-blood ammonia ratio (from 2:1 in normal to 4:1 in ALF) [31]. Although some 
experiments do not show decreased arterial ammonia level after hypothermia treatment 
[121], the results from my experiments (in this thesis [499]), clinical ALF patients 
[39, 311], and urea-cycle deficiency [614], clearly show that blood ammonia is 
decreased after hypothermia treatment. The differences may be explained by different 
depths of induced-hypothermia, controlled in different experimental or clinical 
settings. More importantly, hypothermia leads to decreased cerebral ammonia 
concentration in ALF. In an ammonia-intoxication experiment, the dose needed to 
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induce 50% mortality is two times higher in hypothermic mice than normothermic mice 
[424]. Decreased cerebral ammonia is observed in hypothermic mice after ammonia 
administration, indicating decreased ammonia transfer from blood to brain under 
hypothermia. In another study, decreased CSF ammonia by hypothermia treatment 
accompanies un-altered arterial ammonia levels, which again indicates reduced blood to 
brain transfer of ammonia by hypothermia [254]. The capacity of hypothermia to reduce 
cerebral ammonia in ALF may be due to lowering of CBF, BBB permeability, and 
increased arterial ammonia. In addition, hypothermia reduces bacterial ammonia 
generation from feces and ammonia extraction from the colon [425, 615]. Hypothermia 
also decreases kidney-derived ammonia release [426] and ammonia production from 
proteolysis [427].   
4.2.2 Cerebral osmotic changes 
Cerebral osmotic changes have been suspected as the cause of brain edema in ALF for 
many years. Glutamine is a well known osmolyte, and is also an ammonia metabolite 
mainly formed in astrocytes via GS [68]. Increased cerebral glutamine has been 
observed in various experimental models of ALF and hyperammonemia [156]. 
Preventing glutamine synthesis by MSO, decreases ammonia-induced astrocyte 
swelling in vitro [616] and brain edema in vivo [85, 86, 617]. However, hypothermia 
does not lower cerebral glutamine levels [115, 121], which indicates that glutamine is 
not the only osmotic determinant during brain edema formation in ALF. Alterations of 
other osmolytes have been observed, such as increased cerebral glucose, alanine and 
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lactate in ALF [47, 115]. It has been demonstrated that elevated cerebral lactate and 
alanine show a very close relationship with the progressive development of HE and 
brain edema in experimental ALF [31, 115]. Hypothermia is effective in correcting the 
disturbances of cerebral lactate and alanine [114, 124, 254], and, in this way, may 
attenuate the overall cerebral osmotic stress created during ALF.   
4.2.3 Extracellular cerebral amino acids 
Altered extracellular cerebral amino acids have been demonstrated in experimental 
ALF. Hypothermia treatment attenuates the increase of alanine and phenylalanine, 
normalizes the elevation of glutamate, aspartate, glycine, and tryptophan, but has no 
effects on increased glutamine, taurine, valine, tyrosine, and leucine [254]. Increased 
extracellular cerebral glutamate is consistently observed in ALF [113, 158, 164, 251, 
252], and the mechanism involves decreased glutamate uptake by astrocytes [259, 261, 
262] as well as increased astrocytic glutamate release [267]. High extracellular 
glutamate induces astrocyte swelling in culture [547, 618], probably through high K
+  
uptake in astrocyte [428] and high RNOS production following NMDA-R stimulation 
[407, 497]. Hypothermia-induced reduction of extracellular cerebral glutamate may 
thus prevent brain edema in ALF [121, 254]. Increased excellular glycine in ALF may 
induce its harmful effect by acting as a positive allosteric NMDA-R modulator, and this 
is also attenuated by hypothermia. Increased aromatic amino acids have the capacity 
to enhance the synthesis of monoamine neurotransmitters in ALF [619], which is also 
ameliorated by hypothermia. The unaltered profile of branched chain amino acids after 
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hypothermia treatment excludes their role in the pathogenesis of cerebral edema in 
ALF.   
4.2.4 Cerebrovascular autoregulation and CBF 
Impairment of cerebrovascular autoregulation and increased CBF are consistently 
observed in ALF patients [157, 620], which is closely associated with brain edema 
and high ICP [379]. As a result of compromised cerebrovascular autoregulation, brain 
becomes vulnerable to systemic blood pressure, which generates increased CBF during 
high arterial pressure, and produces hypoxia during low arterial pressure. In addition, it 
has been shown that increased CBF correlates with the development of brain edema 
and high ICP in ALF [313, 621], whose mechanisms involve high cerebral blood 
volume load, high pressure across the BBB, and increased ammonia transfer from-
blood-to-brain [379]. Hypothermia successfully re-establishes the cerebrovascular 
autoregulation in ALF [622, 623], and effectively prevents the increase of CBF in 
experimental ALF [114, 121] and in ALF patients [39, 40, 311, 314], with improvement 
of brain edema and high ICP.   
  
4.2.5 Cerebral energy metabolism 
An inefficient, partially blocked cerebral energy metabolic state is observed in the brain 
during ALF. Due to inhibited cerebral alpha-ketoglutarate dehydrogenase activity by 
hyperammonia, cerebral pyruvate oxidation is reduced [115], leading to increased de 
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novo synthesis of lactate from glucose [115] and a compensatory activation of 
glycolytic enzyme phosphofructokinase [168, 194]. Hence, increased cerebral and CSF 
lactate is consistently demonstrated in various ALF animal models [163, 197] and in 
ALF patients [158]. Elevated cerebral lactate concentrations show a close association 
with the development of HE, brain edema and high ICP in experimental ALF [115, 
163].  
   
Mild hypothermia prevents CSF lactate accumulation in ischemic ALF animals [197]. 
By using NMR spectroscopy and 
13
C-glucose [114], hypothermia was shown to 
attenuate brain lactate synthesis from 1.7 times increase to 1.3 times increase, 13C-
labeled cerebral lactate from 4.5 times high to a level not different from controls. In a 
study involving ALF patients with uncontrolled ICP [39], hypothermia treatment 
decreased cerebral glucose metabolism more than ninety percent, which indicates a 
more efficient cerebral energy metabolism induced by hypothermia. The beneficial 
effects of hypothermia to improve pyruvate oxidation, decrease glucose consumption, 
and reduce lactate accumulation may contribute to decreased cerebral ammonia 
concentrations by hypothermia.  
   
4.2.6 Inflammation 
Inflammation (SIRS) and infection are frequently demonstrated in ALF. The correlation 
between the degree of inflammation (SIRS) and infection and the development of HE 
and brain edema has been described in clinical [303, 304, 624] as well as experimental 
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[312] studies. Hence, inflammation is recognized as a pathogenic factor in producing 
HE, cerebral edema, and high ICP in ALF [303, 312]. At the molecular level, increased 
systemic pro-inflammatory cytokines are closely associated with the increased CBF and 
high ICP in ALF patients [40, 306]. Positive cerebral cytokine efflux was described in 
ALF patients with uncontrolled ICP, but not in those ICP below 20mmHg [521]. 
Elevated systemic and central pro-inflammatory cytokines may increase CBF and BBB 
ammonia permeability, or induce astrocyte swelling directly [294, 625]. Hypothermia 
treatment effectively reduces systemic and brain levels of proinflammatory cytokines in 
ALF patients with uncontrolled high ICP, resulting  in ICP restoration [311]. 
Hypothermia also prevents  high ICP surges in ALF patients who were waiting for liver 
donors [314] or during liver transplant operations [40, 314], by preventing high 
systemic cytokine and brain cytokine production.  
4.2.7 RNOS 
Increased cerebral RNOS production has been observed in ALF. The causative 
factors include increased ammonia, pro-inflammatory cytokines, extracellular 
glutamate, PTBR ligands, and hyponatremia. The underlying mechanisms for high 
cerebral RNOS production involve induction of NOS isoforms, stimulation of 
NMDA-R, as well as activation of mitochondrial, antioxidant enzymes, and swollen 
astrocytes. Results from this thesis clearly show that hypothermia decreases 
systemic and central production of NO, with the reduction of cerebral iNOS and 
eNOS expression in ischemic liver failure animals [500]. In this ALF model, 
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decreased cerebral NO production by hypothermia is shown to be associated with 
attenuation of cerebral edema. The decreased iNOS and eNOS expression may also 
be a secondary effect of reduced cerebral ammonia resulting from hypothermia.   
4.2.8 Seizures  
Seizures are often seen in ALF patients, which is more likely to present as a preceding 
event before the development of cerebral edema [370]. Hypothermia reduces seizures in 
experimental epilepsy models [626-628]. The delay of seizures by hypothermia has also 
been observed in ischemic ALF rats (unpublished data). 
4.2.9 Gene expression 
Altered cerebral gene expression has been consistently reported in experimental ALF, 
which includes genes coding for AQP4, EAAT2, GFAP, GLUT-1, PTBR, SOD, HO-1 
[208, 219, 227, 262, 325, 539]. Most of these genes are expressed in astrocytes, some 
in endothelial cells, and some are in both cell types. Mild hypothermia 
attenuates/restores gene expression to a normal levels in experimental ALF [220]. The 
molecular mechanism relating these altered gene expressions to cerebral edema in 
ALF awaits further investigation.   
4.2.10 Systemic effects (cardiovascular and liver) 
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Hypothermia treatment in ALF patients has been shown to dramatically enhance 
cardiovascular function, resulting in increased blood pressure, elevated vascular 
resistance, and decreased noradrenaline need [311]. The therapeutic dilemma that using 
vasopressors in ALF to increase blood pressure, may also lead to high CBF and 
increased ICP (due to lack of cerebrovascular autoregulation in ALF [320, 629]) could 
be reasonably resolved by hypothermia. Regarding liver, mild hypothermia ameliorates 
various toxins or ischemia-reperfusion  induced liver injury [446, 630-635], through 
mechanisms that probably involve decreased hepatic necrosis [446] and preserving 
hepatic regeneration [446]. The beneficial effect of hypothermia on the 
cardiovascular system and liver could also prevent the onset of multiple organ 
failure in ALF.   
4.3 Undesired side-effects of mild hypothermia  
Due to technical limitations, when mild hypothermia is applied to patients, the whole 
body has to be cooled, rather than the brain only [636]. This systemic cooling approach 
induces systemic side effects of hypothermia [637, 638], which potentially include 
respiratory infection, coagulopathy, arrhythmias, myocardial ischemia, fluid and 
electrolyte imbalance, hyperglycemia, hyperlactatemia, and shivering. Prolonged 
treatment and increased degree of hypothermia increases the possibility of developing 
side-effects. In ALF patients, controlling body temperature between 32C-35
o
C has 
demonstrated efficacy [377, 639, 640], with no side-effects reported so far [39, 311, 
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314, 622]. Co-treatment with recombinant factor VIIa [641] or granulocyte colony-
stimulating factor [642] may decrease the risk of coagulopathy and infection. 
4.4 Indications for mild hypothermia treatment in ALF patients  
Patients with ALF, who response to NAC or supportive care, who have an excellent 
chance of spontaneous recovery and who would not be listed for liver transplantation, 
would not be priority candidates for therapeutic hypothermia. 
Four groups of ALF patients have been identified that will benefit from mild 
hypothermia therapy.     
  
First group: ALF patients, who are waiting for OLT, and have uncontrolled ICP. 
Uncontrolled ICP is defined as continuing high ICP more than 25 mmHg, after 
treatment with two boluses of mannitol and removal of 500ml fluid by hemofiltration. 
Mortality rate in these patients is more than 90 percent. Mild hypothermia might be life 
saving for them, as it reduces uncontrolled ICP levels to a normal range, and may 
bridge them to OLT [39, 40, 311, 314].  
  
Second group: ALF patients, who are waiting for OLT, have a high risk of increased 
ICP (although not with increased ICP yet), or are developing high ICP levels. The high 
risk group could be defined as ALF patients with severe/deep HE but ICP less than 20 
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mmHg. Mild hypothermia could be used as a prophylactic treatment in these patients 
[377].   
Third group: patients who are undergoing OLT need to prevent increased ICP during 
surgery. A steep increase of ICP is frequently observed during dissection or 
reperfusion phases of OLT [422, 423]. Hypothermia has been shown to effectively 
prevent the surge of high ICP during OLT [314]. In this sense, intra-operation re-
warming should be prevented.   
Fourth group: patients who fulfill criteria for bad prognosis, but have no option to 
undergo OLT. This group of ALF patients either do not have access to OLT, or have 
contra-indication for OLT. Mild hypothermia might be applied to these patients for up 
to 7 days, until spontaneous recovery of liver function. However, re-warming without 
spontaneous liver recovery has a poor prognosis [39]. ALF patients with hepatitis A 
virus or acetaminophen-induced ALF, who have more chance of liver regeneration, 
may be the best candidates for hypothermia therapy in this situation.  
5. Protective mechanism of minocycline in the treatment of ALF 
5.1 General introduction 
Minocycline is a second-generation, semi-synthetic tetracycline derivative that is a 
highly lipophilic drug easily crossing the BBB [643]. The cerebral minocycline level is 
168 
nearly 35% of plasma level [644]. It is traditionally used as an antibiotic against gram-
positive and gram-negative bacterial infections [645, 646], through the mechanism of 
inhibiting protein synthesis by acting on ribosome (16S rRNA) [647]. Recently, 
minocycline has been described as a neuroprotective agent mainly via its anti-
inflammatory action. Minocycline has demonstrated beneficial effects in treating 
various neurologic diseases in experimental animal models, such as intracerebral 
hemorrhage [648], traumatic brain injury [649], spinal cord injury [650, 651], 
Parkinson’s disease [652, 653], amyotrophic lateral sclerosis [654], and Huntington’s 
disease [655].    
  
5.2 Mechanisms of minocycline’s beneficial effects in ALF 
5.2.1 Anti-inflammatory effects 
Minocycline manifests anti-inflammatory effects with both central and systemic actions 
via modulating microglia, astrocytes, neutrophils, macrophages and other immune cells, 
which subsequently decrease the release of cytokines (TNF-α, IL-1β and IL-6), 
chemokines, NO, ROS, lipid mediators of inflammation, MMPs both in the brain and in 
the circulation [463].  
Activated microglia represents the major cell-type in the brain contributing to the 
cerebral production of IL-1, IL-6, TNF-, ROS, RNS [656-661]. The inhibition of 
microglia activation by minocycline, which is evident by decreased CD11b/OX42 or 
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isolectine-B4 immuno-staining in animal models of ALF, ischemic brain injury, and 6-
hydroxydopamine-injected mouse [499, 501, 662, 663], could substantially decrease the 
generation of these pro-inflammatory cytokines and RNOS in the brain [499, 500, 659], 
leading to its protective action.  
Chemokines are potent chemoattractants that guide microglia, astrocytes, and peripheral 
neutrophils, macrophages and other immune cells to the site of increased inflammation 
in various neurologic diseases. Chemokines could be expressed and released from 
microglia, astrocytes, and brain-infiltrating immune cells. It has been demonstrated that 
minocycline decreases the expression of both chemokines (MIP-1, RANTES, IP-10) 
and chemokine receptors (CXCR3, CCR5) in microglia [664, 665] or other immune 
cells [666] in animal models of cerebral inflammation [665, 666], and brain injury [657, 
664]. In addition, altered chemokine and chemoattractant expression has been 
demonstrated in the brain of ischemic ALF animals (unpublished data). These findings 
suggest that minocycline may exert its protective action by suppressing the expression 
of genes coding for chemokines or chemokine receptors, leading to decreased 
recruitment of resident microglia and peripheral-derived immune cells to the site of 
inflammation in ALF. 
Lipid mediators of inflammation include a group of molecules generated through 
successive enzymes, including phospholipases (to produce arachidonic acid), 
cyclooxygenases (to give rise to prostaglandins) or lipoxygenases (to generate lipoxins 
and leukotrienes). PGE2, for instance, could be produced by monocytes, 
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macrophages/microglia, and neutrophils, which induce pyrogenicity, vasodilation, and 
increased vascular permeability. In ALF, increased cerebral PGE2 level has been 
demonstrated in ischemic liver failure animals at the coma stage (unpublished data). It 
has been demonstrated that minocycline inhibits phospholipase A2 (sPLA2) activity 
[667], decreases COX2 expression, reduces PGE2 production in cultured microglia 
[668]. These findings support the view that minocycline may exert protection via 
reducing the production of lipid mediators of inflammation in ALF. 
Leukocytes could generate MMPs, which function to degrade the basement membrane 
of blood vessels, and facilitate leukocyte movement into the brain [669]. Increased 
circulating MMP-9 activity has been reported in ALF models and has been implicated 
in the functional alteration of BBB [670]. It has been shown that minocycline 
effectively decreases both MMP-9 production and MMP-9 activity, concomitant 
suppresses T cell migration into the brain in autoimmune encephalitis [671]. These 
findings indicate that minocycline may exert its anti-inflammatory effects at least 
partially through the inhibition of MMPs-mediated leukocyte migration into the brain in 
ALF.  
Interestingly, minocycline exposure does not alter microglial expression of neurotrophic 
factors, such as brain-derived neurotrophic factor (BDNF) and glial cell line derived 
neurotrophic factor (GDNF) in in vitro conditions [672], which function to promote the 
survival of neurons.  
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5.2.2 Inhibition of p38 MAPK signalling pathway 
Minocycline treatment down-regulates p38 MAPK expression to ~20% of control [673]. 
P38 MAPKs are serine/threonine kinases, whose signalling pathway plays a role in 
mediating cell migration, proliferation and differentiation. P38 MAPK is activated by 
inflammatory cytokines, LPS, and other stress stimuli [674]. The neuroprotective 
effects from minocycline-induced inhibition of p38 MAPK were thought to be due to 
the subsequent reduction of expressions of TNF-α, IL-1β, iNOS, and COX-2 [463, 
675], during which both central and peripheral inflammatory cells are involved.  
Addition of minocycline to glutamate-, kainate-, or NMDA-intoxicated mixed spinal 
cord cultures was found to prolong the survival of neurons. This minocycline-induced 
beneficial effect is attributed to decreased microglia activation and the production of IL-
6, IL-1β, TNF-a, and NO, in relation to the decrease of p38 MAPK activity [471, 676]. 
Moreover, minocycline treatment increases the survival of NO-intoxicated cultured 
neurons, which is directly associated with the decrease of p38 MAPK activity in these 
neurons [677]. These findings indicate that neuroprotective effects of minocycline 
relating to the down-regulation of p38 MAPK involves both microglia and neurons. 
Moreover, increased p38 MAPK activity is found in association with neutrophil 
response to inflammatory stimulation, and subsequent increased generation of IL-8 and 
superoxide, high neutrophil chemotaxis [678], and prolonged neutrophil survival [679]. 
In addition, elevated p38 MAPK activity has also been shown to relate to increased 
TNF-α, IL-12, IL-6, IL-1β, and NO production in macrophages [680, 681]. Thus, the 
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inhibition of p38 MAPK pathway by minocycline could potentially reduce the systemic 
inflammatory response mediated by neutrophils and macrophages. 
5.2.3 Reduction of MPT 
It has been proposed that mitochondrial dysfunction leads to increased RNOS production 
in ALF. Among the causative factors, ammonia [488, 503], glutamine [127, 128], and 
PTBR [565, 566] have been suggested. Following further investigation, increased 
opening of the MPT pore, in the inner mitochondrial membrane, has been demonstrated 
in cultured astrocytes following exposure to ammonia [100], glutamine [129], and 
PTBR ligands [567], which was considered to cause subsequent mitochondrial 
dysfunction and increase ROS production. It has been demonstrated that minocycline 
can reduce MPT directly [651, 654], which may subsequently decrease cerebral RNOS 
generation from mitochondria in ALF.     
5.3 Side effects 
In general, less than 10% of minocycline users report side effects, which present as an 
allergic reaction, tissue hyper-pigmentation, or autoimmune disorders [682-686]. In a 
retrospective study of minocycline-induced autoimmune disorders during the past 32 
years, over 60 cases of minocycline-induced systemic lupus erythematosus (SLE) and 
25 cases of minocycline-induced autoimmune hepatitis (AIH) were identified. In 13 
cases diagnosed with both SLE and AIH, patients presented with symmetrical 
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polyarthritis, increased ALT/AST, and positive antinuclear antibodies (ANA). 
Fortunately, stopping the use of minocycline is effective in resolving their symptoms, 
and in dramatically improving and/or normalizing abnormal lab tests [687].   
  
174 
CHAPTER 4 
CONCLUSIONS 
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Results of the findings from the articles published and included in this thesis 
demonstrate that:   
1. Experimental ALF leads to increased brain production of proinflammatory cytokines 
(IL-6, IL-1β, TNF-), and provides the first direct evidence that central inflammatory 
mechanisms play a role in the pathogenesis of the encephalopathy and brain edema in 
ALF (chapter 2.1 - article 1; chapter 2.2 - article 2). 
  
2. Activation of microglia, measured by OX-42, OX-6, predicts the presence of severe 
encephalopathy (coma) and brain edema in rats with ischemic ALF, which accompanies 
the increased production of brain proinflammatory cytokines (chapter 2.1 - article 1; 
chapter 2.2 - article 2). 
3. Oxidative/nitrosative stress participates in the pathogenesis of brain edema and its 
complications in experimental ALF animals with ischemic liver failure. Furthermore, 
the increases in cerebral NOS isoform expression caused by ALF are sufficient to cause 
increased NO production in the brain (chapter 2.3 - article 3; chapter 2.4 - article 4). 
4. Anti-inflammatory treatment, such as hypothermia or antibiotics, is beneficial in the 
prevention of neurological complication of ALF due to hepatic devascularsation 
(chapter 2.1 - article 1; chapter 2.2 - article 2).
176 
5. The beneficial effect of both hypothermia and minocycline on the neurological 
complications of experimental ALF is mediated, at least in part, by reduction of brain-
derived oxidative/nitrosative stress (chapter 2.3 - article 3; chapter 2.4 - article 4). 
177 
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